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SUMMARY
A series of N -substituted 7-halogeno-l,5- 
naphthyridin-4-amines have been prepared from 5-halogeno- 
pyridin-3-amines through 4-chloro-7-halogeno-l,5- 
naphthyridines. Mono- and di-Mannich bases derived from 
4-(7'-halogeno-1',5'-naphthyridin-4'-ylamino)phenol were 
prepared from the above 4-chloro compound by reaction with 
p-aminophenol followed by the Mannich reaction, or from 
the chloro compound with 4-amino-2-diethylaminomethylphenol.
General synthetic routes to various N^-substituted 
2-methoxy (and 2-hydroxy)-1,5-naphthyridin-4-amines and 
1,8-naphthyridines from ethyl 3-aminopyridine-2-carboxylate 
and 6-substituted pyridin-2-amine, respectively, are also 
reported.
Whereas a mono-Mannich base was prepared directly from 
the commercially available 4-chloro-7-trifluoromethyl- 
quinoline and 4-amino-2-diethylaminomethylphenol, a series 
of di-Mannich bases was prepared via the key intermediate 
4-(7'-trifluoromethyl-4'-ylamino)phenol. Analogous mono-
and di-Mannich bases derived from 4-[2',7'- and 2',8'-bis- 
(trifluoromethyl)quinolin-4'-ylamino]phenols were prepared 
through the known 4-bromoquinolines.
The above compounds were evaluated for antimalarial 
activity in a preliminary in vivo screen against Plasmodium 
vinckei vinckei in mice. Those showing significant 
activity in this preliminary rodent screen were examined 
(by others) against both chloroquine-sensitive (FCQ-27) and 
chloroquine-resistant (K-l) strains of Plasmodium falciparum
4
V(a human Plasmodium species) in an in vitro test.
Three di-Mannich bases derived from 4-(7'-bromo- 
1' ,5'-naphthyridin-4'-ylamino)phenol were found to be 
highly effective against P. vinckei vinckei and to have 
a potency approaching, and not significantly differing 
from that of the new antimalarial agent, mefloquine, in
the in vitro screen described above.
4The N -substituted 7-bromo (and chloro)-l,5- 
naphthyridin-4-amines were active in the P. vinckei vinckei - 
mouse model but, unfortunately, all showed significant cross­
resistance with chloroquine against P. falciparum in vitro.
The series of N^-substituted 2-methoxy (and 2-hydroxy)- 
1,5-naphthyridin-4-amines and 1,8-naphthyridines were found 
to be totally inactive as blood schizontocides in the 
preliminary screen but the efficacy of the first series 
(also considered as derivatives of 8-aminoquinolines) as 
tissue schizontocides (active against hepatic stages of 
malaria parasites) is yet to be evaluated.
Not only were all the seven mono- and di-Mannich bases 
of 4-(7'-trifluoromethylquinolin-4'-ylamino)phenols highly 
effective against P. vinckei vinckei in mice, but they were 
also far superior in activity to the classical antimalarial 
agent, chloroquine in the in vitro screen; several appeared 
to be significantly better than either amodiaquine or 
mefloquine against both FCQ-27 and K-l isolates of P . 
falciparum, as measured by their ID50 (concentration of a 
drug causing 50% inhibition of 3H-hypoxanthine uptake)
values.
vi
The above three 1, 5-naphthyridines and the seven 
active quinolinylaminophenols are compounds worthy of 
further study especially when their preliminary in vivo 
rodent screens indicated much lower toxicity than the 
widely used 4-aminoquinoline drug, chloroquine. 
Furthermore, their ID50 values for both the FCQ-27 and 
K-l isolates are essentially the same, strongly indicating 
minimal or no cross-resistance with chloroquine. The 
latter phenomenon coincides with the call for a search for 
new drugs which would overcome or at least alleviate the 
ever increasing problem of the parasites' resistance to 
antimalarial agents.
vii
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1CHAPTER I 
INTRODUCTION
1-1 Malaria - Historical Background
Malaria, derives its name from mala aria - the Italian 
for bad air. It was also known as AGUE, PALUDISM, JUNGLE 
FEVER, MARSH FEVER or PERIODIC FEVER. In 1880, the 
causative agent of malaria was discovered by Alphonse 
Laveran1 when he observed the presence of minute parasites 
in the corpuscles of blood of soldiers in Algeria.
Golgi2 in 1889 produced clear evidence of the existence of 
multiple species of malaria parasites by defining the 
characteristic periodicity of the fever in relation to the 
rupture of schizonts in the blood. An all-important 
discovery was made in 1897 and 1898 when Sir Ronald Ross3 
was able to demonstrate the genus Anopheles as the insect 
in which development of the malaria parasite takes place. 
The four species of malaria parasites affecting man are all 
members of the subphylum Sporozoa, the family Plasmodiidae, 
and the genus Plasmodium. It was not until 1954 that 
they received official validation as Plasmodium falciparum, 
P. vivax, P. ovale and P. malariae.
Through the use of such antimosquito measures as 
drainage and the application of larvicides and short-acting 
insecticides, considerable reduction in malaria was 
accomplished in many of the temperate and more highly 
developed areas of the world, particularly where 
transmission was of short duration. Even so, malaria, as 
late as 1943, still caused at least 3,000,000 deaths and
2300,000,000 cases of fever annually.4 Today, this 
parasitic disease is world-wide covering vast areas in 
Africa, Asia and Latin America5 and it has been 
estimated that more than 200 million people are affected 
each year.6
The UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Diseases has given 
malaria the highest priority because of its immense public 
impact over a large area of the world and because the 
efficacy of current control measures is being increasingly 
compromised by the emergence and spread of resistance of 
Plasmodium falciparum to drugs and of resistance of the 
mosquito vector to commonly used insecticides.
1-2 General Life Cycle of Human Malaria Parasites
A conception of the life cycles of the Plasmodium 
species is not only essential knowledge in chemotherapy but 
also in epidemiology, pathogenesis and immunology. The 
general structure of the malaria parasite life cycle is 
shown diagrammatically in Fig. 1.1 and relates specifically 
to P. vivax and P. ovale in which true relapses of malaria 
occur. The exoerythrocytic stages 6-9 are absent in
P. falciparum and P. malariae.
33
Fig. 1.1. Life cycle of human Plasmodium species.
Various stages of the parasite life cycle are illustrated 
above from the introduction of sporozoites into man by 
infected mosquitoes. The steps in this cycle are 
described as follows:
1. Sporozoites of two types penetrating the 
parenchymatous cells of the liver.
2-4. One initiates immediate exoerythrocytic schizogony.
5. Mature and rupturing exoerythrocytic schizont 
releasing merozoites.
6. The other type of sporozoites becomes hypnozoites, 
and eventually relapse forms (6-9).
7-9. Activated and mature hypnozoites.
49.
10.
11- 12.
13-14.
15.
16-20.
21- 22.
23-24.
25.
26.
27.
28.
29.
30. 
31-33.
34.
35.
Mature hypnozoites rupture liver cell to release 
merozoites.
Merozoites enter red blood cells (RBCs).
Trophozoites in RBC.
Immature schizonts in RBCs.
Mature erythrocytic schizont discharging merozoites.
Merozoite re-establishes blood cycle. Asexual 
cycles in RBCs require approximately 3 days in the 
case of P. malariae and 2 days for the other 
plasmodia of man. Episodes of chill and fever 
follow the massive release of merozoites from 
ruptured RBCs.
Developing microgametocytes in blood.
Developing macrogametocytes in blood.
Entry of gametocytes into midgut of Anopheles.
Exflagellation of microgametocyte with production 
of eight microgametes.
Macrogamete released from RBC.
Free microgamete.
Macrogamete about to be fertilized by 28.
Zygote elongating into ookinete.
Oocysts on surface of midgut.
Rupture of mature oocyst and discharge of 
sporozoites into haemocoele.
Invasion of salivary glands by sporozoites.
5The phenomena of periodicity during different stages 
of the life cycle are highly significant and provide 
criteria for the preliminary diagnosis into quotidian, 
tertian or quartan groups as regards the blood cycles.
1-3 Acquired and Natural Immunity
The development of resistance to malaria in man depends 
on the frequency and duration of exposure to the parasite.7'8 
The acquired immunity keeps parasite levels very low but 
this is maintained only if sporozoite challenge continues.
In areas where transmission is irregular, an effective 
immunity may never be attained. Patients may sometimes be 
classified as non-immune if they have not previously or 
recently been exposed to Plasmodium infection and as semi- 
immune or immune if they have a history of prolonged 
exposure.
Natural resistance to malaria in man is well known and 
has been shown to be due to various genetic traits, of 
which the following three examples are the most common and 
the best substantiated:
(a) Haemoglobin S. Possession of the sickle-cell gene 
confers a strong resistance against P. falciparum 
malaria.9
(b) Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
limits the multiplication of P. falciparum and 
reduces this infection in the community.10
6(c) The absence of the Duffy blood group inhibits
invasion of erythrocytes by merozoites of P. vivax. 
The pure negroes of West Africa exhibit this 
character and are totally immune to benign tertian 
malaria, as was first demonstrated by Miller et al.11 
in 1975.
1-4 Development of Antimalarial Agents
Two and a half centuries before the causative agent of 
malaria was known, the curative property of the bark of the 
Cinchona tree had already been exploited. Today, 350 
years later, modern medicine must still rely on quinine 
(1.1), the major alkaloid constituent of the bark, as a 
life-saving medicament in severe cases of falciparum 
malaria.
Chloroquine (I.2a) is generally considered to be one 
of the most fascinating, useful and versatile antimalarial 
drugs developed during the modern era of synthetic organic 
chemistry.12 It was first prepared in 1934 by H. Andersag 
as part of a programme which included the synthesis of such 
important compounds as mepacrine (1.3), pentaquine (I.4a), 
isopentaquine (I.4b), pamaquine (I.4c), primaquine (I.4d), 
and sontoquine (I.2b).13 The objective of this programme 
was to develop substitutes for quinine.
The development of amodiaquine (I.5a), a Mannich 
base-type antimalarial, and related compounds14'15 was 
first initiated when a search for 4-aminoquinolines
7superior to chloroquine during the World War II 
antimalarial drug development programme led to the 
incorporation of a 4-aminoquinoline moiety into a Mannich 
base. Because of the apparent structural relationship 
and an outstanding similarity in antimalarial activity, 
these Mannich base antimalarials are considered by most 
workers as 4-aminoquinolines.
Schmidt et al_. 16 highlighted the usefulness of 
amodiaquine (I.5a) and amopyroquine (I.5b) (also a Mannich 
base antimalarial) against chloroquine-resistant strain 
of P. falciparum in Aotus monkeys. Ren et al. 17 in China 
observed the superiority in both antimalarial activity and 
toxicity in the di-Mannich base (I.5c) over chloroquine.
More recently, reports18'19 of Mannich bases WR 194,965 
(1.6) and WR 228,258 (1.7), as being highly active in both 
rodent malaria and P. falciparum in vitro, further 
expanded the scope of Mannich base compounds in the 
clinical treatment of malaria.
Curd et al.2 0 first claimed certain biguanides as 
possessing good activity against Plasmodium gallinaceum 
in chicks. The biguanide, proguanil (1.8) and its active 
metabolite, cycloguanil21 (1.9) like pyrimethamine (I.10),
all share the powerful selective inhibition of the activity 
of malarial dihydrofolate reductase.22 The sulphonamides, 
notably sulphadiazine (I.11) and sulphadoxine (1.12) and 
sulphones such as dapsone (1.13) have been used as 
antimalarials in combination with pyrimethamine. The 
regimen which has replaced sulphadoxine-pyrimethamine in 
areas where malaria parasites' resistance to this
combination is problematic includes tetracycline (1.14), 
a highly effective but slow blood schizontocide, in 
association with a short course of quinine.23 Early work 
establishing the efficacy of the tetracycline antibiotics 
was provided by Clyde et al.2 4
The antimalarial development programme of the U.S.
Army Research and Development Command, based on the Walter 
Reed Army Institute of Research (WRAIR) has carried out, 
since its inception in 1964, an unprecedented volume of 
research involving not only the mass primary screening of 
over 300,000 candidate compounds, but also basic studies 
on the biology and immunology of malaria. From this 
programme has emerged mefloquine (1.15), (a 4-quinoline- 
methanol which has an unusually long half-life in man) 
which is in an advanced state of clinical trial 
particularly in areas of Asia25 and South America26 where 
multiple drug-resistant P. falciparum is a major problem, 
and in parts of Africa27 where the problem is rapidly 
becoming established. While various other compounds have 
been described in recent literature, very few outside the 
WRAIR programme28 have passed their preclinical trial stage 
New developments were recently reviewed29'30 and have been 
further detailed by various authors.31 Among the newer 
compounds, hydroxypiperaquine (1.16), pyronaridine (1.17) 
and halofantrene (1.18) are known to be in clinical trial.3
Artemisinine (1.19) (Qinghaosu),36 an endoperoxide of 
a sesquiterpenoid lactone, is a natural constituent of the 
plant Artemesia annua. This novel compound is a potent
9blood schizontocide which bears no structural resemblance 
to any other antimalarial agent. In view of the poor 
solubility of artemisinine, semi-synthetic derivatives of 
this lactone are being evaluated. Two of these, 
artesunate (I.19a) and artemether (I.19b) are more 
soluble and active, and artesunate is currently being 
developed for further clinical trials in i.v. therapy of 
cerebral malaria.37'38
Several new 8-aminoquinolines that are being 
evaluated as possible replacements for primaquine show 
promise in having a strong blood schizontocidal as well as 
tissue schizontocidal effect. Such a compound is 
WR 225,448 (1.20).
Hanson39 has drawn attention to an area of possible 
interaction between chemotherapy and immunological 
resistance that deserves further investigation, namely the 
combination of antimalarial therapy with compounds that 
enhance immunity. A recent report on the combined use of 
chloroquine and glucan is strong support for this approach. 
Glucan is a known immunopotentiating agent, again when 
given alone or as an adjuvant.40 Against P. bergei 
malaria, it is not very effective when used alone but 
Bliznakiv (1980, cited by Hanson39) has reported that 
glucan combined with chloroquine was much more active 
against P. bergei in mice than either compound used 
separately.
With the progressive recognition of deficiencies in 
control programs based upon insecticides, drugs have 
become more important in prevention while continuing their
10
vital roles in the specific treatment of clinical attacks. 
This increased reliance upon drugs is hampered by two 
important limitations, namely (a) no single compound is 
suitable for all purposes and (b) the efficacy of 
available agents suffers from the widespread and, 
evidently increasing, occurrence of drug-resistant 
parasites.
Structures of antimalarial compounds
NHCHMe(CH2)3NEt2
(1 .3)
NH(CH2)5NHCHMe2
(b) R = NHCHMe(CH2)3NHCHMe2
(c) R = NHCHMe(CH2)3NEt2
(d) R = NHCHMe(CH2)3NH2
(e) R = NH(CH2) 3 CHMeNH2
11
R
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CH 2NHCMe 3
(1.6)
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(1.9)
12
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Me
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1-5 Immunization and Vaccination
Recent advances in biochemistry, molecular biology, 
cell culture, and the monoclonal antibody development have 
provided new tools for immunologists and parasitologists 
for the identification of target antigens for immune 
effector mechanisms. Considerable effort is now being 
directed towards the production of vaccines for malaria.
The three main approaches are development of an anti­
sporozoite vaccine to abort the infection at its source,41 
an antimerozoite vaccine to alleviate clinical disease,42 
and an antigamete vaccine which blocks transmission.43 
Reducing transmission is an essential part of any 
vaccination programme and one could envisage appropriate 
combinations of a vaccine to stop transmission and 
chemotherapy to suppress clinical malaria.
The present limitations concern the purification of 
adequate quantities of potentially 'protective' antigens 
for immunization studies. The recent successful cloning 
of the genes coding respectively for surface antigens of 
P. knowlesi and P. falciparum4 4 ' 45 and of the genes 
expressing P. falciparum schizont and merozoite specific 
polypeptides46'47 may solve the problem in the near future 
and render possible the mass production of malaria antigens 
either using the DNA recombinant technology or biochemical 
synthesis of polypeptides after elucidation of the DNA 
sequence of the malaria cloned genes. Despite encouraging 
perspectives, several problems remain to be solved before 
an effective anti-malaria vaccine can be developed for 
human use, such as the development of adjuvants acceptable
15
for human use, the production on a large scale of 
adequate malarial antigens, the definition of the role 
of antigenic diversity among various isolates of 
P. falciparum, and the extent of cross-protection with 
other plasmodia species infecting man.
1- 6 Classification of Antimalarials
The existing antimalarial drugs may be divided into 
the following categories according to the sites at which 
they act to interrupt the life cycle of plasmodia.
(a) Causal prophylactic agents
Strictly speaking these agents bring about total 
prevention of the infective stages, the sporozoites, from 
developing into pre-erythrocytic schizonts (see Fig. 1.1;
2- 4) or, in P. vivax and P. ovale, hypnozoites (Fig. 1.1; 
6-9). In practice the term 'causal prophylaxis' is 
taken to mean the blockage of development of these 
intrahepatic stages. The antifolates proguanil (1.8) and 
pyrimethamine (I.10) effectively block pre-erythrocytic 
schizogony, certainly of P. falciparum and P. malariae and 
probably of P. vivax and P. ovale. It is questionable 
whether they influence the establishment and survival of 
hypnozoites of the latter two species when used in the 
normal manner. Primaquine (I.4d), although fulfilling 
all the above three roles is, unfortunately, too toxic to 
be deployed as a causal prophylactic.
16
(b) Anti-relapse drugs (acting against latent tissue
stages, Fig. 1.1; 6-9)
This group of drugs effect radical cure, in which the 
latent tissue stages (hypnozoites) that are responsible for 
true relapses of P, vivax and P. ovale in the blood, 
sometimes years after the initial infection, are 
eliminated. At the present time the only compound used 
for this purpose is the 8-aminoquinoline, primaquine (I.4d), 
although some of its more toxic analogues such as pamaquine 
(I.4c) are also available.
(c) Blood schizontocides
Quinine (1.1) and the 4-aminoquinolines, chloroquine 
(I.2a) and amodiaquine (I.5a), all act against erythrocytic 
schizonts, as does the obsolete agent mepacrine (1.3)
(Fig. 1.1; 11-15). Mefloquine (1.15) and Qinghaosu (1.19) 
act exclusively as blood schizontocides. Pyrimethamine 
(I.10) and proguanil (1.8) are both slowly active against 
blood schizonts. The sulfas (sulphadiazine and 
sulphadoxine) are only moderately active when given alone 
but highly effective when administered in synergistic 
combination with the antifolate pyrimethamine. Primaquine 
(I.4d) also has schizontocidal activity, but only at toxic 
doses.
(d) Gametocytoeides
The gametocytes (Fig. 1.1; 21-24) of P. vivax,
P. malariae and presumably P. ovale, are killed by usual 
doses of the effective blood schizontocides, but mature 
gametocytes of P. falciparum are not affected. Primaquine
(I.4d) and quinocide (I.4e) which kill gametocytes of all
17
species, are particularly useful for interrupting 
transmission of P. falciparum.
(e) Sporontoeides
Primaquine (I.4d) as well as pyrimethamine (I.10) and 
proguanil (1.8) when given to a gametocyte carrier, are 
known to prevent or inhibit the development of oocysts 
(Fig. 1.1; 31-34) in mosquitoes feeding on that carrier.
They thus prevent the formation of sporozoites and thereby 
transmission of the disease.
1-7 Drug Resistance in Malaria
Resistance of Plasmodium falciparum to antimalarial 
drugs is emerging as one of the two most important 
technical factors obstructing the world-wide effort to 
eradicate, or at least control, the disease. The other 
major factor is entomological - viz. the diminishing 
efficacy of residual insecticidal spraying of dwellings. 
There are two reasons for the diminishing impact of 
spraying on vector populations: physiological resistance
of certain mosquito vectors to insecticides and strain 
differences or adaptive mechanisms in some anophelines 
resulting in the avoidance of sprayed surfaces.
The earliest reports of antimalarial drug resistance 
came from Brazil in 1910,48 when failures of quinine were 
suspected. Details of the dates of introduction of 
antimalarials and the first recognition of resistance to 
them are shown in Table 1.1 (data from ref. 49).
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To date, the exact mechanism as to how malaria 
parasites become resistant to various drugs is still 
unclear. However, several postulates have been put 
forward which include three major categories of change,50 
namely (a) inactivation of drug by the microorganism,
(b) decreased penetration of drug into the cell, (c) 
alteration of microbial metabolism so as to eliminate the 
step or steps previously susceptible to the drug.
An appropriately selected drug combination can be 
useful in protecting the individual components against 
resistance. Merkli et a]..51 have shown that the triple 
combination of mefloquine, pyrimethamine and sulphadoxine 
is extremely effective in delaying the emergence of 
resistance to any of the three in malaria infected mice. 
Further details on the use of drug combinations in the 
prevention of resistance have been discussed.52
1-8 Naphthyridines as Potential Antimalarials
Naphthyridines are diazanaphthalenes or pyridopyridines 
in which one nitrogen atom is present in each six-membered 
ring and none at the bridgehead positions. There are six 
possible isomers as shown:
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I-8-A 1,5-Naphthyridine Derivatives
Interest in the 4-amino-l,5-naphthyridines as potential 
prophylactic antimalarial agents has been generated by the 
structural similarity of this ring system to both 4- and 
8-aminoquinolines. Earliest report in the literature53'54 
confirmed the interesting antimalarial activity of 
4-(4'-diethylamino-1'-methylbutylamino)-1,5-naphthyridine 
(I.21a) comparable to quinine itself.
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NHCHMe (CH 2) 3NEt
(1.21)
(a) R = R 1 = H
(b) R = H, R 1 = OMe
(c) R = Cl, R 1 = H
(d) R = Cl, R 1 = OMe
Goldberg et al.55 disclosed significant antimalarial 
activity for the 4-amino-l,5-naphthyridines which are 
substituted with alkoxy groups in both 2- and 6-positions. 
McCaustland and Cheng56 in 1970 reported the synthesis of 
7-chloro-4-(4'-diethylamino-1'-methylbutylamino)-2-methoxy- 
1, 5-naphthyridine (I.21d) in which the structural features 
of both chloroquine (I.2a) and pamaquine (I.4c) were 
incorporated. Analogous compounds "5-azachloroquine"
(I.21c) and "5-azapamaquine" (I.21b) were also reported 
and their antimalarial activities evaluated.
"5-Azachloroquine" (I.21c) was found to be comparable to 
chloroquine in activity when screened for blood 
schizontocidal activity in the P. bergei - mouse model; 
it was however much less toxic than chloroquine. No 
acute toxicity was noted at a dose of 640 mg/kg whereas 
chloroquine was 100% lethal at a dose of 320 mg/kg.56
Compounds (I.21d) and (I.21b) were however less active
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than "5-azachloroquine". Nevertheless, Schmidt57 later 
confirmed compound (I.21c) was devoid of radical curative 
activity in a P. cynomolgi - Rhesus monkey model.
In a programme to expand upon the derivatives of 
4-amino-l,5-naphthyridines in an effort to secure an 
optimal prophylactic antimalarial drug, the Exxon Research 
and Engineering Company, sponsored by the U.S. Army Medical 
Research and Development Command, furnished a total of 26 
naphthyridine target and 145 naphthyridine intermediates 
for biological testing.58 One of the target structures, 
2-hydroxy-4-(5-isopropylaminopentylamino)-1,5-naphthyridine 
(1.22), proved to be curative in the Rhesus monkey infected 
with sporozoites of the B strain of P. cynomolgi at a 
dosage level of 10 mg/kg.57'58
Several unsubstituted and 2,6-disubstituted 1,5- 
naphthyridine compounds carrying double Mannich basic chains 
of p-aminophenol were explored by Chen et al. 5 9 in China. 
Some of these (I.23a), (I.23b) and (I.23c), were rather
effective in a P. bergei - mouse model.
NH(CH2) 5NHCHMe 2
(1.22)
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CHoNR
(1.23)
(a) R 1 = R 2 = H, N R 2
(b) R 1 = OMe, R 2 = Me, N R 2 = N(Et)2
(c) R 1 = OMe, R 2 = Me, N R 2 =
I-8-B 1,6-Naphthyridine Derivatives
Carroll et al_. 6 0 in 1981 described the synthesis of 
several 1,6-naphthyridine derivatives, (1.24), (I.25a) and
(I.25b).
0
NHCHMe(CH2) 3NH
OR
(1.25)
(1.24) (a) R = H
(b) R = CH2C F 3
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Both (1.24) and (I.25b) were found to be toxic at 
the minimal dose tested (40 mg/kg) when evaluated for 
antimalarial activity in the P. bergei - mouse model. 
When assayed for radical curative activity in the 
P. cynomolgi - Rhesus monkey model, (I.25b) was inactive 
at the maximal dose tested (10 mg/kg per day) and (1.24) 
was found to be less active than primaquine.
I-8-C 1,7-Naphthyridine Derivatives
Chien and Cheng61 reasoned that the electron- 
withdrawing effect produced by the Cl substituent in the 
chloroquine (I.2a) molecule may also be produced by a 
nitrogen in the ring in the place of the C-Cl group. If 
so, the 1,7-naphthyridine analogues of the 4-amino- 
quinolines may retain similar antimalarial activity. To 
test this hypothesis, they synthesized the 7-aza congeners 
of chloroquine, (I.26a), (I.26b) and an amodiaquine (I.5a) -
related analogue (I.26c).
R
(1.26)
(a) R = NHCHMe(CH2)3NEt2
(b) R = NH(CH2)3NEt2
CH2NEt2
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When evaluated for blood schizontocidal activity in 
the P. bergei - mouse model, (I.26b) was devoid of 
activity; (1.26a) and (1.26c) produced only a slight 
extension in survival time of the treated mice compared 
with the untreated controls. Neither (I.26a) nor 
(I.26c) approached the potency of chloroquine or 
amodiaquine.
I-8-D 1,8-Naphthyridine Derivatives
Antimalarial compounds with 1,8-naphthyridine as the 
heterocyclic nucleus have not been examined extensively in 
the past. However, Adams et ctl. 5 4 in 1946 first reported 
the synthesis of 7-acetamido-4-(4'-diethylamino-1'- 
methylbutylamino)-1,8-naphthyridine (1.27) as a potential 
antimalarial agent, but no biological activity was 
described.
AcNH
NHCHMe(CH2)3NEt2
(1.27)
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1-9 Trifluoromethylquinolines as Potential Antimalarials
The replacement of the 7-halogeno substituent in the 
quinoline nucleus of known antimalarials by a trifluoro- 
methyl group gives compounds which retain their potent 
activities. This was first shown62 in compound (1.28).
Soon thereafter, various fluorine-containing a-dialkyl- 
aminomethyl-2-phenyl-4-quinolinemethanol derivatives were 
prepared63 for evaluation against Plasmodium bergei in 
mice and the preliminary biological data indicated the 
fluoro compounds to be more potent at comparable doses 
than the corresponding chloro derivatives. 2— (4 —
Chlorophenyl)-a-dibutylaminomethy1-7-trifluoromethyl-4- 
quinolinemethanol (1.29) when administered to mice in a 
single subcutaneous dose was curative at 40 mg/kg.63 
Pinder and Burger6 4 also observed antimalarial activity in 
the series of a-(2-piperidyl)-2-trifluoromethyl-4-quinoline- 
methanols carrying OCH3, CH3/ or Cl in positions 6 or 8.
However, these compounds were moderately phototoxic.
With the support from the U.S. Army Medical Research 
and Development Command, the synthesis of several bis- 
(trifluoromethyl) analogues of the above soon followed65 
in which all four target compounds (I.30a), (I.30b), (1.15)
and (I.30c) were found to be curative against P. bergei in 
mice at 160 mg/kg or lower. Further toxicological, 
pharmacological and clinical data for compound (1.15) 
(mefloquine) were established and results show that it is 
therapeutically effective in single doses against both 
chloroquine-resistant and chloroquine-sensitive 
P. falciparum, with a cure rate approaching 100%. 66
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NHCHMe(CH2 )3 NEt2
(1.28) OH Bu/
H-C-CH,N
(1.29)
(a) R = 6 -CF 3
(b) R = 7 -CF 3
(c) R = 8 -CF 3 with 6 -OMe
R = 8 -CF 3 (1.15)
(1.30)
CHAPTER II
SYNTHESIS OF SOME N_4-SUBSTITUTED 2-METHOXY (AND 2- 
HYDROXY)-1,5-NAPHTHYRIDIN-4-AMINES, N4-SUBSTITUTED 
7-BROMO (AND CHLORO)-1,5-NAPHTHYRIDIN-4-AMINES 
AND 4 — [7 *-BROMO (AND CHLORO)-1' ,5'-NAPHTHYRIDIN-
4'-YLAMINO]PHENOLS.
II-1 Introduction
In view of the strong blood schizontocidal property 
and curative activity of several 1,5-naphthyridine 
derivatives, coupled with the low toxicity of "5- 
azachloroquine" described in CHAPTER I, it was decided to 
prepare further derivatives of this heterocyclic nucleus. 
Thus, it was resolved to prepare 2-methoxy (and 2-hydroxy)
1.5- naphthyridin-4-amines with various aminoalkyl side 
chains attached at N4 and similar N_4-substituted 7-bromo 
(and chloro)-1,5-naphthyridin-4-amines as well as mono- 
and di-Mannich bases derived from 4-[7'-bromo (and chloro) 
1',5'-naphthyridin-4'-ylamino]phenols.
In practice the starting materials for the 7-bromo-
1.5- naphthyridin-4-amines were obtained in much higher 
overall yield than their chloro analogues, and past 
experience15 had also shown that bromo- and chloro- 
analogues generally exhibit comparable antimalarial 
activity.
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II-2 General Methods for Synthesis of
1,5-Naphthyridines
Two principal methods are generally employed in the 
synthesis of 1, 5-naphthyridines; namely the Skraup 
reaction and the ethoxymethylenemalonic ester method.
(a) The Skraup Reaction
Various unsubstituted and substituted 1,5- 
naphthyridines (II.2) can be prepared from pyridin-3- 
amines (II.1) by application of the Skraup reaction (with 
glycerol) or modified Skraup reaction (with other 
condensing reagents such as methylacrolein and acetaldehyde). 
Unfortunately, these syntheses do not lead to the 4-halogeno-
or 4-hydroxy-l,5-naphthyridines required in this work.
Rapoport and Batcho,67 starting from pyridin-3-amine 
with glycerol under the conditions of the Skraup reaction, 
prepared 1,5-naphthyridine but no 1,7-naphthyridine 
(II.3, R = H) was observed. When a blocking group was 
present in the 2-position of the pyridin-3-amine(s) 
differing results were observed leading to the formation 
of 1,5- or 1,7-naphthyridines. 2-Halogenopyridin-3-amines 
gave 1,5-naphthyridine68 and 2-hydroxypyridin-3-amine gave 
8-hydroxy-l,7-naphthyridine.6 9
Pyridin-3-amines with groups other than halogeno or 
hydroxy in the 2-position gave only tarry products.68
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(II.2)
(b) Ethoxymethylenemalonic Ester (EMME) Method
Adaptation of the excellent quinoline synthesis of 
Adams et clI. 5 4 and Price and Roberts70 is the most 
practical preparative method for the synthesis of 
substituted 1,5-naphthyridines. This requires the 
heating of the condensation product of pyridin-3-amine or 
a substituted pyridin-3-amine with diethyl ethoxymethylene- 
malonate (EMME) in refluxing "Dowtherm A" to afford the 
ethyl 4-hydroxy-l,5-naphthyridine-3-carboxylate(s) (II.4). 
This product can be hydrolysed and decarboxylated to form 
the 1,5-naphthyridin-4-ol(s) (II.5) in good yield.54'55'70
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(II.5)
In this way, the 1,5-naphthyridin-4-ols required in this 
work were prepared.
(c) Miscellaneous Preparations
Several 2,4-disubstituted-l,5-naphthyridines can be 
prepared from 3-aminopicolinic acid or its ester with 
suitable condensing agents. Baumgarten, Su and Barkley71 
claimed that 3-aminopicolinic acid (II. 6) was converted 
by ethyl acetoacetate into the intermediate (II.7), which 
then underwent hydrolysis and decarboxylation to give 
2-methyl-l,5-naphthyridin-4-ol (II.8) but in low yield.
In an attempt to prepare 2,4-dichloro-l,5-naphthyridine 
(11.12), Oakes and Rydon72 reported that ethyl 3-amino- 
picolinate (II.9) condensed with malonic ester to give the 
intermediate (II.10) which readily underwent Dieckmann 
cyclization; hydrolysis and decarboxylation of the 
cyclized product then gave the dihydroxy-compound (II.11), 
which with phosphoryl chloride readily yielded the 
dichloro-compound (11.12).
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OH
(II.8)
CH 2 (COOEt)2
COOEt
NHCOCH 2COOEt
(II.9) (II.10)
(11.12) (II.11)
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II-3 Reactivity of Halogeno-substituents in
1,5-Naphthyridine
Kinetic data for nucleophilic substitution of various 
halogeno-1, 5-naphthyridine compounds are not available to 
date. However Oakes and Rydon,72 by application of an 
approximate quantum-mechanical treatment, were able to 
calculate that in 2,4-dichloro-l,5-naphthyridine (11.12), 
the 2-chloro substituent is more reactive towards 
nucleophiles than the chloro substituent at the 4-position. 
The predicted preferential reactivity of the 2-chloro 
substituent in (11.12) towards nucleophilic reagents was 
exhibited in its reactions with ammonia, water and 
hydrazine, in all of which only the 4-chloro-2-substituted- 
1,5-naphthyridines were obtained. The structures of the 
products derived from reaction with ammonia and water were 
established by subsequent conversion into 1,5-napthyridin- 
2-ol through the 4-(p-toluenesulfonylhydrazide).72
In a study of nucleophilic substitution of 2,4,7- 
trichloro-1,5-naphthyridine (11.13) with one equivalent of 
sodium methoxide in methanol, McCaustland and Cheng56 were 
able to use *H n.m.r. data to prove that the structure of 
the major product was 4,7-dichloro-2-methoxy-l,5- 
naphthyridine (11.14) rather than its 4-methoxy isomer
(11.15).
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Cl Cl
(11.14)
(11.15)
(11.13)
Methanolysis of 2,4-dichloro-l, 5-naphthyridine 
(11.12) in the presence of an acid catalyst has also been 
found to favour reaction at the 2-position56 so giving 
rise to 4-chloro-2-methoxy-l,5-naphthyridine (11.16) in 
good yield. In addition, the nucleophilic substitution 
of 3-bromo-8-chloro-l,5-naphthyridine with sodium 
methoxide in methanol (as described in the Experimental 
Section of this Chapter) gave the expected 3-bromo-8- 
methoxy-1,5-naphthyridine, leaving the bromo-substituent 
untouched (confirmed by XH n.m.r. and analyses data).
(11.12) (11.16)
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From these data it would appear that 4,7-dihalogeno-
1.5- naphthyridines react with nucleophiles by replacement 
of the 4-halogeno substituent but that differences in 
reactivity of halogeno substituents in the 2,4-dihalogeno-
1.5- naphthyridine would be significantly less and, 
moreover, apparently favour reaction at the 2-position 
with either methanolic hydrogen chloride or sodium 
methoxide in methanol.
II-4 Preparation of N^-Substituted 2-Methoxy
(and 2-Hydroxy)-1,5-naphthyridin-4-amines 
The method employed for the preparation of 2,4- 
disubstituted-1,5-naphthyridines involved the condensation 
of diethyl malonate with a 2-substituted pyridin-3-amine. 
Thus, ethyl 3-aminopyridine-2-carboxylate (II. 9) with 
diethyl malonate, under conditions modified from those 
described by Oakes and Rydon72 for the preparation of 2,4- 
dichloro-1,5-naphthyridine and without isolating the 
intermediate, gave 1,5-naphthyridine-2,4-diol (II.11). 
Treatment of the latter with phosphoryl chloride afforded 
2,4-dichloro-l,5-naphthyridine72 (11.12) which with
methanolic sodium methoxide at reflux gave 4-chloro-2- 
methoxy-1,5-naphthyridine (11.16) (SCHEME II-l), the 
structure of which was established as described below.
The reaction of (11.12) with methanolic hydrogen chloride 
at reflux, as described by McCaustland and Cheng,56 to 
give (11.16) proved unsatisfactory. Instead it gave 
4-chloro-l,5-naphthyridin-2-ol (11.17) which was also
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prepared by hydrolysis of (11.12) with 5 M hydrochloric 
acid in dioxan,72 as well as by hydrolysis of (11.16) with 
5 M hydrochloric acid in dioxan. Compound (11.17), when 
dechlorinated through the p-toluenesulfonylhydrazide72 
gave 1,5-naphthyridin-2-ol (11.18) (SCHEME II-2).
4-Chloro-2-methoxy-l,5-naphthyridine (11.16) reacted 
with 4-amino-2-diethylaminomethylphenol in aqueous 
solution at 100° to give 2-diethylaminomethyl-4-(2'- 
methoxy-15'-naphthyridin-4'-ylamino)phenol (11.19) and 
with a series of amines (namely 2-diethylaminoethylamine,
3- diethylaminopropylamine, propane-1,3-diamine, butane- 
1, 4-diamine, pentane-1,5-diamine and hexane-1,6-diamine) 
together with one equivalent of sodium carbonate in heptane 
in an autoclave at 160° for 20 h by replacement of the
4- chloro substituent and formation of the corresponding 
N4-substituted 2-methoxy-l,5-naphthyridin-4-amines (II.20a-f) 
(SCHEME II-3).
Brown and Lee73 have studied the thermal rearrangement 
of 2- and 4-alkoxypyrimidines to their N-alkyl isomers and 
McCaustland and Cheng56 have observed 0 to N rearrangement 
in the aminolysis of (11.16) with novaldiamine 
[IS^CHMe (CH2 ) 2 NEt2 ] alone. However the latter authors 
also found that in excess amine with one molar equivalent 
of potassium carbonate no significant rearrangement took 
place. Aminolyses, as illustrated in (SCHEME II-3), were 
carried out in the presence of one equivalent of sodium 
carbonate and no sign of rearranged product was detected.
The :H n.m.r. of the neutral molecules in deuterochloroform 
showed the methoxy group at 6 4.01-4.02, and should be
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compared with that of (11.16) at 4.07 (N-methyl groups of 
various heterocycles have shown resonances between 6 3.35 
to 4.4374); and the 13C n.m.r. spectra of the products 
(II.20a) and (II.20c) as dihydrobromides in deuterium 
oxide, showed resonances at 6 58.40 and 58.28 respectively 
which are indicative of methoxy groups.74 The resonance 
signal due to the carbon of the methoxy group has been 
found in a variety of heterocycles to occur in the range 
6 53.20 to 61.87 and that of the N-methyl group in the 
range from 34.29 to 49.62.7 4
4-Chloro-l,5-naphthyridin-2-ol (II.17)72 also reacted 
with the same series of aliphatic amines in the presence 
of sodium carbonate (as its 2-methoxy analogue but at the 
higher temperature of 180°) to give the 4-(N-substituted) 
amino-1,5-naphthyridin-2-ols (II.21a-f); but (11.17) 
failed to react with 4-amino-2-diethylaminophenol in water 
at 100° (SCHEME II-4).
Ledochowski and Chimiak7 5 reported that 9-chloro- 
acridine with butane-1,4-diamine (hydrochloride) in phenol 
at 200° gave N,N'-bis(acridin-9'-yl)butane-1,4-diamine; and 
3-chloro-7-methoxy-9-phenoxyacridine with the same reagents 
(at 100°) gave both the mono- and bis-acridinyl derivatives. 
However in the reactions illustrated in both SCHEME II-3 
and SCHEME II-4, no bis(1,5-naphthyridin-4-yl)compounds 
were obtained: analyses, integration of the *H n.m.r. and
mass spectra gave no indication of any of these products.
COOEt
(II.9)
COOEt
NHCOCH2 COOEt
u
OH
(II.11)
COOEt
(11.12) (11.16)
SCHEME II-l
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(11.16) (11.18)
SCHEME II-2
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Cl
(11.16)
(11.20)
(a) R = NH(CH2)2NEt2
(b) R = NH(CH2) 3 NEt2
(c) R = NH(CH2)3NH2 
(b) R = NH(CH2)4NH2
(e) R = NH(CH2)5NH2
(f) R = NH(CH2)6NH2
(11.19)
SCHEME II-3
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(a)
(b)
(c)
(d)
(e)
(f)
CHzNEtz
R
(11.21)
R = NH(CH2) 2NEt 2 
R = NH(CH2) 3NEt2 
R = NH(CH2)3NH2 
R = NH(CH2)4NH2 
R = NH(CH2)5NH2 
R = NH(CH2)6NH2
SCHEME II-4
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II-5 Preparation of N -Substituted 7-Bromo (and Chloro)-
1, 5-naphthyridin-4-amines 
Ethyl 7-bromo-4-hydroxy-l,5-naphthyridine-3- 
carboxylate76 (11.26) was prepared from nicotinic acid
(11.22) through 5-bromonicotinic acid (II.23),77'78 its 
amide (11.24)78 and 5-bromopyridin-3-amine (11.25) 7 8 • 79 
which was condensed with diethyl ethoxymethylenemalonate 
and ring-closed in boiling diphenyl ether (not "Dowtherm A" 
as in ref. 76) to the known ester (11.26). The latter 
(11.26), in aqueous sodium hydroxide was hydrolysed to the 
corresponding acid (11.27) which in turn was decarboxylated 
in refluxing quinoline to give 7-bromo-l,5-naphthyridin-4- 
ol (11.28). Chlorination of this hydroxy compound (11.28) 
gave 3-bromo-8-chloro-l,5-naphthyridine (11.29) in 
excellent yield (SCHEME II-5).
Ethyl 7-chloro-4-hydroxy-l, 5-naphthyridine-3- 
carboxylate56 was prepared similarly from nicotinic acid 
but the 5-bromonicotinic acid (11.23) was converted to 
5-aminonicotinic acid (11.30)77 and thence via a 
diazonium salt to the required intermediate 5-chloro- 
nicotinic acid (II.31).77 The amide, 5-chloronicotinamide,80 
also undergoes Hofmann reaction to 5-chloropyridin-3-amine81 
as for the bromo-analogue but in poor yield. The ester, 
ethyl 7-chloro-4-hydroxy-l,5-naphthyridine-3-carboxylate,5 6 
was saponified, decarboxylated and finally chlorinated to 
the required 4,7-dichloro-l,5-naphthyridine (II.32).56
Both bromochloronaphthyridine (11.29) and the dichloro- 
naphthyridine (11.32) with a series of amines in heptane at 
160° for 20 h, gave the N^-substituted 7-bromo (and chloro)
4
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-1,5-naphthyridin-4-amines (II.33a-h) and (II.34a-b) 
(SCHEME II-6).
The bromochloronaphthyridine (11.29) with aqueous 
sodium 2-diethylaminoethanethiolate or methanolic sodium 
methoxide at reflux, undergoes nucleophilic substitution 
with the replacement of its 4-chloro substituent to give 
N ,N-diethyl-2-(7'-bromo-1',5'-naphthyridin-4'-ylthio)- 
ethylamine (11.35) or 3-bromo-8-methoxy-l,5-naphthyridine 
(11.36) respectively. Nevertheless 3-bromo-8-chloro- 
1,5-naphthyridine (11.29) with one equivalent of benzene- 
1, 4-diamine in aqueous methanol at 100° gave N,N'-bis(7"- 
bromo-1",5"-naphthyridin-4"-yl)benzene-1,4-diamine (11.37) 
hydrochloride as the major product and some 4-(7'-bromo- 
1',5'-naphthyridin-4'-ylamino)aniline (11.38) as shown by 
analyses, :H n.m.r. and mass spectral data (SCHEME II-7).
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(11.26) (11.25)
V
OH OH
COOH
(11.27) (11.28)
Cl
(11.29)
SCHEME II-5
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( 1 1 . 2 3 ) ( 1 1 . 3 0 ) ( 1 1 . 3 1 )
( I I . 3 2 )
( 1 1 . 3 3 )( 1 1 . 2 9 )
( a ) R = NHCHMe( CH2 ) 3N E t 2
( b) R = NH( CH2 ) 2N E t 2
( c ) R = NH( CH2 ) 3N E t 2
( d) R = NH( CH2 ) 4N E t 2
( e ) R = NH( CH2 ) 4NH2
( f ) R = NH( CH2 ) 5NH2
(g) R = NH( CH2 ) 6NH2
( h) R = NH( CH2 ) 3NMe2
( 1 1 . 3 4 )( 1 1 . 3 2 )
( a )  R = NH( CH2 ) 2N E t 2
( b)  R = NH( CH2 ) 4 N E t 2
SCHEME I I - 6
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Cl S (CH 2) 2NEt 2
(11.29) (11.35)
(II.36)
(11.37)
(11.38)
SCHEME II-7
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II-6 Preparation of 4-[7'-Bromo (and Chloro)-
1', 5'-naphthyridin-41-ylamino]phenols
3-Bromo-8-chloro-l,5-naphthyridine (11.29), when 
heated with aqueous 4-amino-2-diethylaminomethylphenol 
at 100°, gave 4-(7'-bromo-1' ,5'-naphthyridin-4'-ylamino)- 
2-diethylaminomethylphenol (11.39). Similarly, the 
bromochloronaphthyridine (11.29) by reaction with p-amino- 
phenol hydrochloride in aqueous methanol afforded 4-(7'- 
bromo-1',5'-naphthyridine-4'-ylamino)phenol (11.40) in good 
yield. This product, with formalin in ethanol and a 
moderate amount of dimethylamine, dipropylamine or 
pyrrolidine at reflux gave the mono-Mannich bases (II.41a-c) 
respectively (SCHEME II-8).
Nevertheless, 4 —(7'-bromo-1',5'-naphthyridin-4'- 
ylamino)phenol (11.40) with ethanolic formalin and a large 
excess of dimethylamine, diethylamine, dipropylamine, 
pyrrolidine, piperidine, 2-methylpiperidine, 3,5-dimethyl- 
piperidine, morpholine or N-methylpiperazine at reflux for 
20 h gave the di-Mannich bases (II.41d-l). 4-(7'-Bromo-
1',5'-naphthyridin-4'-ylamino)-2-pyrrolidin-l”-ylmethyl- 
phenol (II.41c) when refluxed with ethanolic dimethylamine 
and formalin for 10 h afforded 4-(7'-bromo-1',5'- 
naphthyridin-4'-ylamino)-6-dimethylaminomethyl-2-pyrrolidin- 
l"-ylmethylphenol (11.42) (SCHEME II-9). However 
transaminations rendered unsatisfactory the attempted 
preparation of 4-(7'-bromo-1',5'-naphthyridin-4'-ylamino)- 
2-(diethylaminomethyl)-6-(pyrrolidin-l"-ylmethyl)phenol from 
4-(7'-bromo-1',5'-naphthyridin-4'-ylamino)-2-(diethylamino­
methyl) phenol by reflux with formalin and pyrrolidine
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in ethanol; and the attempted preparation of 4-(7'-bromo- 
1',5'-naphthyridin-4'-ylamino)-2-(diethylaminomethyl)-6- 
(dimethylaminomethyl)phenol from 4-(7'-bromo-1',5'- 
naphthyridin-4'-ylamino)-2-(diethylaminomethyl)phenol with 
formalin and dimethylamine, or from 4-(7'-bromo-1', 5'- 
naphthyridin-4'-ylamino)-2-(dimethylaminomethyl)phenol with 
formalin and diethylamine in ethanol.
Similarly, 4,7-dichloro-l,5-naphthyridine56 (11.32)
with 4-amino-2-diethylaminomethylphenol gave 4-(7'-chloro- 
1' , 5 '-naphthyridin-4'-ylamino)-2-diethylaminomethylphenol 
(11.43) and with aqueous methanolic p-aminophenol 
hydrochloride gave 4-(7'-chloro-1' ,5'-naphthyridin-4'- 
ylamino)phenol (11.44) which when refluxed with ethanolic 
formalin in large excess of dimethylamine, diethylamine, 
dipropylamine or pyrrolidine afforded the di-Mannich bases 
(II.45a-d) , respectively (SCHEME II.10).
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(11.39)(11.29)
(11.41)(11.40)
(a) R = H , R1 = CH2NMe2
(b) R = H, R 1 = CH2NPr2
(c) R = H, R1 r= c h 2n
SCHEME II-8
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(11.41)
(d) R = R1
(e) R = R1
(f) R = R :
CH 2 NMe 2 
CH2NEt2 
CH2NPr2
(g) R = R1 = CH2N
(h) R = R 1
(i) R = R 1
(j) R = R 1
(k) R = R 1
(l) R = R 1
CH2N 0W  / \CH2N N— MeW
'\ r CH2NMe2
(11.42)
SCHEME I1-9
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Cl
(11.43)
OH
(a) R = CH2NMe2
(b) R = CH2NEt2
(c) R = CH2NPr2
(d) R = rc h 2n v
SCHEME 11-10
II- 7 Experimental
Solids for analysis were dried in an oven at 100° 
(unless otherwise specified), and melting points were taken 
in Pyrex capillaries. Analyses were performed by the 
Australian National University Analytical Services Unit.
1H and 13C n.m.r. Spectra were recorded (by Dr M. D. Fenn) 
at 90 M Hz and 30° with a Jeol FX 90 Q Fourier transform 
spectrometer with digital resolution of 0.12 Hz with 
tetramethylsilane in CDCl^ or CD^SOCD^ and sodium 
3-trimethylsilylpropanesulfonate (in D20) as internal 
standards. Mass spectra were recorded on an Incos data 
system attached to a VG Micro Mass 7070 F spectrometer 
with perfluorokerosene as standard.
1,5-Naphthyridine-2, 4-diol (II.11)
1,5-Naphthyridine-2,4-diol was prepared in improved 
yield as described below from quinolinic acid through 
quinolinic acid imide,82 3-aminopyridine-2-carboxylic acid8 
and its ethyl ester83 [*H n.m.r. (CDCl^): 6 1.45, t, J 7 Hz, 
CH3CH2 ; 4.46, q, J 7 Hz, CH2CH3; 5.6, b, NH2; 7.02, q,
J4 5 8.5 Hz, J4 6 1.5 Hz, H 4; 7.16, q, J4 5 8.5 Hz, J5 g 
4.0 Hz, H 5; 8.08, q, J_ , 4.0 Hz, J „ , 1.5 Hz, H 6] by aZ) j o 4 / u
modification of the troublesome literature72 procedure.
Ethyl 3-aminopicolinate (6.0 g) was added in portions 
over 15 min to diethyl malonate (45 ml) stirred in an open 
flask at 120° and maintained at that temperature for 5 h. 
Excess malonic ester was removed under reduced pressure, 
and the residue refluxed with ethanolic sodium ethoxide 
(from 1.05 g sodium and 90 ml ethanol) for 5 h, then
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evaporated to half volume, and diluted with ether (45 ml).
The solid was filtered off, dried, powdered, 
suspended in water (9.0 ml) and refluxed with 10 M sodium 
hydroxide (21 ml) until effervescence ceased. Boiling 
water was then added dropwise to give an almost clear 
solution which was filtered, and the filtrate adjusted to 
pH c. 5.5 with acetic acid. The dense yellow precipitate 
was filtered off, washed with water and dried to give 
1,5-naphthyridine-2,4-diol (5.7 g), m.p. >360° (lit.72
>360°). lE n.m.r. (CD3SOCD3): 6 5.91, s, H 3; 7.53, q,
7,8 8.5 Hz, J 6 4.0/ ' Hz, H 7; 7.67, q, J 0 8.5/, b Hz ,
6,8 2 Hz, H 8; 00 q, Jr _ 4 Hz, Jr 0 2 Hz, HU / / U / o 6.
2.4- Dichloro-l,5-naphthyridine (11.12)
2.4- Dichloro-l,5-naphthyridine was prepared from
1.5- naphthyridine-2,4-diol (3.0 g) with phosphoryl chloride 
as described by Oakes and Rydon.72 The crude product was 
recrystallized from light petroleum (b.p. 60-80°) to give 
the dichloro compound as white crystals (2.7 g), m.p.
138-140° (lit.72 140°). 1H n.m.r. (CDCl3): 6 7.71, q, J? 8 
8.5 Hz, Jc - 4.0 Hz, H 7; 7.73, s, H 3; 8.32, q, 0 8.5 Hz,O f /  I/O
Jc o 1.5 Hz, H 8; 9.05, q, Jr _ 4.0 Hz, Jc 0 1.5 Hz, H 6.0,0 b , / b,o
4-Chloro-2-methoxy-l,5-naphthyridine (11.16)
2.4- Dichloro-l,5-naphthyridine72 (4.0 g) and methanolic
sodium methoxide (from 0.6 g sodium and 180 ml methanol) 
were refluxed for 1 h. Excess methanol was removed under 
reduced pressure and the product purified by column 
chromatography in ether over silica to give 4-chloro-2-
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methoxy-1,5-naphthyridine (2.5 g), m.p. 113-114° (lit.56
114-115°). *H n.m.r. (CDC13): 6 4.07, s, MeO; 7.27, s,
H 3; 7.59, q, J_ 0 8.5 Hz, Jc _ 4.5 Hz, H 7; 8.16, q,/ , o b , /
J_ 0 8.5 Hz, Jr Q 2 Hz, H 8; 8.87, q, Jc _ 4.5 Hz, J, 0
I/O U/O b , / b / o
2 Hz, H 6.
4-Chloro-l,5-naphthyridin-2-ol (11.17)
(A) This compound was prepared in quantity from 2,4-
dichloro-1,5-naphthyridine as described by Oakes and Rydon.72 
It has m.p. 263° (lit.72 263°). * 1H n.m.r. (CDCl^): 6 7.13,
s, H 3; 7.53, q, J„ 0 8.5 Hz, Jc n 4.5 Hz, H 7; 7.81, q,
If o b / /
J_ 0 8.5 Hz, Jc 0 1.5 Hz, H 8; 8.71, q, Jc n 4.5 Hz, Q
If o b , o b , I b f o
l. 5 Hz, H 6.
(B) 4-Chloro-2-methoxy-l,5-naphthyridine (0.4 g), 5 ^ 
hydrochloric acid (5.0 ml) and dioxan (5.0 ml) were 
refluxed for 1 h. The mixture was diluted with water, 
made basic with sodium carbonate, and evaporated to 
dryness. The residue was boiled with chloroform (3 x 50 ml), 
and the product extracted was recrystallized from ethyl 
acetate to give white crystals of 4-chloro-l,5-naphthyridin- 
2-ol (0.22 g), m.p. 262-263°, not depressed on admixture 
with the product from (A), and with the same :H n.m.r. 
spectrum as the product from (A).
This product obtained in (B) was also dechlorinated 
through the p-toluenesulfonylhydrazide as described by 
Oakes and Rydon72 to give 1,5-naphthyridin-2-ol (11.18),
m. p. 256-258° (lit. 258°,72 259°84). 1,5-Naphthyridin-
4-ol is reported to have m.p. 340°.85
55
2-Diethylaminomethyl-4-(21-methoxy-11,5'-naphthyridin- 
4 1-ylamino)phenol (11.19)
4-Chloro-2-methoxy-l,5-naphthyridine (11.16) (1.0 g)
4-amino-2-diethylaminomethylphenol dihydrochloride (1.37 g) 
water (20 ml) and ethanol (10 ml) were heated in an oil 
bath with stirring at 100° for 4 h. The mixture was 
evaporated under reduced pressure and then evaporated three 
times with water (3 x 20 ml) to remove unchanged chloro 
compound. The residue was diluted with water (20 ml), 
adjusted to pH c. 7.3 with aqueous ammonia and extracted 
with chloroform. The extract was dried (Na2 SO^) and 
evaporated to give an oil which was subjected to column and 
thin-layer chromatography in chloroform over alumina to 
give, as a yellow oil, 2-diethylaminomethyl-4-(21-methoxy- 
1 1,51-naphthyridin-4'-ylamino)phenol (0.85 g). (Found, 
for a sample dried at 20° under vacuum: C, 68.3; H, 6.9.
C20H24N4°2 requires c, 68.. 2 ; H , 6.9%) . M, 352, XH n.m.r.
(CDCIj): 6 1.11, t r j 7 H 2 c h 3ch 2 ; 2.63, q, J 7 Hz,
CH CH,; 3. 75, s, CH2N; 3.<) 9, s, Me 0; 6.37, s , H 3' ; 6.83,
d ' J5,6 8. 5 Hz, H 6; 6• 96 j, d, J3^c 2.5 Hz, H 5 3; 7. 15, q,
J3,5 2‘5 Hz, J c3 r 6 8. 5 Hz, H 5 ; 7. 48, q, J^, gV 8.5 Hz,
J6’,7’ 4.5 Hz, H 7 1r •/ 8. 03, q, J?lf 0, 8.5 Hz, J o 6' ,8' 1.5 Hz,
H 8 ' ; 8.56 , q/ J 6' ' 1 4.5 H z ,  JgI g i 1.5 Hz, H 6’ ; 9.5, b,
/
NH.
The dipicrate, prepared in ethanol, had m.p. 200-201°
(Found, for sample dried at 100° for 1 h: C, 47.7; H, 3.8;
N, 17.1. C00H0-N-. 0, , requires C, 47.4; H, 3.7; N, 17.3%). j Z jU JLU lb
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N-(21-Diethylaminoethyl)-2-methoxy-l,5-naphthyridin- 
4-amine (II.20a)
4-Chloro-2-methoxy-l,5-naphthyridine (11.16) (1.0 g),
2-diethylaminoethylamine (3.0 g), anhydrous sodium 
carbonate (0.54 g) and heptane (20 ml) were heated in an 
autoclave at 160° for 20 h, then the solvent and excess 
amine removed under vacuum, and the remaining oil 
chromatographed in chloroform over alumina. The product 
was treated with ethanolic hydrogen bromide and the 
precipitate recrystallized from ethanol to give white 
crystals of N-(21-diethylaminoethyl)-2-methoxy-l,5- 
naphthyridin-4-amine dihydrobromide (1.5 g), m.p. 169-170° 
(Found: C, 41.5; H, 5.7; Br, 36.6; N, 12.9. c15H24Br2N4° 
requires C, 41.3; H, 5.6; Br, 36.6; N, 12.8%). 1H n.m.r.
(free base in CDC13): 6 1.04, t, J 7 Hz, CH3CH2; 2.58, q,
J 7 Hz, CH2CH3; 2.76, t, J 5.5 Hz, CH2NEt2; 5.62, complex, 
CH2NH; 4.01, s, MeO; 5.97, s, H 3; 6.81, b, NH; 7.40, q,
J_ 0 8.5 Hz, J_ _ 4.0 Hz, H 7; 7.97, q, J_ _ 8.5 Hz, Jr _
If O U / / If O U/O
1.5 Hz, H 8; 8.50, q, Jr _ 4.0 Hz, Jc 0 1.5 Hz, H 6.
O  f / O / O
13C n.m.r. (dihydrobromide in D20): 6 8.15, CH3CH2; 
37.46, 49.38, CH2CH2NEt2; 47.86, CH2CH3; 58.40, CH30; 82.67, 
C 3; 126.85, C 7; 128.50, C 8; 129.88, C 4; 132.10, C 8a; 
148.14, C 6; 156.70, C 4a; 162.03, C 2.
N - (31-Diethylaminopropyl)-2-methoxy-l,5-naphthyridin- 
4-amine (II.20b)
4-Chloro-2-methoxy-l,5-naphthyridine (0.5 g), 3- 
diethylaminopropylamine (1.68 g), anhydrous sodium 
carbonate (0.28 g) and heptane were heated at 160° for
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20 h as for compound (II.20a). The product was
subjected to chromatography in ether over alumina (8 cm)
and after elution with ether, the product was eluted
with ethanol which was evaporated to give a light yellow
oil (0.51 g). M, 288. 1H n.m.r. (CDCl^): 5 1.03, t,
J 7 Hz, CH^CH^; 1.85, complex, CH2 CH2 CH2 ; 2.53, q, J 7 Hz,
CH^CH^; 2.57, complex, CH_2NEt2  ; 3.32, complex, CH^NH; 4.01,
s, MeO; 5.97, s, H 3; 7.0, b, NH; 7.42, q, J_ 0 8.5 Hz,
/ ,  0
Jc - 4.5 Hz, H 7; 7.98, q, J_ _ 8.5 Hz, Jr 0 1.5 Hz, H 8;O / /  I f  O O / O
8.49, q, Jc _ 4.5 Hz, Jc 0 1.5 Hz, H 6.O / / O / O
A sample of this oil was treated with ethanolic picric 
acid and the product recrystallized from ethanol to give 
N-(31-diethylaminopropyl)-2-methoxy-l,5-naphthyridin-4- 
amine dipicrate, m.p. 185-187° (Found: C, 44.7; H, 4.0;
N, 18.4. C28H30N10^15 rec3u^res C' 45.0; H, 4.0; N, 18.8%).
N-(3'-Aminopropyl)-2-methoxy-l,5-naphthyridin-4-amine 
(11.20c)
4-Chloro-2-methoxy-l,5-naphthyridine (0.50 g), propane-
1,3-diamine (1.9 g), anhydrous sodium carbonate (0.27 g) and
heptane (10.0 ml) were heated at 160° for 20 h. Column
and thin-layer chromatography (alumina; chloroform) gave
a light yellow oil (0.32 g). *H n.m.r. (CDCl^): 6 1.85,
complex, CH2 CH2 CH2 ; 2.86, t, 3.34, complex, CH^NH;
4.01, s, MeO; 5.98, s, H 3; 6.6, b, NH; 7.43, q, J_ 0 8.5
/ ,  0
Hz, - 4.0 Hz, H 7; 7.99, q, J_ 0 8.5 Hz, J, 0 1.5 Hz,D / / / / o b / o
H 8; 8.50, q, Jr _ 4.0 Hz, Jr 0 1.5 Hz, H 6.0 , / b , o
This oil with ethanolic hydrogen bromide gave bright 
yellow crystals of N-(3'-aminopropyl)-2-methoxy-l,5-
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naphthyridin-4-amine dihydrobromide (0.45 g) (from ethanol),
m.p. >169° (dec.) (Found: C, 36.5; H, 4.7; Br, 40.3; N,
14.0. c,0H, ^ N,0.2HBr requires C, 36.6; H, 4.6; Br, 40.5; N,12 16 4
14.2%). 13C n.m.r. (D20): 6 25.54, CH2CH2CH2; 37.05, 39.76,
CH2CH2CH2; 58.28, CH30; 81.50, C 3; 126.39, C 7; 128.28, C 8; 
129.45, C 4; 131.70, C 8a; 137.76, C 6; 156.32, C 4a; 161.44, 
C 2.
N-(4'-Aminobutyl)-2-methoxy-l,5-naphthyridin-4-amine 
(II.20d)
4-Chloro-2-methoxy-l,5-naphthyridine (0.5 g), butane-
1,4-diamine (3.0 g), anhydrous sodium carbonate (0.28 g)
and heptane (10.0 ml) were heated at 160° for 20 h.
Column and thin-layer chromatograph (alumina; methanol)
gave a light yellow oil (0.4 g). 1E n.m.r. (CDCl^): 6
1.67, complex, CH2CH2CH2CH2; 2.74, t, CH2NH2; 3.27, complex,
CH2NH; 4.01, s, MeO; 5.97, s, H 3; 6.5, b, NH; 7.44, q,
J7 8 8.5 Hz, J6 7 4.0 Hz, H 7; 7.99, q, J7 8 8.5 Hz, Jg g
1.5 Hz, H 8; 8.50, q, Jc _ 4.0 Hz, Jc 0 1.5 Hz, H 6.
0,1 0,0
This oil was treated with ethanolic hydrogen bromide 
and the product recrystallized from isopropyl alcohol 
(charcoal) to give N - (4'-aminobutyl)-2-methoxy-l,5- 
naphthyridin-4-amine dihydrobromide (0.5 g), which 
decomposed above 166° (Found: C, 38.6; H, 5.3; N, 13.7.
^13H20Br2N4^ requires C, 38.3; H, 4.9; N, 13.7%).
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N— (5'-Aminopentyl)-2-methoxy-l,5-naphthyridin-4-amine 
(II.20e)
4-Chloro-2-methoxy-l,5-naphthyridine (0.5 g) , pentane- 
1,5-diamine (3.0 g) , anhydrous sodium carbonate (0.28 g) 
and heptane (10.0 ml) were heated at 160° for 20 h.
Column and thin-layer chromatography (alumina; methanol) 
gave a yellow oil (0.45 g). :H n.m.r. (CDCl^): 5 1.57, 
complex, CH^(CH2) ; 2.68, complex, CH^NH^; 3.25, complex, 
CH^NH; 4.01, s, MeO; 5.96, s, H 3; 6.5, b, NH; 7.44, q,
J_ 0 8.5 Hz, Jr _ 4.5 Hz, H 7; 7.99, q, 0 8.5 Hz, Jr 0
/  /  O O /  /  /  /  O O / O
1.5 Hz, H 8; 8.50, q, Jr _ 4.5 Hz, 0 1.5 Hz, H 6.b , / b , o
This oil with ethanolic hydrogen bromide gave a 
precipitate which was recrystallized from ethanol (charcoal) 
to give N - (5'-aminopentyl)-2-methoxy-l,5-naphthyridin-4- 
amine dihydrobromide (0.6 g) which decomposed above 164° 
(Found, for product dried at 100° under vacuum: C, 40.1;
H, 5.4; N, 13.4. C]_4H2 2Br 2N4 ^ requires C, 39.8; H, 5.3;
N, 13.3%).
N-(6* 1-Aminohexyl)-2-methoxy-l,5-naphthyridin-4-amine
(II.20f)
4-Chloro-2-methoxy-l,5-naphthyridine (0.5 g), hexane-
I, 6-diamine (3.0 g), anhydrous sodium carbonate (0.28 g)
and heptane (10 ml) were heated at 160° for 20 h. Column 
and thin-layer chromatography (silica; methanol) gave a 
yellow oil (0.54 g). 1H n.m.r. (CDCl^): 6 1.44, b,
CH 2 (CH2)  ^CH 2 ; 2.69, complex, CH2NH2; 3.28, complex, CH2NH; 
4.02, s, MeO; 5.98, s, H 3; 6.4, b, NH; 7.45, q, g 8.5 
Hz, _ 4.0 Hz, H 7; 8.00, J_ 0 8.5 Hz, Jr 0 1.5 Hz, H 8;O / / / / O  O / O
8.51, q, Jr n 4.0 Hz, 0 1.5 Hz, H 6.
O f /  O f o
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The free base was treated with ethanolic hydrogen 
bromide and the yellow solid recrystallized from ethanol 
(charcoal) to give N - (61-aminohexyl)-2-methoxy-l,5- 
naphthyridin-4-amine dihydrobromide (0.65 g) which 
decomposed above 163° (Found, for sample dried at 100° 
under vacuum: C, 41.0; H, 5.7; N, 12.9. cg5H24Br2N4^ 
requires C, 41.3; H, 5.6; N, 12.9%).
4-(21-Diethylaminoethylamino)-1,5-naphthyridin-2-ol 
(II.21a)
4-Chloro-l,5-naphthyridin-2-ol (11.17) (0.5 g),
2-diethylaminoethylamine (1.68 g), anhydrous sodium 
carbonate (0.3 g), and heptane (10.0 ml) were heated in 
an autoclave at 180° for 20 h. The product was 
subjected to column chromatography in methanol over 
alumina and recrystallized from ethyl acetate to give 
white crystals of 4 — (2'-diethylaminoethylamino)-1,5- 
naphthyridin-2-ol (0.6 g), m.p. 155-156° (Found: C, 64.8;
H, 7.9; N, 21.6. C14H2oN4° requires C, 64.6; H, 7.7; N, 
21.5%). *H n.m.r. (CDC13): 6 1.07, t, J 7 Hz, CH3CH2;
2.61, q, J 7 Hz, CEL^CH^; 2.79, t, CH2NEt2; 3.28, complex, 
CH2NH; 5.70, s, H 3; 6.98, b, NH; 7.37, q, J? g 8.0 Hz,
Jr _ 4.5 Hz, H 7; 7.70, q, J_ 0 8.0 Hz, J, 0 1.5 Hz, H 8;
O , / / , O 0,0
8.39, q, Jr - 4.5 Hz, 0 1.5 Hz, H 6.6, / b,o
4 — (3'-Diethylaminopropylamino)-1,5-naphthyridin-2-ol 
(II.21b)
4-Chloro-l,5-naphthyridin-2-ol (0.5 g), 3-diethylamino- 
propylamine (1.8 g), anhydrous sodium carbonate (0.29 g),
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and heptane (10.0 ml) were heated at 180° for 20 h as 
described above. The yellow solid obtained was 
subjected to thin-layer chromatography (silica; methanol) 
and recrystallized from cyclohexane (charcoal) to give 
white crystals of 4-(31-diethylaminopropylamino)-1, 5- 
naphthyridin-2-ol (0.3 g), m.p. 115° (Found, for sample 
dried at 100° under vacuum: C, 65.7; H, 8.1; N, 20.6. 
C15H22N4^ requires C, 65.7; H, 8.1; N, 20.4%). *H n.m.r. 
(CDC13): 6 1.05, t, J 7 Hz, CH3CH2; 1.87, complex, 
CH2CH2CH2; 2.55, q, J 7 Hz, CH2CH3; 2.59, complex,
CH2NEt2; 3.35, complex, CH2NH; 5.68, s, H 3; 7.36, q
04 -0 00 0
0 o Hz, J r _ 4.5 Hz, H 7; 7.70, q, 00r- 8.0 Hz,
J6,8 1.5 Hz, H 8; 8.36, q, J r6 /  ^ 4.5 Hz, CO
•o 1.5 Hz,
4-(31-Aminopropylamino)-1,5-naphthyridin-2-ol (II.21c)
4-Chloro-l,5-naphthyridin-2-ol (0.5 g) , propane-1,3- 
diamine (2.05 g), anhydrous sodium carbonate (0.3 g) and 
heptane (10.0 ml) were heated at 180° for 20 h. The 
solid (0.69 g) obtained was subjected to chromatography in 
methanol over a short column of silica, and recrystallized 
from a mixture of methanol and ethyl acetate to give light 
yellow crystals of 4-(3'-aminopropylamino)-1,5- 
naphthyridin-2-ol (0.3 g), m.p. 188-189° (Found, for 
sample dried at 120° under vacuum: C, 61.0; H, 6.7; N, 25.5.
C11H14N4^ re(3uires C ' 60.5; H, 6.5; N, 25.7%). M, 218. 
lU n.m.r. (CDC13): 6 1.89, complex, CH2CH2CH3; 2.91, t, 
CH2NH2; 3.39, complex, CH^NH; 5.72, s, H 3; 6.8, b, NH;
C00ror- U| -j 00 0
0 ui K N J r _ 4.5 6,7 Hz, H 7; 7.72, q, <
u
-J 00 0
0
H z' J6,8 1.5 Hz, H 8; 0
0 00 -J J r 4.56,7 HZ' J6,8
tSJLDi—1
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4-(41-Aminobutylamino)-1,5-naphthyridin-2-ol (II.21d)
4-Chloro-l, 5-naphthyridin-2-ol (0.5 g) , butane-1,4- 
diamine (2.5 g), anhydrous sodium carbonate (0.3 g) and 
heptane (10.0 ml) were heated at 180° for 20 h. The 
product was recrystallized from water (charcoal) to give 
light yellow crystals of 4-(41-aminobutylamino)-1,5- 
naphthyridin-2-ol (0.60 g), m.p. 149-150° (Found, for 
sample dried at 100° under vacuum: C, 61.6; H, 7.0; N,
23.8. C]_2H16N4^ rec3uires C, 62.0; H, 6.9; N, 24.1%).
M + 1 , 233. 1H n.m.r. (CDCl^) : <5 1.70, complex,
CH2(CH2)2CH2; 2.78, t, CH2NH2; 3.32, complex, CH^NH; 5.71, 
s, H 3; 6.6, b, NH; 7.39, q, J_ 0 8.5 Hz, Jr _ 4.5 Hz, H 7;/, o b , /
7.75, q, J_ 0 8.5 Hz, Jr 0 1.5 Hz, H 8; 8.36, q, Jr _ 4.5/ , o o,o b,/
Hz, J, 0 1.5 Hz, H 6. b , o
4-(51-Aminopentylamino)-1,5-naphthyridin-2-ol (II.21e)
4-Chloro-l,5-naphthyridin-2-ol (0.5 g) , pentane-1,5- 
diamine (3.0 g), anhydrous sodium carbonate (0.3 g) and 
heptane (10.0 ml) were heated at 180° for 20 h. The 
product was recrystallized twice from water with charcoal 
filtration to give white crystals of 4-(51-aminopentylamino)- 
1,5-naphthyridin-2-ol (0.5 g), m.p. 157-159° (Found: C,
63.0; H, 7.3; N, 22.3. c-^H^gN^0 requires C, 63.4; H, 7.4;
N, 22.7%). M + 1, 247. lR n.m.r. (CDCl^): 6 1.54, complex, 
CH2(CH2)gCH2; 2.73, complex, CH2NH2; 3.27, complex, CH2NH; 
5.71, s, H 3; 6.5, b, NH; 7.38, q, J_ 0 8.5 Hz, J, _ 4.5 Hz,If O D f I
H 7; 7.71, q, J_ 0 8.5 Hz, Jr 0 1.5 Hz, H 8; 8.37, q, Jr _/,o b ,o b,/
1.5 Hz, H 6.4.5 Hz, J
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4-(61-Aminohexylamino)-1,5-naphthyridin-2-ol (II.21f)
4-Chloro-l, 5-naphthyridin-2-ol (0.4 g), hexane-1,6- 
diamine (2.57 g) , anhydrous sodium carbonate (0.24 g) and 
heptane (10.0 ml) were heated at 180° for 20 h. The crude 
product was extracted with ether (3 x 50 ml) and the solid 
residue was chromatographed in methanol over a short 
column of silica and recrystallized from water with 
charcoal filtration to afford white crystals of 4- (6’- 
aminohexylamino)-1,5-naphthyridin-2-ol (0.34 g), m.p.
177-178° (Found, for sample dried at 120° under vacuum:
C, 64.9; H, 7.9; N, 21.6. C}.4 H2 0 N4  ^ requires C, 64.6; H,
7.7; N, 21.5%). M,260. ^n.m.r. (CDC13): 6 1.45,
complex, CH2 (CH3)^CH2; 2.71, complex, CH^NI^; 3.29, complex, 
CH2NH; 5.71, s, H 3; 6.5, b, NH; 7.39, q, J? 8 8.5 Hz,
J. _ 4.5 Hz, H 7; 7.72, q, J_ 0 8.5 Hz, Jr 0 1.5 Hz, H 8;
D  / / / f O  O / O
8.37, q, Jc - 4.5 Hz, Jr 0 1.5 Hz, H 6.
U  / / U  / o
7-Bromo-4-hydroxy-l,5-naphthyridine-3-carboxylie acid 
(11.27)
Ethyl 7-bromo-4-hydroxy-l,5-naphthyridine-3-carboxylate7 6 
(11.26) (10.0 g) and 2.5 ^ sodium hydroxide (100 ml) were
refluxed for 1 h. The solid dissolved and a gelatinous 
precipitate was produced. This mixture was diluted with 
boiling water (300 ml) and filtered with charcoal; the 
filtrate was acidified with glacial acetic acid. After 
cooling, the precipitate (8.0 g) was filtered off, washed 
with water and dried. A sample was purified by 
reprecipitation from aqueous sodium hydroxide with glacial 
acetic acid to give 7-bromo-4-hydroxy-l,5-naphthyridine-3-
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carboxylic acid, m.p. >295° (dec.) (Found: C, 40.2; H,
2.0; Br, 29.6; N, 10.3. CgH^BrN^^ requires C, 40.2; H,
I. 9; Br, 29.7; N, 10.4%). XH n.m.r. (NaOD): 6 8.22, d,
J, 0 1.0 Hz, H 8; 8.60, br, H 2,6.
0,0
7-Bromo-l,5-naphthyridin-4-ol (11.28)
7-Bromo-4-hydroxy-l,5-naphthyridine-3-carboxylic acid 
(11.27) (8.0 g), was added in portions over 10 min to
stirred refluxing quinoline (400 ml), and the mixture 
refluxed for 1 h. The mixture was cooled and diluted with 
acetone (1200 ml), and the precipitate was filtered off, 
washed with acetone and dried. The product was 
reprecipitated from aqueous sodium hydroxide with glacial 
acetic acid to give a white solid (6.0 g). A sample was 
purified for analysis by sublimation and gave 7-bromo-l,5- 
naphthyridin-4-ol, m.p. >360° (Found: C, 43.1; H, 2.3;
N, 12.2. CgH5BrN20 requires C, 42.7; H, 2.2; N, 12.4%).
1E n.m.r. (NaOD; 90°): 6 6.64, d, J2 3 6 Hz, H 3; 8.29, d, 
Jn  ^ 6.0 Hz, H 2; 8.33, d, Jc 0 2 Hz, H 8; 8.65, d, J, 0
Z f «0 O / Ö D / O
2 Hz, H 6.
3-Bromo-8-chloro-l,5-naphthyridine (11.29)
7-Bromo-l,5-naphthyridin-4-ol (11.28) (7.0 g) and
phosphoryl chloride (200 ml) were refluxed for 10 h; excess 
phosphoryl chloride was distilled under reduced pressure 
and the residue poured onto ice. This cold mixture was 
neutralized with aqueous ammonia, and the solid was 
filtered off, washed with water and dried. It was 
recrystallized from heptane to give white needles of
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3-bromo-8-chloro-l,5-naphthyridine (6.4 g) , m.p. 181-183° 
(Found: C, 39.7; H , 1.6; N, 11.3. Cgl^BrCl^ requires C,
39.4; H, 1.7; N, 11.5%) * 1H n.m.r. (CDCl^):: 6 7.77
J r  5.06 ,7 Hz, H 7; 8.62, d, J2 4 2.0 Hz, H 4; 8.85, d
J r  -7 5.06 ,7 Hz, H 6; 9.07, d, J2 4 2 Hz, H 2.
7-Bromo-N-(41-diethylamino-11-methylbutyl)-1,5- 
naphthyridin-4-amine (II.33a)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine (11.29) 
(0.5 g) , 5-diethylaminopentan-2-amine (3.25 g) and heptane 
(10.0 ml) were heated in an autoclave at 160° for 20 h. The 
reaction mixture was washed out with methanol and the 
solvent evaporated. The excess of amine was then removed 
by distillation at c. 100°/0.5 mm. The residue was 
subjected to thin-layer chromatography (alumina; chloroform), 
and gave the product as a light yellow oil (0.5 g).
1H n.m.r. (CDClg): 6 1.01, t, J 7 Hz, CH3CH2; 1.33, d,
J 6.5 Hz, CH^CH; 1.62, complex, Cf^CI^CHMe; 2.52, q,
J 7 Hz, CH^CH^; 2.50, complex, CH2NEt2; 3.62, complex, CH; 
6.52, d, Jn 0 5.5 Hz, H 3; 8.36, d, Jc 0 2 Hz, H 8; 8.48,^ ^  J O f o
d, J0 0 5.5 Hz, H 2; 8.65, d, J. 0 2 Hz, H 6.O / O
The 7-bromo-N-(4'-diethylamino-11-methylbutyl)-1,5- 
naphthyridin-4-amine dipicrate, prepared in and 
recrystallized from ethanol, had m.p. 220-222° (Found:
C, 42.3; H, 3.8; Br, 9.9; N, 16.8. C29H 3iBrNio°14 re(3uires 
C, 42.3; H, 3.8; Br, 9.7; N, 17.0%).
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7-Bromo-N-(21-diethylaminoethy1)-1,5-naphthyridin- 
famine (II.33b)
3-Bromo-8-chloro-l, 5-naphthyridine (0.5 g), 2- 
diethylaminoethylamine (2.5 g) and heptane (10.0 ml) were 
heated at 160°, and the product was purified as for 
compound (II.33a) to give a yellow oil (0.6 g). 1H n.m.r.
(CDC13): 6 1.08, t, J 7 Hz, CH3CH2; 2.63, q, J 7 Hz,
CH_2CH3; 2.81, complex, CH2NEt2; 3.33, complex, CH 2 NH; 6.50, 
d, J_ _ 5.5 Hz, H 2; 7.0, br, NH; 8.37, d, J , „ 2 Hz, H 8;
Z  f «3 0 , 0
8.51, d, Jn 0 5.5 Hz, H 3; 8.69, d, Jr 0 2.0 Hz, H 6.Z ^  j b ^  o
This oil with ethanolic hydrogen bromide gave 7-bromo- 
N- (2'-diethylaminoethyl)-1,5-naphthyridin-4-amine 
dihydrobromide, m.p. 274-276° (from ethanol) (Found:
C, 34.9; H, 4.4; Br, 49.4; N, 11.2. ci4H21Br3N4 re<luires 
C, 34.7; H, 4.4; Br, 49.4; N, 11.5%).
7-Bromo-N-(31-diethylaminopropyl)-1,5-naphthyridin- 
4-amine (II.33c)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine (0.5 g), 
3-diethylaminopropylamine (3.0 g) and heptane (10.0 ml) was 
heated at 160° and the product was purified as for compound 
(II.33a) to give a light yellow oil (0.6 g). XH n.m.r. 
(CDCl^) : 6 1.06, t, J 7 Hz, CH^CH^- 1.88, complex,
CH2CH2CH2; 2.57, q, J 7 Hz, CH_2CH3; 2.61, complex, CH2NEt2; 
3.36, complex, CH2NH; 6.48, d, J2 3 5.5 Hz, H 3; 7.6, br,
NH; 8.35, d, Jr 0 2 Hz, H 8; 8.48, d, J„ 0 5.5 Hz, H 2;
0 ^ 0  Z* f o
8.65, d, Jr 0 2 Hz, H 6.
0,0
A portion of this oil with ethanolic hydrogen bromide 
gave 7-bromo-N- (31-diethylaminopropyl)-1,5-naphthyridin-
4-amine dihydrobromide, m.p. 214-216° (from ethanol)
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(Found: C, 36.6; H, 4.7; Br, 48.1; N, 11.5. C-^H^BrN^.2HBr 
requires C, 36.1; H, 4.6; Br, 48.0; N, 11.2%).
7-Bromo-N-(41-diethylaminobutyl)-1, 5-naphthyridin- 
4-amine (II.33d)
3-Bromo-8-chloro-l,5-naphthyridine (0.5 g) , 4- 
diethylaminobutylamine (1.5 g) and heptane (10.0 ml) were 
heated in an autoclave at 160° for 20 h and the product 
purified as described for compound (II.33a). The 
7-bromo-N-(41-diethylaminobutyl)-1,5-naphthyridin-4-amine 
(0.58 g) was obtained as a yellow oil. (Found: C, 55.0;
H , 6.8; N, 16.0. C]_gH2 3 B r N 4 requires C, 54.7; H , 6.6; N, 
16.0%). lR n.m.r. (CDC13): 6 1.02, t, J 7 Hz, CH3CH2;
I. 70, complex, CH2 (CH2)2CH2; 2.49, q, J 7 Hz, CH3CH2; 2.50,
complex, CH2NEt2; 3.34, complex, NHCH_2; 6.50, d, J2 3 5.5
Hz, H 3; 8.36, d, g 2 Hz, H 8; 8.50, d, J2 3 5.5 Hz,
H 2; 8.65, d, Jr 0 2 Hz, H 6. The dihydrobromide,b,o ------------------
prepared in and recrystallized from ethanol had m.p. 
237-239° (Found: C, 37.5; H, 4.8; N, 10.9. C16H23BrN4.2HBr 
requires C, 37.5; H, 4.9; N, 10.9%).
4-(7 *-Bromo-11,51-naphthyridin-41-ylamino)butylamine 
(II.33e)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine 
(0.5 g), butane-1,4-diamine (4.0 g) and heptane (10.0 ml) 
was heated at 160°, and the product was purified as 
described for compound (II.33a) to give a low-melting 
semi-solid (0.45 g). 1E n.m.r. (CDC13): 6 1.71, complex, 
CH2 (CH2) 2CH2; 2.78, complex, CH2NH2; 3.31, complex, CH_2NH;
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6.49, d, J2, 3, 5.5 Hz, H 3'; 6.6, br, NH; 8.36, d,
ol 2.0 Hz, H 8'; 8.50, d, J0, 5.5 Hz, H 2'; 8.65,u  ^o 2 f 2
d, J., OI 2.0 Hz, H 6'. M + 1, 296. b , o
This product with ethanolic hydrogen bromide gave 
4 — (7'-bromo-11,51-naphthyridin-4'-ylamino)butylamine 
dihydrobromide, m.p. 225-227° (from ethanol) (Found:
C, 32.3; H, 3.9; N, 12.4. C^H-^BrN^ . 2HBr requires C, 31.5;
H, 3.8; N, 12.3%).
5- (7'-Bromo-1',51-naphthyridin-41-ylamino)pentylamine 
(II.33f)
3-Bromo-8-chloro-l,5-naphthyridine (0.5 g) with 
pentane-1,5-diamine (4.0 g) and heptane (10.0 ml) gave a 
low-melting semi-solid (0.3 g). 1H n.m.r. (CDCl^): 6
I. 45, complex, CH^(CH^)3CH2; 2.73, complex, CH^N^; 3.30, 
complex, CH^NH; 6.49, d, J^ , 3, 5.5 Hz, H 3'; 6.6, br,
NH; 8.36, d, J,, OI 2 Hz, H 8'; 8.50, d, J„, 5.5 Hz,o ^ o  2 f 2)
H 2'; 8.65, d, J_ , of 2 Hz, H 6'. M + 1, 310.b , o
The 5-(71-bromo-1',5'-naphthyridin-41-ylamino)- 
pentylamine dihydrobromide, prepared in and recrystallized 
from ethanol, had m.p. 244-246° (Found: C, 33.4; H, 4.1;
N, 11.4. C^H-^Br^N^ requires C, 33.1; H, 4.1; N, 11.9%).
6- (71-Bromo-1',5'-naphthyridin-41-ylamino)hexylamine 
(II.33g)
6-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)hexylamine 
was prepared from 3-bromo-8-chloro-l,5-naphthyridine (0.5 g) 
and hexane-1,6-diamine (5.0 g) in heptane (10.0 ml). The 
product was purified as described for compound (II.33a)
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and was obtained as a low-melting semi-solid (0.45 g).
*H n.m.r. (CDCl^) : 6 1.60, complex, CE^ (CH^) ' 2.70,
complex, CH2NH2; 3.29, complex, CH^NH; 6.50, d, 3,
5.5 Hz, H 3'; 8.37, d, J-, ol 2.0 Hz, H 8'; 8.50, d,0 , o
Jol _, 5.5 Hz, H 2'; 8.66, d, Jc, OI 2.0 Hz, H 6'. M, 323.^ / J D , O
This product with ethanolic hydrogen bromide gave
6- (7 *-bromo-11,51-naphthyridin-4'-ylamino)hexylamine 
dihydrobromide, m.p. 195-197° (from ethanol) (Found:
C, 35.2; H, 4.5; N, 11.4. C^^H^^BrN^.2HBr requires C, 34.7; 
H, 4.4; N, 11.6%).
7- Bromo-N- (3'-dimethylaminopropyl)-1,5-naphthyridin- 
4-amine (II.33h)
7-Bromo-N-(31-dimethylaminopropyl)-1,5-naphthyridin- 
4-amine was prepared from 3-bromo-8-chloro-l,5- 
naphthyridine (0.5 g) and 3-dimethylaminopropylamine (2.0 g) 
in heptane (10.0 ml). The product was purified as 
described for compound (II.33a) and was obtained as a 
yellow oil (0.6 g). XH n.m.r. (CDCl^): 6 1.88, complex, 
C^ C H ^ C ^ ;  2.26, s, Me2N; 2.43, complex, Ctb^Niy^; 3.36,
complex, CH2NH; 6.51, d, J2 3 5.5 Hz, H 3; 7.1, br, NH;
8.35, d, J, 0 2
0,0
Hz, H 8; 8.49, d, J 5.5 Hz, H 2; 8.65,
d, J6 8 2 Hz, H 6.
7-Bromo-N-(31-dimethylaminopropyl)-1,5-naphthyridin- 
4-amine dihydrobromide prepared in, and recrystallized from, 
ethanol had m.p. 258-260° (Found: C, 33.2; H, 4.2; N, 11.8. 
C13H19Br3N4 rec3u -^res C ' 33.1; H, 4.1; N, 11.9%).
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7-Chloro-N-(2'-diethylaminoethyl)-1,5-naphthyridin- 
4-amine (II.34a)
4.7- Dichloro-l,5-naphthyridine56 (11.32) (0.4 g),
2-diethylaminoethylamine (1.2 g) and heptane (10.0 ml) 
were heated and the product purified as for compound 
(II.33a) to give 7-chloro-N-(2'-diethylaminoethyl)-1,5- 
naphthyridin-4-amine (0.48 g) as a brownish orange oil. 
(Found: C, 60.5; H, 7.1; N, 20.0. C-^H^CIN^ requires
C, 60.3; H, 6.9; N, 20.1%). lE n.m.r. (CDC13): 6 1.06, 
t, J 7 Hz, CH3CH2; 2.61, q, J 7 Hz, CH3CH2; 2.79, t, J 6 
Hz, CH2NEt2; 3.34, complex, CH^NH; 6.48, d, J2 3 5.5 Hz,
H 3; 7.0, b, NH; 8.17, d, Jc 0 2 Hz, H 8; 8.51, d, J. 0
D , O Z ^ J
5.5 Hz, H 2; 8.60, d, Jß 8 2 Hz, H 6.
The dihydrobromide, prepared in and recrystallized 
from ethanol, had m.p. 265-267° (Found: C, 38.2; H, 4.8;
N, 12.4. C14H19C1N4.2HBr requires C, 38.2; H, 4.8; N,
12.7%).
7-Chloro-N-(4'-diethylaminobuty1)-1,5-naphthyridin- 
4-amine (II.34b)
4.7- Dichloro-l,5-naphthyridine (0.4 g), 4-diethylamino- 
butylamine (1.5 g) and heptane (10.0 ml) were heated at 160° 
for 20 h and the mixture worked up as for compound (II.33a) 
as described above, to give 7-chloro-N-(4'-diethylamino- 
butyl)-1,5-naphthyridin-4-amine (0.47 g) as a brownish 
yellow oil. (Found: C, 62.6; H, 7.8; N, 18.0. C16H23C1N4 
requires C, 62.6; H, 7.6; N, 18.3%). XH n.m.r. (CDC13):
6 1.02, t, J 7 Hz, CH3CH2; 1.70, complex, CH2 (CH2) 2<3H2 ;
2.53, q, J 7 Hz, CH3CH_2; 2.57, complex, CH2NEt2; 3.33,
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complex, CH^NH; 6.47, d, J2 3 5.5 Hz, H 3; 6.7, b, NH;
8.16, d, Jr 0 2 Hz, H 8; 8.50, d, J„ 5.5 Hz, H 2; 8.54,
0/0 A f o
d, J. 0 2 Hz, H 6.
0,0
The dihydrobromide, prepared in ethanolic hydrogen 
bromide, and recrystallized from propan-2-ol had m.p. 210-212° 
(Found: C, 40.8; H, 5.4; N, 11.7. ^-^H^CIN^. 2HBr requires 
C, 41.0; H, 5.4; N, 11.9%).
N,N-Diethyl-2-(71-bromo-11,51-naphthyridin-41-ylthio)- 
ethylamine (11.35)
3-Bromo-8-chloro-l,5-naphthyridine (11.29) (0.3 g)
and 2-diethylaminoethylmercaptan hydrochloride (0.25 g) in 
a solution of sodium hydroxide (0.12 g) in ethanol (15 ml) 
were refluxed for 3 h. The mixture was evaporated, the 
product extracted into chloroform, and subjected to thin- 
layer chromatography (alumina; chloroform). It gave 
N,N-diethyl-2-(7'-bromo-11,51-naphthyridin-41-ylthio)- 
ethylamine (0.33 g) as a brownish-yellow oil which slowly 
crystallized on standing. It had m.p. 64-65° (Found:
C, 49.3; H, 5.4; N, 12.3. C-^H^gBrN^S requires C, 49.4; H,
5.3; N, 12.3%). *H n.m.r. (CDClg): 6 1.08, t, J 7 Hz, 
CHgCH2; 2.64, q, J 7 Hz, CH^CH^; 3.05, complex, CH2CH2;
7.37, d, J2 3 5 Hz, H 3'; 8.51, d, Jg 8 2 Hz, H 8'; 8.72, 
d, J2 3 5 Hz, H 2'; 8.91, d, Jg 8 2 Hz, H 6'.
3-Bromo-8-methoxy-l,5-naphthyridine (11.36)
3-Bromo-8-chloro-l,5-naphthyridine (0.2 g) was 
refluxed with methanolic sodium methoxide (from 0.2 g 
sodium and 20 ml methanol) for 2 h, then the solvent was
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evaporated. The product was extracted into chloroform 
and subjected to thin-layer chromatography (alumina; 
chloroform), and recrystallized from cyclohexane to give 
white needles of 3-bromo-8-methoxy-l, 5-naphthyridine 
(0.12 g), m.p. 167-169° (Found: C, 45.1; H, 2.9; N, 11.7. 
CgH^Br^O requires C, 45.2; H, 2.9; N, 11.7%). 1H n.m.r.
(CDC13): 6 4.15, s, MeO; 7.00, d, Jg ? 5.5 Hz, H 7; 8.54, 
d, J0 . 2.0 Hz, H 4; 8.82, d, Jr _ 5.5 Hz, H 6; 8.95, d,
^  * U  / /
J2 4 2 Hz, H 2.
4-(71-Bromo-11,51-naphthyridin-4'-ylamino)aniline (11.38), 
and N,N 1 -Bis (7"-bromo-1" , 5,l-naphthyridin-4"-yl) benzene- 
1,4-diamine (11.37) as the hydrochloride.
3-Bromo-8-chloro-l,5-naphthyridine (0.5 g, 0.002 mol), 
benzene-1,4-diamine dihydrochloride (0.38 g, 0.002 mol), 
water (20.0 ml) and methanol (5.0 ml) were heated with 
stirring in an oil bath at 100° for 2 h. After cooling 
the reaction mixture, the yellow precipitate was filtered 
off and recrystallized from water (which was adjusted with 
hydrochloric acid to pH 2) to give yellow crystals of 
N,N' -bis (7"-bromo-1" . 51 -naphthyridin-41 -yl) benzene-1,4- 
diamine hydrochloride (0.30 g), m.p. >360° (Found: C,
47.5; H, 2.7; N, 15.2. C22H14Br2N6 • HC1 requires C, 47.3;
H, 2.7; N, 15.1%). M, 522. lE n.m.r. (CD3SOCD3): 6 4.69, 
d, J2„ 3„ 6.5 Hz, H 3"; 5.17, s, H 2,3,5,6; 6.12, d,
J_„ „„ 6.5 Hz, H 2"; 6.25, d, Jr„ _„ 2 Hz, H 8"; 6.63, d,Z  ^j o f o
J6„ 8„ 2 Hz, H 6".
The filtrate from the reaction mixture above was 
adjusted to pH 8-9; the precipitate was filtered off,
washed with water, dried and recrystallized from ethanol 
to give yellow needles of 4-(71-bromo-l1,51-naphthyridin-
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4 1-ylamino)aniline (0.2 g), m.p. 215-216° (Found: C,
53.4; H, 3.6; N, 17.6. C]_4 H ]_]_B r N 4 requires C, 53.4; H, 3.5; 
N, 17.8%). M + 1, 316. *H n.m.r. (CDCl^) : <$ 6.75, d,
J2 3 8.5 Hz, H 2,6; 6.84, d, J2 , 3 , 5.5 Hz, H 3'; 7.16, d,
, 8.5 Hz, H 3,5; 8.14, br, NH; 8.41, d, J-, ol 2.0 Hz,^ ^  J D / O
H 8'; 8.48, d, J„, OI 5.5 Hz, H 2'; 8.74, d, , OI 2 Hz,^  ^j b / o
H 6 ' .
4-(71-Bromo-l1,51-naphthyridin-41-ylamino)-2- 
diethylaminomethylphenol (11.39)
3-Bromo-8-chloro-l,5-naphthyridine (0.3 g, 0.0013 mol), 
4-amino-2-diethylaminomethylphenol dihydrochloride 
(0.33 g, 0.0013 mol) and water (45.0 ml) were heated with 
stirring in an oil bath at 100° for 2 h. The cooled 
reaction mixture was adjusted with aqueous ammonia to 
pH 7-8, and the dense yellow precipitate was filtered off, 
washed with water and dried. It was recrystallized from 
cyclohexane to give yellow crystals of 4 — (71-bromo-l',51 - 
naphthyridin-4'-ylamino)-2-diethylaminomethylphenol (0.4 g), 
m.p. 163-165° (Found: C, 56.6; H, 5.3; Br, 20.0; N, 13.7. 
C19H21BrN4° re<3u -^res c ' 56.9; H, 5.3; Br, 19.9; N, 14.0%).
*H n.m.r. (CDC13): 6 1.14, t, J 7 Hz, CH_3CH2; 2.67, q,
J 7 Hz, CH2CH3; 3.80, s, CH2N; 6.86, d, J2 , 3, 5.5 Hz, H31; 
6.87, d, Jc c 8 Hz, H 6; 6.99, d, J- _ 2.5 Hz, H 3; 7.17, 
q, J3 5 2.5 Hz, J5 6 8 Hz, H 5; 8.2, br, NH; 8.44, d,
J,, OI 2 Hz, H 8'; 8.48, d, J0, 5.5 Hz, H 2'; 8.74, d,b f o Z  ^j
J6' ,8' 2 Hz, H 6'.
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4-(71-Bromo-11, 5'-naphthyridin-4'-ylamino)phenol 
(11.40)
3-Bromo-8-chloro-l,5-naphthyridine (2.0 g) , 
p-aminophenol hydrochloride (1.2 g), water (40.0 ml) and 
methanol (20.0 ml) were heated with stirring in an oil 
bath at 100° for 2 h. The methanol was then evaporated 
under reduced pressure and the remaining aqueous solution 
was adjusted to pH 8 with ammonium hydroxide. The yellow 
precipitate which formed was filtered off, washed with 
water, dried, and recrystallized from methanol to give 
4-(71-bromo-11,51-naphthyridin-41-ylamino)phenol (2.5 g), 
m.p. 245-247° (Found: C, 53.6; H, 3.2; N, 13.2.
C14H10BrN3° requires c, 53.2; H , 3.2; N , 13 .3%) • *H n.:
(CD3SOCD3): 6 6.86, d, J2,3 9 Hz, H 2,6; 6. 86, d, J2',3'
5.5 Hz, H 3' » 7.23, d , J2,3 9 Hz, H 3,5; 8. 44, d, J2',3'
5.5 Hz, H 2' ' 8.48, d, J6 ’,8' 2 Hz, H 8' ; 8.88, d ' J6 ’,8
2 Hz, H 6 ' ; 9. 2 , b, NH; 9.4, b, OH.
4-(7'-Bromo-1*,51-naphthyridin-4'-ylamino)-2- 
dimethylaminomethylphenol (II.41a)
4-(7'-Bromo-1',51-naphthyridin-4'-ylamino)phenol (11.40) 
(0.5 g), formalin (2.0 ml; 36%), and ethanolic dimethylamine 
(1.0 ml; 33%) in ethanol (10.0 ml) were refluxed with 
stirring for 20 h. The reaction mixture was evaporated 
under reduced pressure and the residue purified by thin- 
layer chromatography (silica; methanol) to give an oil 
(0.25 g). 1H n.m.r. (CDCl^): 6 2.37, s, Me2N; 3.66, s,
CH2N; 6.85, d, J2 , 3 , 5.5 Hz, H 3'; 6.88, d, J5 6 8.5 Hz,
0 c 3 Hz, H 3; 7.18, q, J_ _ 3 Hz, J_ c
 ^/ J j ^ J D , DH 6; 6.97, d , J 8.5
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Hz , H 5; 8.2, b, NH; n3 0 00 J6',8' 2.0 Hz, H 8'; 8.47,
d, J2 ', 3 1, 5.5 Hz, H 2'; 8.71, d, Jgt 0 , 2 Hz, H 6'; 9.8,/ 0
b, OH.
This oil was treated with ethanolic hydrogen bromide
and the product recrystallized from ethanol to give yellow
crystals of 4-(7* 1-bromo-11,51-naphthyridin-4'-ylamino)-2-
dimethylaminomethylphenol dihydrobromide (0.3 g) , m.p.
>305° (dec.) (Found: C, 38.4; H , 3.7; N , 10.4. C, -7H1 nBr_N.
J- / -L y 3  4
requires C, 38.2; H, 3.6; N, 10.5%).
4-(71-Bromo-11,5'-naphthyridin-41-ylamino)-2- 
dipropylaminomethylphenol (II.41b)
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)phenol (0.5 g), 
dipropylamine (0.48 g) , formalin (2.0 ml; 36%) and ethanol 
(10.0 ml) were refluxed with stirring for 20 h and the 
mixture was worked up as described for compound (II.41a).
The product was purified by thin-layer chromatography 
(alumina; chloroform then silica; ethanol) and 
recrystallized from light petroleum (b.p. 60-80°) to give 
yellow crystals of 4 — (7'-bromo-11,51-naphthyridin-41 - 
ylamino)-2-dipropylaminomethylphenol (0.15 g), m.p. 138-139°
(Found: C, 58.7; H , 5.9; N, 13.2. C21H25BrN4° requires C,
58.7; H, 5.9; N, 13.1%). l U n.m.r. (CDC13): 6 0.92, t,
J 7 Hz, CH3CH2CH2; 1.60, complex, CH3CH2CH2; 2.47, complex, 
CH3CH2CH2; 3.79, s, CH2N; 6.87, d, J2 , 3, 5.5 Hz, H 3';
1, J- c 2.5 Hz, H 3; 7.17,
J / J
6.87, d, J.3 /, 8.5 Hz, H 6; 6.97 6
q, J 3/ 2.5D Hz, J5 6 8.5 Hz, H
00•o 2 Hz, H 8'; 8.49, d, J2 ,
CO O^
2 Hz, H 6'; 9.4, b , OH.
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4-(71-Bromo-11,5'-naphthyridin-41-ylamino)-2- 
pyrrolidin-l"-ylmethylphenol (II.41c)
4 — (71-Bromo-1' ,5'-naphthyridin-4'-ylamino)phenol 
(0.5 g), pyrrolidine (0.15 g) , formalin (2.0 ml; 36%) and 
ethanol (10.0 ml) were refluxed with stirring for 10 h 
and the mixture was worked up and purified as described 
for compound (II.41a). The oil (0.27 g) [ l U  n.m.r. 
(CDCl^) : <5 1.86, complex, H 3" ,4"; 2.66, complex, H 2", 5"; 
3.83, s, CH2N; 6.84, d, J2, 3, 5.5 Hz, H 3'; 6.86, d,
Hz, H 6; 6.96, d, J_ _ 2J / D .5 Hz, H 3; 7.15, q, J3,5
, Jc c 9 Hz, H 5; 8.2, b,«D f vD NH; 8.40, d, J6' ,8' 2 Hz,
8.47, d, J2, 3, 5.5 Hz, H 2'; 8.70, d, J6- / 8 ' 2 Hz,
H 6'; 9.5, b, OH.] was treated with ethanolic hydrogen 
bromide and the solid recrystallized from ethanol to give 
4-(71-bromo-1',51-naphthyridin-41-ylamino)-2-pyrrolidin- 
1"-ylmethylphenol dihydrobromide, m.p. 318° (dec.)
(Found: C, 41.0; H, 3.8; Br, 42.8; N, 9.6. c19H2 iBr3N40 
requires C, 40.7; H, 3.8; Br, 42.7; N, 10.0%).
4-(71-Bromo-1',5'-naphthyridin-41-ylamino)-2,6- 
bis(dimethylaminomethyl)phenol (II.41d)
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)phenol 
(0.5 g), formalin (10 ml; 36%) and ethanolic dimethylamine 
(30 ml; 33%) were refluxed with stirring for 20 h. The 
product was isolated as described above and purified by 
thin-layer chromatography (alumina; chloroform) to give 
4 — (7'-bromo-1',51-naphthyridin-4'-ylamino)-2,6-bis- 
(dimethylaminomethyl)phenol (0.5 g) as a yellow oil. 
(Found: C, 55.4; H, 5.8; N, 16.0. C20H24BrN5° requires
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55.8; H , 5.6; N, 16.3%). 1H n.m.r. (CDC13); 6 2.33,
Me2N ; 3.57, s, CH2N; 5.36, d, J2, 3, 5.5 Hz, H 3';
7.06, S, H 3,5; 8.2, b, NH; 8.41, d, J6, 8, 2 Hz , H 8* ;
cr>00 d, J2',3' 5.5 Hz, H 2'1; 8.73, d, Jgl gl 2 Hz, H 6
The tripicrate was prepared in, and recrystallized
from ethanol. It had m.p. 152-153° (Found: C, 41.0; H,
3.1; N, 17.1. ConH„„BrN[-0.3 (C.H^N^O^) requires C, 40.8;
Z 0 2 4  5 b J j /
H, 3.0; N, 17.5%) .
4 —(71-Bromo-11 ,5'-naphthyridin-41-ylamino)-2,6-bis- 
(diethylaminomethyl)phenol (II.41e)
4 — (7'-Bromo-1' , 5 '-naphthyridin-4'-ylamino)phenol 
(0.5 g), formalin (5.0 ml; 36%), diethylamine (5.0 ml) and 
ethanol (10.0 ml) were refluxed with stirring for 20 h and 
worked up, and the product purified as for compound (II.41a) 
to give a yellow oil (0.7 g) . 1H n.m.r. (CDCl^) : <5 1.10,
t, J 7 Hz, CH3CH2 ' 2.62, q, J 7 Hz, CH3CH2; 3.71, s, CH
6.89, d, J2, 3, 5 Hz, H 31; 7.12, s, H 3,5; 8.2, b, NH;
8.40, d, J6, ^ 8, 2 Hz, H 8'; 8.48, d, J2’,3' 5 Hz, H 2';
8.72, d, J6, ^ 8, 2 Hz, H 6'.
A sample of this oil with ethanolic picric acid gave 
a yellow precipitate which was recrystallized from ethanol 
to yield 4-(71-bromo-11,51-naphthyridin-4'-ylamino)-2,6- 
bis(diethylaminomethyl)phenol tripicrate, m.p. 191-193° 
(Found: C, 42.6; H, 3.4; N, 16.4. c24H32BrN5°* 3 (CgH^C^) 
requires C, 43.0; H, 3.5; N, 16.7%).
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4-(71-Bromo-11, 5 1-naphthyridin-41-ylamino)-2,6- 
bis(dipropylaminomethyl)phenol (II.41f)
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)phenol 
(0.5 g), formalin (5.0 ml; 36%), dipropylamine (5.0 ml) 
and ethanol (10.0 ml) were refluxed with stirring for 
20 h. The 4-(7'-bromo-1',51-naphthyridin-4'-ylamino)- 
2,6-bis(dipropylaminomethyl)phenol (0.5 g) was isolated as 
a yellow oil after thin-layer chromatography (alumina; 
ethanol) (Found: C, 61.8; H, 7.5; N, 12.7. C28H40BrN5° 
requires C, 62.0; H, 7.4; N, 12.9%). XH n.m.r. (CDCl^);
6 0.89, t, J 7 Hz, CH3CH2CH2; 1.55, complex, CH3CH2CH2; 
2.45, complex, CH3CH2CH2; 3.71, s, CH2N; 6.90, d, J2 , 3,
5 Hz, H 3'; 7.13, s, H 3,5; 8.2, b, NH; 8.40, d, Jg , gI 
2 Hz, H 8'; 8.47, d, J_, _, 5 Hz, H 2'; 8.73, d, Jr , OI 
2 Hz, H 6'.
The tripicrate was prepared in, and recrystallized
from, ethanol. It had m.p. 176-178° (Found: C, 45.0; H,
4.0; N, 15.7. C„ 0H . ABrN,_0.3 (C ,H_N_0_) requires C, 44.9; 2840 5 6 3 3 7
H, 4.0; N, 15.9%).
4-(71-Bromo-1*,5'-naphthyridin-4'-ylamino)-2,6- 
bis(pyrrolidin-1"-ylmethyl)phenol (II.41g)
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)phenol 
(0.5 g), formalin (5.0 ml; 36%), pyrrolidine (5.0 ml) and 
ethanol (10.0 ml) were refluxed with stirring for 20 h and 
worked up and the product purified as described for 
compound (II.41a) to give, as a yellow oil, 4 — (7'-bromo- 
1',5'-naphthyridin-4'-ylamino)-2,6-bis(pyrrolidin-1"-
ylmethyl)phenol (0.64 g) (Found: C, 59.9; H, 6.2; N, 14.0.
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C24H28BrN5° rec3u -^res 59.8; H , 5.9; N, 14.5%).
*H n.m.r. (CDCl^) : 6 1.83, complex, H 3",4"; 2.63, complex,
H 2",5"; 3.77, s, CH2N; 6.86, d, J2 , 2 * 5.5Hz, H 00oro
s , H 3,5; 8.2, b , NH; 8.40, d , J6 , 8, 2 Hz, H 8'; 8.48, d,
J 2 1 ßi 5.5 Hz, H 2'; 8.72, d, J, , o , 2 Hz, H 6' .b , o
4-(71-Bromo-11,51-naphthyridin-41-ylamino)-2,6- 
bis(piperidin-lM-ylmethyl)phenol (II.41h)
4 — (7'-Bromo-1' ,5'-naphthyridin-4'-ylamino)phenol 
(0.5 g), formalin (5.0 ml; 36%), piperidine (5.0 ml) and 
ethanol (10.0 ml) were refluxed with stirring for 20 h. 
Work up was as described above for compound (II.41a) to 
give 4 — (7'-bromo-11 ,51-naphthyridin-4'-ylamino)-2,6-bis- 
(piperidin-l"-ylmethyl)phenol (0.6 g) as a yellow oil 
which became a semi-solid. (Found: C, 61.5; H, 6.5; N, 
13.5. C26H32BrN5° requires C, 61.2; H, 6.3; N, 13.7%).
1H n.m.r. (CDCl^): <5 1.55, complex, H 3",4",5"; 2.51, 
complex, H 2", 6"; 3.62, s, Ct^N; 6.89, d, 5.5 Hz,
H 3'; 7.08, s, H 3,5; 8.2, b, NH; 8.40, d, Jg , gI 2 Hz,
H 8'; 8.49, d, , ol 5.5 Hz, H 2'; 8.72, d, Jc , OI 2 Hz,
f O O f o
H 6 ' .
4-(71-Bromo-11,51-naphthyridin-4'-ylamino)-2,6- 
bis(2 n-methylpiperidin-l"-ylmethyl)phenol (II.4Ü)
4-(7'-Bromo-11,5'-naphthyridin-4'-ylamino)phenol 
(0.2 g), formalin (2.0 ml), 2-methylpiperidine (2.0 ml) 
and ethanol (10.0 ml) were refluxed with stirring for 20 h. 
Excess amine was distilled off under vacuum. Traces of 
2-methylpiperidine were removed by triturating with water
(50 ml) before the oily residue was purified by thin- 
layer chromatography (alumina; chloroform) to give 4- 
(7 1 -bromo-11 , 5 1 -naphthyridin-4 1 -ylamino) -2,6-bis (211-
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methylpiperidin-l"-ylmethyl)phenol (0.2 g) as a yellow 
oil. (Found: C, 62.9; H, 6.9; N, 12.8. C28H 36BrN5° 
requires C, 62.5; H , 6.7; N, 13.0%). *H n.m.r. (CDCl^):
6 1.18, d, J 6.5 Hz, CH3; 1.58, complex, H 3", 4", 5"; 2.34, 
complex, H 2"; 2.85, complex, H 6"; 3.36, d, J 14 Hz,
4.10, d, J 14 Hz, CH2 ; 6.90, d, J2 , 3 , 5.5 Hz, H 3'; 7.12, 
s, H 3,5; 8.19, s, NH; 8.41, d, J r , of 2 Hz, H 8'; 8.48,o , o
d, JOI 5.5 Hz, H 2'; 8.73, d, J c , ol 2 Hz, H 6'.^ / J O / O
4-(71-Bromo-11,5'-naphthyridin-4'-ylamino)-2,6-bis(3",5"- 
dimethylpiperidin-l"-ylmethyl)phenol (II.41j)
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)phenol 
(0.2 g), formalin (2.0 ml), 3,5-dimethylpiperidine (2.0 ml) 
and ethanol (10.0 ml) were refluxed with stirring for 20 h. 
Excess amine was distilled off under vacuum and the oily 
residue purified on thin-layer chromatography (alumina; 
chloroform then silica; methanol) to give 4-(71-bromo-11,51 - 
naphthyridin-4'-ylamino)-2,6-bis(3",5"-dimethylpiperidin- 
1"-ylmethyl)phenol (0.12 g) as a yellow oil. (Found:
C, 63.1; H, 7.2; N, 12.1. C30H4QBrN5O requires C, 63.6; H, 
7.1; N, 12.4%). 1H n.m.r. (CDC13) : 6 0.85, d, J 6.5 Hz,
CH3 ; 1.68, complex, H 3",4",5"; 2.90, complex, H 2", 6";
3.63, s, CH2N; 6.92, d, J2 , 3 , 5.5 Hz, H 3'; 7.08, s, H 3,5; 
8.22, s, NH; 8.41, d, J , , OI 2 Hz, H 8'; 8.48, d, J0 , 0 ,O / O  ^
5.5 Hz, H 2'; 8.73, d, J c , 0 ,D , O 2 Hz, H 6'.
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4-(71-Bromo-l1, 5 1-naphthyridin-41-ylamino)-2,6-bis- 
(morpholin-4"-ylmethyl)phenol (II.41k)
4-(7'-Bromo-l' , 5 1-naphthyridin-4'-ylamino)phenol 
(0.5 g), formalin (5.0 ml; 36%), morpholine (5.0 ml) and 
ethanol (10.0 ml) were refluxed as described above.
Excess morpholine was distilled off under vacuum, and the 
product was purified by thin-layer chromatography (alumina; 
chloroform) to give as a yellow oil 4-(71-bromo-l1,51 - 
naphthyridin-4'-ylamino)-2,6-bis(morpholin-4"-ylmethyl)- 
phenol (0.56 g). (Found: C, 56.4; H, 5.7; N, 13.2.
C24H28BrN5°3 rec3uires c / 56.0; H, 5.5; N, 13.6%). *H n.m.r. 
(CDCl^) : <5 2.57, complex, H 2",6"; 3.67, s, Cf^N; 3.76, 
complex, H 3",5"; 6.87, d, J2 , g, 5.5 Hz, H 3'; 7.12, s,
H 3,5; 8.2, b , NH; 8.42, d, J C1 OI 2 Hz, H 8'; 8.50b , o
J2 ' , 3 1 5.5 Hz, H 2'1 ; 8.74, d, J r , 0, 2 Hz, H 6' .b , o
The dipicrate was prepared in and recrystallized from 
ethanol. It had m.p. 216-218° (Found: C, 44.5; H, 3.5;
N, 15.6. C24H2 8BrN5°3 * ^ C6H3N3°7 ^ requires C, 44.5; H, 3.5; 
N, 15.8%) .
4-(71-Bromo-l1,51-naphthyridin-4 *-ylamino)-2,6- 
bis (4,l-methylpiperazin-lll-ylmethyl) phenol (11.411)
4-(7'-Bromo-l',51-naphthyridin-4'-ylamino)phenol 
(0.2 g), formalin (2.0 ml), N-methylpiperazine (2.0 ml) 
and ethanol (10.0 ml) were refluxed with stirring for 20 h 
and the product purified as for compound (II.41k) to give 
as a yellow oil 4-(71-bromo-l1,5'-naphthyridin-4'-ylamino)- 
2,6-bis (4ll-methylpiperazin-l"-ylmethyl) phenol (0.17 g) 
(Found: C, 54.9; H, 6.2; N, 16.8. CorH_„BrN_0.1.8 H„0*z b J 4 / z
*Dihydrate lost water on drying.
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requires C, 54.5; H, 6.6; N, 17.1%). 1H n.m.r. (CDCl^):
6 2.31, s, CH3; 2.55, complex, H 2",3",5",6"; 3.68, s,
CH2N; r-00 d, J2',3' 5.5 Hz, H 3'; 7.09, s, H 3,5; 8.18,
s, NH; 8.42 ' d/ J6',8', 2 Hz, H 8'; 8.49, d, J^ , 3> 5.5 Hz
H 2 ' ; r-00 d/ J6',8' 2 Hz, H 6'.
4- (7 1 -Bromo-11 , 5 ' -naphthyridin-4 * -ylamino)-6-dimethyl- 
aminomethyl-2-pyrrolidin-l"-ylmethylphenol (11.42)
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2- 
pyrrolidin-l"-ylmethylphenol (II.41c) (0.15 g), formalin
(2.0 ml) and ethanolic dimethylamine (10 ml; 33%) were 
refluxed with stirring for 10 h. The reaction mixture 
was evaporated to dryness in vacuo to leave an oil which 
was purified by thin-layer chromatography (alumina; 
chloroform) to give 4-(71-bromo-1',51-naphthyridin-41 - 
ylamino) -6-dimethylamino-2-pyrrolidin-11 -ylmethylphenol 
(0.11 g) as a yellow oil.. (Found: C, 57.5; H, 5.8; N, 14.9.
C22H26BrN5° rec3ui-res c / 57.9; H, 5.7; N, 15.3%). *H n.m.r. 
(CDC13): 6 1.85, complex, H 3",4"; 2.33, s, CH3; 2.67,
complex, H 2" ,5"; 3.57, s, 6-CH2; 3.79, s, 2-CH2; 'Ö0000V-O
J2 ',3' 5*5 Hz, H 3'; 7.07, s, H 3, 5; 8.20, s, NH; 8.41, d,
J6 ' , 8 ' 2 Hz, H 8' ; 8.49, d, J2 , 3, 5.5 Hz, H 2 ' ; 8.72, d,
J6' ,8' 2 Hz, H 6' •
4-(7'-Chloro-11,51-naphthyridin-41-ylamino)-2- 
diethylaminomethylphenol (11.43)
4,7-Dichloro-l,5-naphthyridine56 (11.32) (0.2 g),
4-amino-2-diethylaminomethylphenol dihydrochloride (0.27 g), 
water (15.0 ml) and methanol (5.0 ml) were heated with
stirring in an oil bath at 100° for 2 h. The methanol 
was then evaporated under reduced pressure and the 
aqueous solution adjusted with ammonium hydroxide to
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pH 7-8. The yellow precipitate was collected, washed, 
dried and recrystallized from cyclohexane to give 4 - (7 ' - 
chloro-1',51 2-naphthyridin-41-ylamino)-2-diethylaminomethyl- 
phenol (0.28 g), m.p. 167-169° (Found: C, 64.0; H, 6.0;
N, 15.5. C19H21C1N40 requires C, 64.0; H, 5.9; N, 15.7%).
1 H n.m.r. (CDC1 3} :
i—1r—J , t, j :1 Hz , c h 3ch 2; 2.66 , q.
J 7 H25, CH3CH2; 3. 79, s, CH2N; 6., 85, d ' J2' 5 5,3' Hz,
H 3' 6.86, d, J5, r 8 Hz, b H 6 ; 6.98, d, J 3j c 3 Hz, 5 H 3;
7. 17, q ' J5,6 8 Hz ' J3,5 3 Hz, H 5; 8.2, b , NH ; 8 .23, d,
J6 1/,8', 2 Hz, H 8' ; 8.50, *11 0" 2 i 5’ 5 . 5 Hz , H 2 ' ; 8.65, d,
J6 1/,8', 2 Hz, H 6' .
4- (7'--Chloro-11,5' -naphthyridin-^11-ylamino)phenol (11.44)
A mixture of 4,7-dichloro-l,5-naphthyridine (0.66 g), 
p-aminophenol hydrochloride (0.72 g; - 1:1.5), methanol 
(20.0 ml) and water (20.0 ml) was refluxed with stirring 
for 2 h. The methanol was then evaporated under reduced 
pressure and the aqueous solution adjusted to pH 8 with 
ammonium hydroxide. The yellow precipitate was collected, 
washed with water, and recrystallized from methanol to 
give 4-(71-chloro-11,51-naphthyridin-41-ylamino)phenol
(0.7 g), m.p. 240-241° (Found: C, 61.9; H, 3.8; N, 15.1.
C14H10C^N3° rec2uires c , 61.9; H, 3.7; N, 15.5%). 1H n.m.r
(CD3SOCD3): 6 6.81, d, J2 , 3, 5.5 Hz, H 3'; 6.83, d, J2 3 
8.5 Hz, H 2,6; 7.23, d, J0 0 8.5 Hz, H 3,5; 8.35, d, J., OI
Z   ^J  f O
2 Hz, H 8'; 8.44, d, J2 , 3, 5.5 Hz, H 2'; 8.81, d, Jg , g,
2 Hz, H 6'; 9.18, bs, NH; 9.45, bs, OH.
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4 - (71-Chloro-11,51-naphthyridin-41-ylamino)-2,6-bis- 
(dimethylaminomethyl)phenol (II.45a)
4-(7'-Chloro-1',5'-naphthyridin-4'-ylamino)phenol 
(11.44) (0.2 g) , formalin (2.0 ml), and ethanolic
dimethylamine (20.0 ml; 33%) were refluxed with stirring 
for 20 h. Excess amine was distilled off under vacuum 
and the oily residue purified by thin-layer chromatography 
(alumina; chloroform) to give 4-(71-chloro-1',5'- 
naphthyridin-4'-ylamino)-2,6-bis(dimethylaminomethyl)phenol 
(0.22 g) as a yellow oil. (Found: C, 61.2; H, 6.4; N, 17.7.
C20H24C "^N5°* 2H2° rec3uires c, 60.8; H, 6.4; N, 17.7%). 
lU n.m.r. (CDC13): 6 2.34, s, Me2N; 3.58, s, CH2N; 6.86, 
d, J2,^ 3, 5.5 Hz, R 3'; 6.07, s, H 3,5; 8.18, bs, NH; 8.23, 
d, J6, gI 2 Hz, H 8'; 8.50, d, J2, 3, 5.5 Hz, H 2'; 8.64, 
d, J6, 8, 2 Hz, H 6’.
4-(71-Chloro-11,51-naphthyridin-4'-ylamino)-2,6- 
bis(diethylaminomethyl)phenol (II.45b)
4 — (7 *-Chloro-1',5'-naphthyridin-4'-ylamino)phenol 
(0.2 g), formalin (2.0 ml), diethylamine (2.0 ml) and 
ethanol (10.0 ml) were treated as in the preparation of 
compound (II.45a) and the residue purified by thin-layer 
chromatography (silica; methanol) to give as a yellow oil 
which slowly crystallized, 4-(71-chloro-11,5' 
naphthyridin-41-ylamino)-2,6-bis(diethylaminomethyl)phenol 
(0.19 g), m.p. 106-107° (Found: C, 65.0; H, 7.5; N, 15.7.
C24H32C1N5° rec3uires c' 65.2; H, 7.3; N, 15.8%). *H n.m.r. 
(CDC13): 6 1.10, t, J 7 Hz, CH3CH2; 2.63, q, J 7 Hz, CH3CH2; 
3.71, s, CH2N; 6.88, d, J2, 3, 5.5 Hz, H 3'; 7.11, s, H 3,5;
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8.20, bs, NH; COCN00 d, J6' r  8 ' 2 Hz, H 8 ' ; 8.49, d, J2, 3,
5.5 Hz, H 2' ; LfO00 d, J6',8' 2 Hz , H 6 ' .
4-(71-Chloro-11,51-naphthyridin-4'-ylamino)-2,6- 
bis(dipropylaminomethyl)phenol (II.45c)
4-(7'-Chloro-1',5'-naphthyridin-4'-ylamino)phenol 
(0.2 g), formalin (2.0 ml), dipropylamine (2.0 ml) and 
ethanol (10.0 ml) were refluxed with stirring for 40 h 
(the reaction was incomplete at 20 h). The product was 
purified as for compound (II.45b) to give as a yellow oil 
4-(7'-chloro-11,51-naphthyridin-41-ylamino)-2,6-bis- 
(dipropylaminomethyl)phenol (0.20 g) (Found: C, 66.4;
H, 8.1; N, 13.8. C28H40^N5°* 2H2° requires C, 66.3; H, 8.1; 
N, 13.8%). 1E n.m.r. (CDClg): 6 0.89, t, J 7 Hz, 
CHgCH2CH2; 1.50, complex, C H 2; 2.48, complex,
CH3CH2CH2; 3.70 , s, CH2N; 6.89, d, J2, 3, 5.5 Hz , H 3' /
7.12, s, H 3,5; 8.20, bs, NH; 8.23, d, Jg, „, 2 Hz, H 8' ;
8.49, d, J2,^3, 5.5 Hz, H 2'; 8.65, d, Jg, «, 2 Hz, H 6 ' .
4-(71-Chloro-11,51-naphthyridin-41-ylamino)-2,6- 
bis(pyrrolidin-l"-ylmethyl)phenol (II.45d)
A mixture of 4-(7'-chloro-1',5'-naphthyridin-4'- 
ylamino)phenol (0.2 g), formalin (2.0 ml), pyrrolidine 
(2.0 ml) and ethanol (10.0 ml) was refluxed with stirring 
for 20 h. Excess amine was distilled off under vacuum 
and traces of pyrrolidine were removed by triturating with 
water (50 ml) before the oily residue was purified by 
thin-layer chromatography (silica; methanol) to give as a 
yellow oil 4-(7'-chloro-11,51-naphthyridin-41-ylamino)-
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2,6-bis (pyrrolidin-lll-ylmethyl) phenol (0.21 g) . (Found: 
C, 64.6; H, 6.6; N , 15.4. C24H28C1N5°*2 H20 requires C, 
64.5; H , 6.5; N , 15.7%). *H n.m.r. (CDClg): 6 1.84, 
complex, H 3",4"; 2.64, complex, H 2",5"; 3.77, s, CI^N;
6.87, d, J2, 3, 5.5 Hz, H 3' ; 7.09, s, H 3,5; 8. 18, bs
NH; 8.23, d, J_, ol 2 Hz, H6 , o 8 ’1 ; 8.50, d, J2 1,3' 5.5 Hz
H 2'; 8.65, d, Jc , 01 2 Hz,b , o H 6 ' .
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CHAPTER III
SYNTHESIS OF 1,8-NAPHTHYRIDINES
III-l Introduction
The literature on 1, 8-naphthyridines (summarised in 
CHAPTER I) offered little information upon the potential 
of such compounds in malaria chemotherapy. However, a 
large number of 4-oxo derivatives of the 1,8-naphthyridine 
ring system have been synthesised and found to be 
powerful antibacterial agents.86-08 These include 
l-ethyl-7-methyl-4-oxo-l,4-dihydro-l,8-naphthyridine-3- 
carboxylic acid (nalidixic acid)89 (III.l) which is 
particularly effective against gram-negative bacteria 
found in chronic urinary tract infections.90
COOH
(III.l)
A series of 4-substituted 1,8-naphthyridines (as 
8-aza analogues of chloroquine and amodiaquine) and their 
2- and/or 7-methyl substituted derivatives have been 
prepared and these have been examined for antimalarial 
activity.
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III-2 General Methods for Preparation
of 1,8-Naphthyridines
The starting materials required for this preparative 
programme are 4-halogeno (or hydroxy)-1,8-naphthyridines. 
These can be prepared from pyridin-2-amines (III.2) with 
substituted acrylates to give the 2-substituted 3-(2'- 
pyridylamino)acrylates (III.3) which, upon ring closure, 
may give rise to either pyrido[1,2-a]pyrimidines (III. 4) 
and/or 1,8-naphthyridines (III.5), depending on the 
conditions of cyclization.91
NHCH C
R2
COOEt
and/or
(III.4) (III.5)
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The 6-substituted pyrido[1,2-a]pyrimidines (III.4) can be
converted thermally into 1,8-naphthyridines (III.5) by
1 3N -*■ C-acyl migration.91 Hermecz et ad.91 reported
that ring closure of (III.3) in phosphoryl chloride -
polyphosphoric acid gives (III.4), but in "Dowtherm A"
affords (III.4) and (III.5).
Ring transformation of the pyridopyrimidines (III.4)
to the 1,8-naphthyridines (III.5) is influenced
2primarily by R and, to a lesser extent, by R . With
respect to R, transformation is affected in the following
2order: OH < Me < NHAc, whereas for R the order is:
C02Et ~ CN ~ COCF3 ~ COCH3 > Ph > H > alkyl.91
The condensation of pyridine-2,6-diamine (III.6) with 
ethyl acetoacetate gives 7-amino-4-methyl-l,8-naphthyridin- 
2-ol (III.7), the dianil (III.8), and the monoanil (III.9).92 
Compound (III. 7) corresponds to the "Knorr-type" product, 
whereas compounds (III.8) and (III.9) are the intermediate 
anils expected in a Conrad-Limpach-type condensation.
Thermal cyclization of compounds (III.8) and (III.9) in 
refluxing "Dowtherm A" affords compounds (III.10), (III.11) 
and (III.12). Of these, the first two products 
(III.10) and (III.11) can be converted into the 
naphthyridine (III.12) by base hydrolysis. The structure 
of 7-amino-2-methyl-l,8-naphthyridin-4-ol (III.12) was 
determined by conversion into the corresponding dihydrazino- 
derivative, followed by oxidation of the latter to a
9 2tetrazole.
90
(III.6)
(III.11)
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III-3 Preparation of Some
1,8-Naphthyridine Derivatives
The 1, 8-naphthyridines required in this work were 
prepared from relevant pyridin-2-amines as described below. 
6-Methylpyridin-2-amine (III.13) with diethyl ethoxy- 
methylenemalonate gave diethyl (61-methylpyridin-2'-yl)- 
aminomethylenemalonate93 (III.14) which, on refluxing in 
diphenyl ether, gave ethyl 4-hydroxy-7-methyl-l,8- 
naphthyridine-3-carboxylate93•94 (III.15). The latter was 
hydrolysed in aqueous potassium hydroxide and the 
unisolated acid9 5 was decarboxylated in refluxing 
quinoline to give 7-methyl-l,8-naphthyridin-4-ol94'95 
(III.16). The last-named compound was converted as 
described by Brown94 into 5-chloro-2-methyl-l,8- 
naphthyridine (III.17) and subsequent displacement of the 
chloro substituent occurred with 4-amino-2-diethylamino- 
methylphenol at 100° or 5-diethylaminopentan-2-amine at 
160° to give (III.18a) and (III.18b), respectively 
(SCHEME III-l).
Ethyl 4-hydroxy-7-methyl-l,8-naphthyridine-3- 
carboxylate93'94 (III.15) was oxidized by selenium dioxide 
in good yield to 6-ethoxycarbonyl-5-hydroxy-l,8- 
naphthyridine-2-carboxylic acid (III.19) which was 
hydrolysed in alkali and the dicarboxylic acid (III.20) 
lost carbon dioxide in quinoline to afford 1,8-naphthyridin- 
4-ol (III.21). Direct bromination of the latter with 
phosphoryl bromide gave 4-bromo-l,8-naphthyridine (III.22), 
which had previously been prepared from 2,4-dibromo-l,8- 
naphthyridine.96 4-Bromo-l,8-naphthyridine (III.22)
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reacted with 4-amino-2-diethylaminomethylphenol or 5- 
diethylaminopentan-2-amine under conditions similar to 
those described above to give (III.23a) and (111.23b), 
respectively (SCHEME III-2).
4-Chloro-2,7-dimethy1-1,8-naphthyridine97 (III.26)
prepared from 6-methylpyridin-2-amine (III.13) through
2.6- dimethylpyrido[1,2-a]pyrimidin-4-one (III.24) and
2.7- dimethyl-l,8-naphthyridin-4-ol97 (III.25) reacted with 
amines to give the desired compounds (III.27a) and (III.27b) 
(SCHEME III-3).
1,8-Naphthyridine-2,5-diol (III.32) was prepared from 
6-aminopyridin-2-ol (III.28) and diethyl ethoxymethylene- 
malonate at 110° and subsequent ring-closure of the 
intermediate (III.29) in diphenyl ether followed by 
hydrolysis of the ester (III.30) to the acid (III.31) which 
was decarboxylated by refluxing in diphenyl ether for 9 h. 
This compound has also been prepared from 7-amino-l,8- 
naphthyridin-4-ol98 and reported by Hermecz et al.91 
2,5-Dichloro-l,8-naphthyridine (III.33), prepared from the 
dihydroxy compound (III. 32) by chlorination with phosphoryl 
chloride, reacted with 4-amino-2-diethylaminomethylphenol 
dihydrochloride in water by replacement of the 5-chloro 
substituent to give 4-(7'-chloro-1',8'-naphthyridin-4'- 
ylamino)-2-diethylaminomethylphenol (III.34) in which the 
site of substitution was established by catalytic 
dechlorination to the pre-prepared 2-diethylaminomethyl-4- 
(1',8'-naphthyridin-4'-ylamino)phenol (III.23a). 2,5-
Dichloro-1,8-naphthyridine also reacted with 5-diethylamino- 
pentan-2-amine alone to give monosubstitution but removal
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of excess 5-diethylaminopentan-2-amine was difficult 
(SCHEME III-4).
4,7-Dichloro-2-methyl-l,8-naphthyridine92 (III.37), 
prepared from 7-amino-2-methyl-l,8-naphthyridin-4-ol92
(111.35) through 2-methyl-l,8-naphthyridine-4,7-diol92
(111.36) reacted with 4-amino-2-diethylaminomethylphenol- 
(dihydrochloride) in water at 100°, and the structure of 
the monosubstitution product, 4-(7'-chloro-2'-methyl-1,8- 
naphthyridin-4'-ylamino)-2-diethylaminomethylphenol 
(III.38), was assigned from the similar reaction of 2,5- 
dichloro-1,8-naphthyridine (III.33) described above 
(SCHEME III-5).
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(III.13)
Me N H
COOEt
COOEt
(III.14)
T Cl R
(III.18)
(III.17)
(a) R =
CH2NEt2
(b) R = NHCHMe(CH 2) 3 NEt 2
SCHEME III-l
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OH OH
COOEtCOOEt
HOOC
(III.15) (HI-19)
OH
(III.21)
OH
HOOC
COOH
(III.22)
(III.23)
(b) R = NHCHMe(CH2)3NEt2
SCHEME III-2
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2
(III.13)
V
R
(III.27)
(b) R = NHCHMe(CH2)3NEt2
SCHEME III-3
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(III.28)
(III.29)
.COOEt
CICOOEt
t OH Cl
(III.32) (III.33)
CH2NEt;
(III.23a) (III.34)
SCHEME III-4
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OH
H 2N Me
OH
(III .36)
Cl
(III.37)
(III.38)
SCHEME III-5
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III-4 Experimental
General conditions and procedures for the experimental 
work were as described at the commencement of the 
Experimental Section in CHAPTER II. Compound (23b) proved 
difficult to analyse but *H n.m.r. data and nitrogen 
analyses were satisfactory.
2-Diethylaminomethyl-4-(7'-methyl-1', 8'-naphthyridin- 
4'-ylamino)phenol (III.18a)
5-Chloro-2-methyl-1,8-naphthyridine9 4 (III.17)
(0.447 g, 0.0025 mol), 4-amino-2-diethylaminomethylphenol 
dihydrochloride (0.668 g, 0.0025 mol) and water (15 ml) 
were heated on a steam bath for 2 h. The cooled solution 
was made alkaline with aqueous ammonia and extracted four 
times with chloroform. The combined chloroform extracts 
were washed with sodium chloride solution, dried (Na^SO^) 
and evaporated to give a yellow product (1.0 g). This 
product was recrystallized from ethyl acetate to give 
2-diethylaminomethyl-4-(71-methyl-11,8'-naphthyridin-41 - 
ylamino)phenol (0.6 g) which decomposes above 186°
(Found: C, 71.4; H, 7.3; N, 16.6. C20H24N4° re<3u -^res C ' 
71.4; H, 7.2; N, 16.7%). XH n.m.r. (CDC13): 6 1.13, t,
J 7.5 Hz, CH3CH2; 2.65, q, J 7.5 Hz, CH3CH2; 3.76, s,
CH2N; 6.62, d, J 5.5 Hz, H 3; 6.88, complex, ArH; 7.24, 
d, J 8.5 Hz, H 6; 8.23, d, J 8.5 Hz, H 5; 8.58, d, J 5.5
Hz, H 2.
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N-(4'-Diethylamino-11-methylbutyl)-7-methyl-l, 8- 
naphthyridin-4-amine (III.18b)
5-Chloro-2-methyl-l, 8-naphthyridine (1.0 g, 0.0056 mol) 
and 5-diethylaminopentan-2-amine (4.4 g, 0.0278 mol) were 
heated in an autoclave at 160° for 9 h. The reaction 
mixture was evaporated under reduced pressure, made 
alkaline with 2 M sodium hydroxide and extracted with 
chloroform. The product was subjected to column and thin- 
layer chromatography (alumina; ethyl acetate) to give 
N-(41-diethylamino-11-methylbutyl)-7-methyl-l,8- 
naphthyridin-4-amine (0.7 g) as a yellow oil. (Found:
C, 71.6; H, 9.4; N, 18.4. CpgH28N4 rec3uires C, 71.95; H,
9.4; N, 18.6%). lU n.m.r. (CDC13): 6 0.99, t, J 7.5 Hz, 
CH3CH2 /‘ 1.30, d, J 6.5 Hz, l'-Me; 1.65, complex, 2.42, 
complex, (^22',3',4'; 2.51, q, J 7.5 Hz, CH^CH^; 2.71, s,
7-Me; 3.71, complex, H'; 5.45, d, J 7 Hz, NH; 6.42, d,
J 5.5 Hz, H 3; 7.16, d, J 8.5 Hz, H 6; 8.09, d, J 8.5 Hz,
H 5; 8.63, d, J 5.5 Hz, H 2.
6-Ethoxycarbonyl-5-hydroxy-l,8-naphthyridine-2- 
carboxylic acid (III.19)
Ethyl 4-hydroxy-7-methyl-l,8-naphthyridine-3- 
carboxylate93 ' 94 (III.15) (4.64 g, 0.02 mol), selenium
dioxide (5.31 g, 0.048 mol), water (10.0 ml) and pyridine 
(20 ml) were refluxed with stirring for 10 h. The 
mixture was diluted with pyridine (50 ml), boiled to 
dissolve the yellow crude product, filtered and evaporated. 
The residue was recrystallized from pyridine and the 
product washed with acetone to give 6-ethoxycarbonyl-5-
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hydroxy-1,8-naphthyridine-2-carboxylic acid (4.7 g), 
m.p. >279° (dec.) (Found: C, 54.1; H, 3.8; N, 10.5.
C12H10N2°5 rec3u;’-res c' 54.9; H, 3.8; N, 10.7%). 1U n.m.r. 
(CD3SOCD3): 6 1.29, t, J 7 Hz, CH3CH2; 4.23, q, J 7 Hz,
CH3CH2; 8.05, d, 8.67, d, J 8 Hz, H 5,6; 8.57, b, H 2;
13.12, b, COOH.
4-Bromo-l,8-naphthyridine (III.22)
A mixture of 6-ethoxycarbonyl-5-hydroxy-l,8- 
naphthyridine-2-carboxylic acid (III.19) (9.0 g),
potassium hydroxide (13.0 g) and water (90 ml) were heated 
on a steam bath for 1.75 h. The cooled solution was 
adjusted with 5 ^ hydrochloric acid to pH c. 2.5 and the 
dense light yellow precipitate of the acid (III.20) 
filtered off, washed with water and dried. This solid was 
refluxed with quinoline (120 ml) for 8 h, excess quinoline 
was removed under reduced pressure, and the remaining solid 
dissolved in the minimum volume of 1 | sodium hydroxide and 
extracted with chloroform to remove remaining traces of 
quinoline. The aqueous solution was adjusted with 1 ^ 
hydrochloric acid to pH c. 7 but the hydroxy compound (III.21) 
did not precipitate. The aqueous solution was evaporated to 
dryness to give crude hydroxy compound (III.21) (4.0 g).
[*H n.m.r. (CD30D): 6 6.35, d, J 7.5 Hz, H 3; 7.59, q,
J 8.5 Hz, J 4.5 Hz, H 6; 8.05, d, J 7.5 Hz, H 2; 8.63, q,
J 2 Hz, J 8.5 Hz, H 5; 8.71, q, J 2 Hz, J 4.5 Hz, H 7] 
which was brominated directly.
The crude hydroxy compound (III.21) (4.0 g) and
phosphoryl bromide (20.0 g) were heated in an oil bath at
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140-150° for 0.75 h. Ice was added carefully with 
stirring to the cooled mixture, and the resulting solution 
adjusted with sodium hydrogen carbonate solution to pH c. 
6.5, and extracted with chloroform (4x). The extract 
was dried (Na2SO^) and evaporated under vacuum and the 
product recrystallized from light petroleum (b.p. 60-80°) 
to give colourless plates of 4-bromo-l,8-naphthyridine 
(3.3 g), m.p. 78-79° (lit.96 72-73°) (Found, for material
dried at 20° and 20 mm Hg: C , 45.9; H , 2.4; Br, 38.3; N,
13.4. Calc. for CgH^BrlN^: C, 46.0; H, 2.4; Br, 38.2; N,
13.4%). lE n.m.r. (CDCl^) : 6 7.59, q , J 4 Hz , J 8.5 Hz,
H 6; 7.78, d , J 5 Hz, H 3; 8.56, q , J 2 Hz, J 8.5 Hz , H 5;
8.92, d, J 5 Hz, H 2; 9.17, q, J 4 Hz, J 2 Hz , H 7.
2-Diethylaminomethyl-4-(1',81-naphthyridin-4'- 
ylamino)phenol (III.23a)
4-Bromo-l,8-naphthyridine (III.22) (0.42 g, 0.002 mol)
and 4-amino-2-diethylaminomethylphenol dihydrochloride
(0.534 g, 0.002 mol) in water (15 ml) were heated on a
steam bath for 2 h. The reaction mixture was worked up
as described above for the reaction of 5-chloro-2-methyl-
1,8-naphthyridine (III.17). The chloroform extract gave
a crude product (0.84 g) which recrystallized from toluene
to give yellow crystals of 2-diethylaminomethyl-4-(11,8'-
naphthyridin-4'-ylamino)phenol (0.5 g), m.p. 174° (dec.)
(Found: C, 71.2; H, 6.9; N, 17.4. cg9H22N4° rec2u:*-res C,
70.8; H, 6.9; N, 17.4%). lU n.m.r. (CD3OD): 6 1.14, t,
J 7.5 Hz, CH ch /* 2.69, q, J 7.5 Hz, CH0CH_; 3.83, s, CH_N;_ 3 2 3 — Z Z
6.67, d, J 6 Hz, H 3; 7.08, complex, ArH; 7.50, q, J 4 Hz,
J 8 Hz, H 6; 8.46, d, J 6 Hz, H 2; 8.75, q, J 8 Hz, 
J 2 Hz, H 5; 8.93, q, J 2 Hz, J 4 Hz, H 7.
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N-(41-Diethylamino-1'-methylbutyl)-1,8-naphthyridin- 
4-amine (III.23b)
4-Bromo-l,8-naphthyridine (III. 22) (1.05 g, 0.005 mol)
and 5-diethylaminopentan-2-amine (3.95 g, 0.025 mol) were 
heated in an autoclave at 160° for 9 h. The reaction 
mixture was worked up as described above for the reaction 
of 5-chloro-2-methyl-l,8-naphthyridine (III.17) with 5- 
diethylaminopentan-2-amine. The dried chloroform extracts 
(Na2S04) were evaporated to a viscous brown oil which was 
subjected to column chromatography (alumina; methanol).
The product was washed by decantation with light petroleum 
(b.p. 60-80°) to remove remaining traces of 5-diethylamino- 
pentan-2-amine, and dried at 20° and 20 mm Hg to give 
N - (41-diethylamino-11-methylbutyl)-1,8-naphthyridin-4-amine 
(1.1 g) (Found: N, 19.4. C]_7H26N 4 requires N, 19.6%).
XH n.m.r. (CDC13): 6 0.99, t, J 7 Hz, CH_3CH2; 1.31, d,
J 6 Hz, l'-Me; 1.67, complex, 2.44, complex, CH22',3',4'; 
2.52, q, J 7 Hz, CH^CH^; 3.73, complex, H 1'; 5.68, d,
J 7 Hz, NH; 6.48, d, J 5.5 Hz, H 3; 7.28, q, J 8.5 Hz,
J 5 Hz, H 6; 8.27, q, J 2 Hz, J 8.5 Hz, H 5; 8.69, d,
J 5.5 Hz, H 2; 9.97, q, J 2 Hz, J 5 Hz, H 7.
2-Diethylaminomethyl-4-(2',71-dimethyl-11 , 8 ' - 
naphthyridin-41-ylamino)phenol (III.27a)
4-Chloro-2,7-dimethyl-l,8-naphthyridine9 7 (III.26)
(0.1 g, 0.0005 mol) and 4-amino-2-diethylaminomethylphenol
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dihydrochloride (0.134 g, 0.0005 mol) in water (3.0 ml)
were heated on a steam bath for 2 h. The reaction
mixture was worked up as described above. The product
was subjected to thin-layer chromatography (alumina;
ethyl acetate), treated with 20% ethanolic hydrogen
chloride, the mixture evaporated to dryness and the solid
recrystallized from t-butyl alcohol to give yellow crystals
of 2-diethylaminomethyl-4-(2',71-dimethyl-11,81 -
naphthyridin-41-ylamino)phenol dihydrochloride (0.12 g),
which sublimed at temperatures greater than 175° (Found:
C, 54.6; H, 7.2; Cl, 15.3; N, 11.7. Co,H_rN.0.2HC1.2H_0:z -L z o 4 z
C, 54.9; H, 7.0; Cl, 15.4; N, 12.2%). !H n.m.r. (D2<0) :
6 1.36, t, J 7.5 Hz, CH3CH2; 2.58, s, 2-Me; 2.76, s, 7-Me; 
3.26, q, J 7.5 Hz, CH3CH2; 6.61, s, H 3; 7.41, complex,
ArH; 7.64, d, 8.66, d, J 9 Hz, H 5,6.
N-(41-Diethylamino-11-methylbutyl)-2,7-dimethyl- 
1,8-naphthyridin-4-amine (III.27b)
4-Chloro-2,7-dimethyl-l,8-naphthyridine (1.0 g) and 
5-diethylaminopentan-2-amine (4.11 g) were heated in an 
autoclave at 160° for 9 h. The mixture was worked up as 
described above for compound (III.18b). The chloroform 
extract gave a viscous brown oil which was purified by 
column chromatography and thin-layer chromatography 
(alumina; ethyl acetate) to give oily N-(41-diethylamino- 
11-methylbutyl)-2,7-dimethyl-l,8-naphthyridin-4-amine 
(0.64 g) (Found, for material dried at 20° and 20 mm Hg:
C, 72.4; H, 9.9; N, 17.8. cpgH3 oN 4 requires C, 72.6; H,
9.6; N, 17.8%). lU n.m.r. (CDC13): 6 0.99, t, J 7 Hz,
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CH^CH^- 1.29, d, J 6.5 Hz, 1' -Me; 1.63, complex, 2.40, 
complex, CH22' ,31 ,4' ; 2.51, q, J 7 Hz, CH3CH2; 2.61, s,
2-Me; 2.68, s, 7-Me; 3.70, complex, H 1'; 5.23, d,
J 7 Hz, NH; 6.32, s, H 3; 7.11, d, 7.98, d, J 8.5 Hz,
H 5,6.
1,8-Naphthyridine-2,5-diol (III.32)
6-Aminopyridin-2-ol (III.28) (4.0 g, 0.036 mol) and
diethyl ethoxymethylenemalonate (7.86 g, 0.036 mol) were
heated in an oil bath at 110° for 1.5 h. The cooled
reaction mixture was dissolved in ethanol (c. 100 ml),
filtered, and the filtrate evaporated to give a dark
yellow oil which was refluxed in diphenyl ether (200 ml)
for 9 h. The resultant solid was heated on a steam bath
with sodium hydroxide (3.0 g) in water (100 ml) for 1.75 h,
adjusted to pH 2.5 and the solid filtered off. The solid
was added to diphenyl ether (200 ml) and this mixture
refluxed for a further 9 h, cooled as rapidly as possible,
diluted with light petroleum (b.p. 60-80°) (1000 ml).
The yellow precipitate (2.5 g) was filtered off, washed
with light petroleum (b.p. 60-80°) and dried. A sample
of this material was recrystallized from a large volume
of methanol to give 1,8-naphthyridine-2,5-diol m.p. 355-357°
(lit.91/98 >320°, >360°) (Found: C, 59.2; H, 3.2; N, 17.9.
Calc, for CoHcN„0n: C, 59.3; H, 3.7; N, 17.3%). XH n.m.r. o b z z
(1 M NaOD): 6 6.30, d, J 6 Hz, H 3; 6.50, d, 8.18, d,
J 9 Hz, H 5,6; 8.07, d, J 6 Hz, H 2.
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2,5-Dichloro-l,8-naphthyridine (III.33)
Crude 1,8-naphthyridine-2,5-diol (III.32) (1.0 g) and
phosphoryl chloride (10.0 ml) were heated in an oil bath 
at 120° for 0.75 h. The cooled reaction mixture was 
cautiously poured onto ice, and adjusted with aqueous 
sodium hydrogen carbonate to pH c. 5.5. This mixture was 
extracted with chloroform, the extract dried (Na2S04), 
solvent evaporated and the product recrystallized from 
light petroleum (b.p. 60-80°) to give 2,5-dichloro-l,8- 
naphthyridine (0.8 g), m.p. 131-132° (Found: C, 48.1; H, 
2.1; N, 14.1. CgH4Cl2N2 requires C, 48.3; H, 2.0; N, 14.1%). 
lU n.m.r. (CDClg): 6 7.58, d, J 9 Hz, H 3; 7.59, d, 9.00, 
d, J 5 Hz, H 5,6; 8.54, d, J 9 Hz, H 2.
4-(71-Chloro-11,81-naphthyridin-4'-ylamino)-2- 
diethylaminomethylphenol (III.34)
A mixture of 2,5-dichloro-l,8-naphthyridine (III.33) 
(0.12 g, 0.0006 mol) and 4-amino-2-diethylaminomethylphenol 
dihydrochloride (0.16 g, 0.0006 mol) in water (10 ml) were 
heated on a steam bath for 2 h. After cooling, the 
reaction mixture was made alkaline with 14 M ammonium 
hydroxide, and gave a dense yellow precipitate. This 
product was collected and recrystallized from toluene to 
give 4 — (71-chloro-11,81-naphthyridin-41-ylamino)-2- 
diethylaminomethylphenol (0.15 g), m.p. >360° (Found: C, 
63.3; H, 6.1; Cl, 9.95; N, 15.4. C ^ H ^ C I N ^ O  requires C,
6 3.9; H, 5.9; Cl, 9.9; N, 15.7%). *H n.m.r. (CD3OD): 6
1.14, t, J 7 Hz, CH3CH2; 2.67, q, J 7 Hz, CH3CH2; 3.83, s,
CH2N; 6.67, d , J 6 Hz, H 3; 7.07, complex, ArH; 7.47, d,
C7\UD00 d, J 8 Hz, H 5,6 ; 8.42, d, J 6 Hz, H 2.
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Dechlorination of 4-(71-chloro-1', 81-naphthyridin- 
41-ylamino)-2-diethylaminomethylphenol (III.34) to 
2-Diethylaminomethyl-4-(11, 8 '-naphthyridin-4'- 
ylamino)phenol (III.23a)
A mixture of 4-(7'-chloro-1',8'-naphthyridin-4'- 
ylamino)-2-diethylaminomethylphenol (III.34) (0.036 g),
magnesium oxide (0.5 g), ethanol (30 ml) and 10% palladium 
- charcoal (0.05 g) was hydrogenated at room temperature 
and pressure until hydrogen uptake ceased. The reaction 
mixture was filtered through Celite, the filtrate 
evaporated to dryness, and the solid subjected to thin- 
layer chromatography (silica; methanol). The product was 
dissolved in methanol, the solution diluted with light 
petroleum (b.p. 80-100°), and the mixture concentrated to 
give a yellow precipitate of 2-diethylaminomethyl-4- 
(11,81-naphthyridin-41-ylamino)phenol, m.p. 174° (dec.),
undepressed on admixture with authentic material prepared 
above. The 1H n.m.r. and i.r. spectra were also 
identical with those of the authentic compound.
4-(71-Chloro-21-methyl-11,81-naphthyridin-41-ylamino)- 
2-diethylaminomethylphenol (III.38)
4,7-Dichloro-2-methy1-1,8-naphthyridine9 2 (III.37) 
(0.213 g, 0.001 mol) and 4-amino-2-diethylaminomethylphenol 
dihydrochloride (0.267 g, 0.001 mol) in water (15 ml) were 
heated on a steam bath for 2 h. The mixture was worked 
up as described above and the yellow precipitate was 
recrystallized from cyclohexane to give 4 — (71-chloro-2 ' -
methyl-1',81-naphthyridin-41-ylamino)-2-diethylaminomethyl-
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phenol (0.3 g), m.p. 174-176° (Found: C, 65.1; H, 6.4; 
Cl, 9.55; N, 14.9. C2 0H2 r e q u i r e s  C, 64.8; H, 6.3; 
Cl, 9.6; N, 15.1%). *H n.m.r. (CDCl^): <5 1.14, t,
J 7 Hz, CH3CH2; 2.54, s, 2-Me; 2.66, q, J 7 Hz, CH3CH2; 
3.78, s, CH2N; 6.55, s, H 3; 6.91, complex, ArH; 7.31, 
d, 8.15, d, J 8.5 Hz, H 5,6.
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CHAPTER IV
SYNTHESIS OF 4 —(7'-TRIFLUOROMETHYLQUINOLIN-4'- 
YLAMINO)PHENOLS, 4-[2',7'- AND 2',8'-BIS- 
(TRIFLUOROMETHYL)QUINOLIN-4'-YLAMINO]PHENOLS 
AND N4-SUBSTITUTED 2,7- (AND 2,8-)
BIS(TRIFLUOROMETHYL)QUINOLIN-4-AMINES
IV-1 Introduction
The value of substituting a fluoro or fluorine- 
containing groups for halogens, hydrogen, hydroxyl or amino 
in prototype medicinals has been demonstrated in the past.99 
Such an effect is shown by mono and bis(trifluoromethyl) 
substituents in the quinoline nucleus of antimalarials 
described in CHAPTER I. This effect and the observation 
by Schmidt et al.16 that the cross-resistance between 
chloroquine and amodiaquine (a Mannich base) in resistant 
strains of P. falciparum was not absolute, prompted us to 
examine various mono and bis(trifluoromethyl)quinolin- 
4'-ylaminophenols carrying mono- and di-Mannich bases for 
antimalarial activity.
IV-2 Methods of Preparation of Some
Quinolin-4-ols
The 4-chloro-7-trifluoromethylquinoline required in 
this study is commercially available but methods for 
synthesis of its precursor, the quinolinol, are briefly 
reviewed below for completeness.
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IV-2-A 7-(Halogeno or Trihalogenomethyl)
Substituted- guinolin-4-ols 
Probably the most generally useful method for the 
preparation of quinolin-4-ols is that due originally to 
Gould and Jacobs,100 and later developed by Price and 
Roberts.70 In this, the aromatic amine (IV.1) is 
condensed with ethoxymethylenemalonic ester, and the 
resulting acrylate (IV.2) is cyclized by heating in 
diphenyl ether to give ethyl 7-substituted-4-hydroxy- 
quinoline-3-carboxylates (IV.3) as the major products and 
little or practically undetectable amounts of the 
isomeric 5-substituted compounds (IV.4) .70 '101 Saponifica­
tion and subsequent decarboxylation of compounds (IV.3) 
afforded the 7-(halogeno or trihalogenomethyl) substituted- 
quinolin-4-ols (IV.5).
In this way, 7-trifluoromethylquinolin-4-ol can be 
prepared from 3-trifluoromethylaniline101 and 7-chloro 
(and fluoro)-quinolin-4-ols from 3-chloro-70 and 3- 
fluoroaniline,101 respectively.
Ill
(IV.5)
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IV-2-B 2,7-Disubstituted-quinolin-4-ols
ß-Keto esters, such as ethyl acetoacetate, can react 
with an aromatic amine in either of two ways: (1) by
reaction of the amine with the carbonyl group to give 
ethyl ß-anilinocrotonate or the anil (IV.6); (2) by
reaction of the amine with the ester to give the anilide 
(IV.7). The factors governing the manner in which the 
condensation takes place have been greatly clarified by 
Hauser and Reynolds.102
(IV.1, X = H)
(IV.6) (IV.7)
A A
r r
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However, Coffey et al_. 1 0 3 observed in Conrad-Limpach 
syntheses that B-m-chloroanilinocrotonate (IV.8) was 
obtained in good yield by use of hydrochloric acid as a 
catalyst. Cyclization of the crotonate (IV.8) was 
achieved in refluxing diphenyl to give 7-chloro-2-methyl- 
quinolin-4-ol (IV.9) as the major product and the isomeric 
5-chloro-2-methylquinolin-4-ol (IV.10) in small quantity.104 
The structure of 7-chloro-2-methylquinolin-4-ol (IV.9) was 
established by conversion into 4,7-dichloro-2-methyl- 
quinoline (IV.11) and subsequent comparison with an 
authentic specimen prepared unambiguously10 4 from 7-chloro- 
2-methylquinoline through 7-chloro-2-methylquinoline N- 
oxide and treatment of the N-oxide with phosphoryl chloride 
to give the dichloromethylquinoline (IV.11).
(IV.1, X = Cl) (IV.8)
(IV.9)
(IV.10)
(IV.11)
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In the presence of polyphosphoric acid, condensation 
of 3-trifluoromethylaniline (IV.1, X = CF3) with ethyl 
4,4,4-trifluoroacetoacetate gave a mixture of 2,7- and 
2,5-bis(trifluoromethyl)quinolinones which could be 
converted directly to a mixture of 4-bromo derivatives, at 
which point it was separated into (IV.12) and (IV.13) 
respectively.55 Compound (IV.12) predominated in the 
mixture.6 5
(IV.12) (IV.13)
115
IV-2-C 2,8-Disubstituted-quinolin-4-ols
The condensation of substituted anilines (IV.14) with 
ethyl 4,4,4-trifluoroacetoacetate in the presence of 
polyphosphoric acid gives only the quinolin-4-ols64'65' 1 u5 
(IV.15), whereas this reaction with ethyl acetoacetate 
gives a mixture of quinolin-2(and 4)ols, depending upon 
whether the amine reacts with the ester or the ß-keto 
group.106 Apparently the electron-withdrawing power of 
the trifluoromethyl group leads to exclusive reaction of 
the (now) electron-deficient ß-keto group with the amine.107
OH
CY 3 COCH 2 COOEt/PPA
(IV.14)
e.g.
OH
X
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IV-3 Preparation of 4-(71-Trifluoromethylquinolin-
4'-ylamino)phenols
4-Chloro-7-trifluoromethylquinoline101 (IV.16) when 
refluxed with 4-amino-2-diethylaminomethylphenol 
dihydrochloride or p-aminophenol hydrochloride in water 
gave 2-diethylaminomethyl-4-(7'-trifluoromethylquinolin- 
4'-ylamino)phenol (IV.17) and 4-(7'-trifluoromethylquinolin- 
4'-ylamino)phenol (IV.18), respectively. Compound (IV.18) 
with formalin, ethanol and a large excess of dimethylamine, 
diethylamine, dipropylamine, pyrrolidine, piperidine, 2- 
methylpiperidine, 3,5-dimethylpiperidine, morpholine or 
N-methylpiperazine at reflux for 20 h gave the di-Mannich 
bases (IV.19a-i) (SCHEME IV-1).
IV-4 Preparation of 4-[2',7'- and 2 I,8'-Bis-
(trifluoromethyl)quinolin-4'-ylamino]phenols 
and -Substituted-2,7-(and 2,8-)bis- 
(trifluoromethyl)quinolin-4-amines 
The 2,7-bis(trifluoromethyl)quinolines (IV.21, 
IV.23b-g) were prepared similarly from 4-bromo-2,7-bis- 
(trifluoromethyl)quinoline65 (IV.20) or through 4 — [2 ' , 7 ' — 
bis(trifluoromethyl)quinolin-4'-ylamino]phenol (IV.22), as 
appropriate. However, compound (IV.22) with formalin, 
ethanol and a large excess of diisobutylamine at reflux 
for 72 h gave only the mono-Mannich base (IV.23a)
(SCHEME IV-2).
The 2,8-bis(trifluoromethyl)quinoline (IV.26) was 
similarly prepared through the bromo-compound (IV.24) and
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the quinolinylaminophenol precursor (IV.25). 4-Bromo-2,7-
and 4-bromo-2,8-bis(trifluoromethyl)quinoline65 (IV.20,
IV.24) with 2-diethylaminoethylamine and 5-diethylamino- 
pentan-2-amine at 160° gave the quinolin-4-amines (IV.28a-b, 
IV.27a-b) respectively (SCHEME IV-3).
118
Cl
F 3C
(IV.18)
OH
(a) R = R 1 = CH 2NMe 2
(b) R = R 1 =  CH2NEt2
(c) R = R 1 = CH2NPr2
(d) R = R 1 = CH2N ^ ^ ^
(e) R = R1 /= c h 2nV
(f) R = R1 = CH2N
>Me/
(g) R = R 1 = CH2N
(h) R = R1
(i) R = R 1 CH2N
SCHEME IV-1
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(IV.21)
OH
(a) R = II O U5
(b) R = R 1 = CH2NMe
(c) R = R 1 = CH2NEt
(d) R = R 1 = CH2NPr
(e) R = R 1 = CH2N
(f) R = AR 1 = CH2N
V
(g) R = AR1 = CH2N
V
SCHEME IV-2
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Br
CF 3
(IV.24)
CF 3
(IV.27)
(a) R = NH(CH2 )2NEt2
(b) R = NHCHMe(CH2 )3NEt2
(IV.25)
^ HN
(IV.26)
(IV.20) (IV.28)
(a) R 1 = NH(CH2 )2NEt2
(b) R 1 = NHCHMe(CH2 )3NEt2
SCHEME IV-3
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IV-5 Experimental
General conditions relating to experimental procedures 
were as outlined at the commencement of the Experimental 
Section in CHAPTER II.
2-Diethylaminomethyl-4-(71-trifluoromethylquinolin- 
4'-ylamino)phenol (IV.17)
4-Chloro-7-trifluoromethylquinoline (0.5 g) and 4- 
amino-2-diethylaminomethylphenol dihydrochloride (0.75 g) 
in a mixture of methanol (15.0 ml) and water (5.0 ml) were 
refluxed with stirring for 2 h, and the methanol evaporated 
under reduced pressure. After chilling, the yellow 
precipitate was collected, washed well with water and 
recrystallized from aqueous ethanol to give 2-diethylamino- 
methyl-4-(7'-trifluoromethylguinolin-41-ylamino)phenol 
(0.5 g), m.p. 210-212° (Found: C, 64.3; H, 5.7; N, 10.7.
C21H22F3N3° rec3u^res c, 64.8; H, 5.7; N, 10.8%). 1H n.m.r.
(CDC13): 6 1.14, t, J 7 Hz, CH3CH2; 2.66, q, J 7 Hz,
CH 3 CH2; 3.79, s, CH2; 6.73, d, J2, 3, 5.5 Hz, H 3’; 6.87,
d, Jc r 8.5 5,6 Hz, H 6; 6.93, d, J- _ 3 Hz, H 3; 7.11, q, 3 , D
J0 _ 3 Hz, J
3 f D 5,6 8,5 Hz , H 5; 7.64, q, J5. ^ 6, 9 Hz,  ^8
1.5 Hz, H 6’; 8.03, d, J5,,6’ 9 Hz, H 5’; 8.31, s, H 8';
8.56, d, J2, 5 5,3’ * Hz, H 2’ .
4-(71-Trifluoromethylguinolin-41-ylamino)phenol (IV.18)
4-Chloro-7-trifluoromethylquinoline (IV.16) (0.5 g),
p-aminophenol hydrochloride (0.41 g), methanol (15 ml) and 
water (5.0 ml) were refluxed with stirring for 2 h as 
above. The yellow precipitate was collected, suspended 
in water (30 ml), and adjusted with ammonium hydroxide to
pH 7-8, and then recrystallized from aqueous ethanol to 
give 4-(71 2*-trifluoromethylquinolin-41-ylamino)phenol
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(0.6 g) , m.p. 253-254° (Found: C, 61.3; H, 3.9; N, 8.9.
l
C16H 11F3N 2°*"FH2° rec3ui-res c , 61.3; H , 3.9; N, 8 .9%) .
1U n.m.r. (CD3SOCD3): 6 6.66, d, J , 5,3' *5 Hz, H 3' ;
6.85, d, J2 3 9 Hz, H 2,6; 7.17, d, J2,3 9 Hz , H 3,5; 7.74
q, J 5 , 6 , 9 Hz, J6 , 8 , 1.5 Hz, H 6'; 8.13, b s , N H ; 8.47, d
J~ , 5.5 Hz, H 2'; 8.61, d, Jc .j -D D r O 9 Hz, H 5' ; 8.99, s , :
9.46, s , OH.
2,6-Bis(dimethylaminomethyl)-4-(7'-trifluoromethyl- 
quinolin-41-ylamino)phenol (IV.19a)
4 — (7'-Trifluoromethylquinolin-4'-ylamino)phenol 
(IV.18) (0.3 g) , formalin (5.0 ml) and ethanolic dimethyl-
amine (15.0 ml; 33%) were refluxed with stirring for 20 h. 
The solution was evaporated to dryness and the oily 
residue was subjected to thin-layer chromatography 
(alumina; ether) to give an oil which slowly crystallized 
and was recrystallized from aqueous ethanol to give yellow 
crystals of 2,6-bis(dimethylaminomethyl)-4-(71-trifluoro­
methylquinolin-4 1-ylamino)phenol (0.32 g) m.p. 86-88°
(Found, for a sample dried at 40° and 0.2 mm H g : C, 63.5;
H, 6.2; N, 13.5. C22H25F3N4° re<3u;*-res c , 63.2; H, 6.0; N,
13.4%). *H n.m.r. (CDC13) : 6 2.32, s, CH3 ; 3.57, s,
2 x CH ; 6.71, d , J 5.5Hz, H 3'; 6.8, b , NH ; 7.01, s ,2 z , j
H 3,5; 7.60, q, J _ , c , 9 Hz, Jr, OI 1.5 Hz, H 6'; 8.03, d,D   ^D O / O
J5 , 6 , 9 Hz, H 5'; 8.28, s, H 8'; 8.54, d, J2 , 3 , 5.5 Hz,
H 2' .
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2,6-Bis(diethylaminomethyl)— 4 — (71-trifluoromethy1- 
guinolin-41-ylamino)phenol (IV.19b)
4-(7'-Trifluoromethylquinolin-4'-ylamino)phenol (0.3 g), 
diethylamine (5.0 ml) and formalin (5.0 ml) in ethanol 
(10.0 ml) were refluxed as in the preparation of compound 
(IV.19a). The crude product was subjected to thin-layer 
chromatography (alumina; chloroform) and recrystallized from 
a mixture of methanol and light petroleum (b.p. 60-80° to 
give yellow crystals of 2,6-bis(diethylaminomethyl)-4-(71 - 
trifluoromethylquinolin-41-ylamino)phenol (0.31 g), m.p. 
169-170° (Found: C, 65.8; H, 7.1; N, 12.0. C26H33F3N4° 
requires C, 65.8; H , 7.0; N, 11.8%). :H n.m.r. (CDCl^):
6 1.10, t, J 7 Hz, CH3CH2; 2.64, q, J 7 Hz, CH3CH2; 3.72, 
s, CH2; 6.6, bs, NH; 6.75, d, J2, 3, 5.5 Hz, H 3'; 7.07, 
s, H 3,5; 7.63, q, J_, ., 9 Hz, , OI 1.5 Hz, H 6'; 8.00,
d, J5, 6, 9 Hz, H 5'; 8.30, s, H 8'; 8.56, d, J2, 3, 5.5 Hz, 
H 2 ' .
2,6-Bis(dipropylaminomethyl)-4-(7'-trifluoromethyl­
quinolin-4 1-ylamino)phenol (IV.19c)
4-(7'-Trifluoromethylquinolin-4'-ylamino)phenol (0.3 g) , 
dipropylamine (5.0 ml), formalin (5.0 ml) and ethanol 
(10.0 ml) were refluxed as in the preparation of compound 
(IV.19a). The crude product was subjected to thin-layer 
chromatography (alumina; chloroform then silica; ether) and 
the yellow oil crystallized on standing to give 2,6-bis- 
(dipropylaminomethyl)-4-(71-trifluoromethylquinolin-41 - 
ylamino)phenol (0.20 g), m.p. 113-114° (Found, for sample
dried at 80° and 0.2 mm Hg: C, 67.9; H, 7.8; N, 10.5%.
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C30H41F3N4° rec3uires c > 6 7.9; H, 7.8; N , 10.6%).
1H n.m.r. (CDCl^): 6 0.88, t, J 7 Hz, CH3; 1*50, complex, 
CH 3 CH2; 2.49, complex, CH_2CH2CH3; 3.70, s, CH2; 6.7, b,
NH; 6 • 7 6 f d j lJ" 2 i 3 i 5.5 Hz, H 3' ; 7.08, s, H 3,5; 7.62, q ,
J5 ' ,6' 9 Hz' J6 ',8' 1.5 Hz, H 6' ; 8.04, d, J5 , 6 , 9 Hz,
H 5' ; 8.30, s, H 8' ; 8.54, d , J9- ^, 5.5 Hz, H 2' ./ ^
2,6-Bis(pyrrolidin-l"-ylmethyl)-4-(71-trifluoromethy1- 
quinolin-4'-ylamino)phenol (IV.19d)
4-(7'-Trifluoromethylquinolin-41-ylamino)phenol 
(0.3 g), pyrrolidine (5.0 ml), formalin (5.0 ml) and 
ethanol (10.0 ml) were refluxed as in the preparation of 
compound (IV.19a), and excess pyrrolidine removed by 
distillation in a vacuum. The residue was triturated 
with water (50 ml) and the crude product subjected to 
thin-layer chromatography (alumina; methanol then alumina; 
ether) to give as a yellow oil 2,6-bis (pyrrolidin-1"- 
ylmethyl)-4-(71-trifluoromethylguinolin-41-ylamino)phenol 
(0.23 g) (Found: C, 64.1; H, 6.4; N, 10.9. C26H2gF3N40 
1.1 H20 requires C, 63.7; H, 6.4; N, 11.4%). 1H n.m.r.
(CDC13) : 6 1.86, complex, H 3",4"; 2.69, complex, H 2",5";
o00CO s, CH2 ; 6.45, s , NH; 6.73, d ,  J 2 , 5.5 Hz, H
f  3
3' ;
7.06, s, H 3,5; 7.62, ^6 ' 8 ' Hz, , g , 9 Hz, H 6 ' ;
00 o NJ d  / J5 ’,6’ 9 Hz' H 5'; 8.29, s, H 8'; 8.55, d,
J2',3'■ 5.5 Hz, H 2 1.
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2.6- Bis (piperidin-111-ylmethy 1) — 4 — (7 1 -trifluoromethy1- 
quinolin-41-ylamino)phenol (IV.19e)
4-(7'-Trifluoromethylquinolin-4'-ylamino)phenol 
(0.3 g), piperidine (5.0 ml), formalin (5.0 ml) and 
ethanol (10.0 ml) were treated as in the preparation of 
compound (IV.19d). The crude product was purified by 
thin-layer chromatography (alumina; chloroform) and 
recrystallized from cyclohexane to give 2,6-bis(piperidin- 
l"-ylmethyl)-4-(71-trifluoromethylquinolin-41-ylamino)- 
phenol (0.31 g), m.p. 170-171° (Found: C, 67.5; H, 6.95;
N, 11.3. C28H33F3N40 requires C, 67.5; H, 6.7; N, 11.2%).
*H n.m.r. (CDC13): 6 1.55, complex, H 3",4",5"; 2.51, 
complex, H 2", 6"; 3.62, s, CH2; 6.7, s, NH; 6.74, d,
J2, 3, 5.5 Hz, H 3'; 7.04, s, H 3,5; 7.63, q, J5, gI 9 Hz, 
Jrt OI 1.5 Hz, H 6'; 8.01, Jc, 9 Hz, H 5'; 8.30, s,b f ö j  ^u
H 8'; 8.56, d, J2, 3, 5.5 Hz, H 2’.
2.6- Bis (2,,-methylpiperidin-lll-ylmethyl) -4- (7 1 -trif luoro­
methylquinolin-4 1-ylamino)phenol (IV.19f)
A mixture of 4-(7'-trifluoromethylquinolin-4'-ylamino)- 
phenol (0.2 g), formalin (2.0 ml), 2-methylpiperidine 
(2.0 ml) and ethanol (10.0 ml) was treated and the 
product purified as in the preparation of compound (IV.19e) 
to give a solid which was recrystallized from aqueous 
ethanol affording yellow crystals of 2,6-bis(2"-methyl- 
piperidin-lM-ylmethyl)-4-(71-trifluoromethylquinolin-41 - 
ylamino)phenol (0.18 g), m.p. 102-104° (Found: C, 68.5;
H, 7.3; N, 10.4. C3 qH3 7F3N4° requires C, 68.4; H, 7.1; N,
*H n.m.r. (CDC13): 6 1.18, d, J 6.5 Hz, CH3; 1.58,10.6%).
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complex, H 3",4",5"; 2.32, complex, H 2"; 2.90, complex,
H 6"; 3.36, d, J 14 Hz, 4.10, d, J 14 Hz, CH2N; 6.68, bs,
NH; 6.76, d, J?l g , 5.5 Hz, H 3'; 7.07, s, H 3,5; 7.64, 
q, Jg , g, 8.5 Hz, Jg, g, 1.5 Hz, H 6'; 8.02, d, Jg , g,
8.5 Hz, H 5'; 8.30, s, H 8 ’; 8.56, d, J2 , g, 5.5 Hz, H 2'.
2.6- Bis(3n,5"-dimethylpiperidin-l"-ylmethyl)-4-(71 - 
trifluoromethylquinolin-41-ylamino)phenol (IV.19g)
4-(7'-Trifluoromethylquinolin-4'-ylamino)phenol 
(0.2 g), formalin (2.0 ml), 3,5-dimethylpiperidine (2.0 ml) 
and ethanol (10.0 ml) were treated and the product purified 
as in the preparation of compound (IV.19b) to give, as a 
yellow oil, 2,6-bis (3M , 5,,-dimethylpiperidin-ll,-ylmethyl) - 
4-(71-trifluoromethylquinolin-4'-ylamino)phenol (0.19 g) 
(Found: C, 67.0; H, 7.5; N, 9.7. Cg2H^^FgN^O.1H20 requires 
C, 67.1; H, 7.6; N, 9.8%). lH n.m.r. (CDClg): 6 0.86, 
d, J 6.5 Hz, CHg; 1.65, complex, H 3",4",5"; 2.90, complex,
H 2",6"; 3.64, s, CH2N; 6.78, bs, NH; 6.79, d, J2 , g, 5.5
Hz, H 3'; 7.04, s, H 3,5; 7.63, q, J_ , ,, 8.5 Hz, J,, OI*3 f >3 O ^ O
1.5 Hz, H 6'; 8.02, bs, OH; 8.03, d, Jg , ßI 8.5 Hz, H 5'; 
8.30, s, H 8'; 8.56, d, Jg , g, 5.5 Hz, H 2'.
2.6- Bis(morpholin-1"-ylmethyl)-4-(71-trifluoromethyl­
quinolin-4 1-ylamino)phenol (IV.19h)
4 — (7'-Trifluoromethylquinolin-4'-ylamino)phenol 
(0.3 g), morpholine (5.0 ml), formalin (5.0 ml) and 
ethanol (10.0 ml) were treated as in the preparation of 
compound (IV.19d) to give after thin-layer chromatography 
(alumina; chloroform) and recrystallization from aqueous
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ethanol, yellow needles of 2,6-bis (morpholin-11 -ylmethyl) - 
4 — (7'-trifluoromethylguinolin-41-ylamino)phenol (0.29 g) , 
m.p. 198-200° (Found: C, 62.45; H, 5.9; N, 11.4.
C26H29F3N4°3 rec2u:*-res C ' 62.1; H, 5.8; N, 11.15%).
!H n.m.r. (CDCl^): 6 2.56, complex, H 2",6"; 3.66, s,
CH2N; 3.75, complex, H 3 " , 5 " ; 6.72, d, J2 , 2 , 5.5 Hz,
H 3 ' ; 6.81, s, NH; 7.07, s, H 3,5; 7.62, q, J5 , ß , 9 Hz,
COt) , 1.5 Hz, H 6 ' ;
oCO J5 , 6 , 9 Hz, H 5'; 8.29, s,
H 8 ' ; 8.56, d , J2' ,3 , 5.5Hz, H 2 ' .
2,6-Bis (4 "-methylpiperazin-111-ylmethyl) - 4- (7 1 -trif luoro- 
methylquinolin-4 *-ylamino)phenol (IV.19i)
4 — (7 *-Trifluoromethylquinolin-41-ylamino)phenol 
(0.2 g), formalin (2.0 ml), N-methylpiperazine (2.0 ml) and 
ethanol (10.0 ml) were treated as in the preparation of 
compound (IV.19d). The oily residue was purified by 
column (alumina; chloroform) and thin-layer chromatography 
(silica; methanol) to give, as a yellow oil which 
crystallized, 2,6-bis(4"-methylpiperazin-ln-ylmethyl)-4- 
(7 *-trifluoromethylquinolin-4'-ylamino)phenol, m.p. 163-164° 
(Found: C, 62.9; H, 7.2; N, 15.7. C28H35F3N6°.2 h 20 requires
C , 6 2.6; H , 6. 8; N, 15.6%). 1H n.m.r. (CDC13): 6 2.30, s,
CH^; 2.53, complex, H 2", 3",5 ",6"; 3.67, s, CH2N; 6.73, d,
J2 , 2 , 5.5Hz, H 3'; 6.86, bs , NH; 7.04, s, H 3,5; 7.63, d,
Jr, , 8.5 Hz ,5 , 6 H 6'; 8.85, d , Jr, r | 8 . 55 , 6 Hz, H 5' ; 8.30, s,
T5LDinCOCOS3 J 2 , 2 , 5 .5 Hz, H 2 ' .
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2-Diethylaminomethy1-4-[2',7'-bis(trifluoromethyl)- 
quinolin-4'-ylamino]phenol (IV.21)
4-Bromo-2,7-bis(trifluoromethyl)quinoline6 5 (IV.20)
(0.2 g), 4-amino-2-diethylaminomethylphenol dihydrochloride 
(0.2 g), methanol (10.0 ml), and water (3.0 ml) were 
refluxed as in the preparation of compound (IV.18) but 
for 72 h. The product was recrystallized from water with 
a little hydrochloric acid to give 2-diethylaminomethy1- 
4 — [2 1 , 7'-bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
hydrochloride (0.21 g), m.p. 150° (Found: C, 53.4; H, 4.5;
N, 8.2. C22H21F6N3° * rec3u^reS: C ' 53.5; H, 4.5; N, 8.5%). 
1H n.m.r. (free base in CD^SOCD^) : <5 1.12, t, J 7 Hz,
CH3CH2; 2.76, q, J 7 Hz, CH3CH2; 3.93, s, CH2; 6.83,
H 3'; 6.93, d, J  ^ /6 , 8.5 Hz, H 6; 7.22, d, J_, 85 , 6
H 5; 7.28, bs, H 3; 7.91, q, J6 , OI 1.5 Hz, H 6 ’; 8.
r °
H 81; 1.73, d, J5 , , 8.5 Hz, H 5' ; 9.62, s , OH.
4 — [21 ,71-Bis(trifluoromethyl)quinolin-41-ylamino]phenol 
(IV.22)
4-Bromo-2,7-bis(trifluoromethyl)quinoline (0.4 g), 
p-aminophenol hydrochloride (0.26 g), methanol (15.0 ml) 
and water (5.0 ml) were refluxed with stirring as in the 
preparation of compound (IV.18) but for 48 h. The yellow 
precipitate was collected and recrystallized from aqueous 
methanol to give 4-[21,71-bis(trifluoromethyl)quinolin-41 - 
ylamino]phenol (0.23 g), m.p. 245-246° (Found: C, 54.4;
H, 2.65; N, 7.5. Cp7H]_oF6N2° rec2ui-res C ' 54.85; H, 2.7; N, 
7.5%). lE n.m.r. (CD3OD): 6 6.88, s, H 3'; 6.94, d,
J2 3 9 Hz, H 2,6; 7.22, d, J2 3 9 Hz, H 3,5; 7.80, q,
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Jcl CI 8.5 Hz, J_, ol 1.5 Hz, H 6'; 8.28, bs, H 8'; 8.53,D  ^u O j o
d, J , 8.5 Hz, H 5'.5 / d
2-Diisobutylaminomethyl-4-[2',71-bis(trifluoromethyl)- 
guinolin-41-ylamino]phenol (IV.23a)
4-[2',7'-Bis(trifluoromethyl)quinolin-4'-ylamino]- 
phenol (IV.22) (0.2 g), diisobutylamine (3.0 ml), formalin
(3.0 ml) and ethanol (10.0 ml) were refluxed with stirring 
for 72 h and worked up as in the preparation of compound 
(IV.19d). The product was subjected to column and thin- 
layer chromatography (alumina; chloroform) to give, as a 
yellow oil, the mono-Mannich base, 2-diisobutylaminomethyl- 
4-[21,71-bis(trifluoromethyl)quinolin-41-ylamino]phenol 
(0.15 g) (Found: C, 60.5; H, 5.8; N, 8.15. C26H29F6N3° 
requires C, 60.8; H, 5.7; N, 8.2%). 1H n.m.r. (CDCl^) :
6 0.95, d, J 6 Hz, CH^; 1.96, complex, CH; 2.25, d, J 6 Hz,
CH2CH; 3.71, s, CH2N; 6.91, d, J5 6^ 7.5 Hz, H 6; 6.95,
H 3' ; 6.97, bs, H 3; 7.13, q, J5 6^ 7.5 Hz, J  ^f 5 2.5 Hz,
H 5 ; 7.71, q,  ^6. 8.5 Hz, Jg, g, 1.5 Hz, H 6 '; 8.06,
Jr, r  i 8.5 Hz, H 5'; 00KinrPo00 .
2,6-Bis(dimethylaminomethy1)-4-[21,7'-bis(trifluoromethyl)- 
guinolin-41-ylamino]phenol (IV.23b)
4 — [2 * ,7'-Bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
(0.2 g), ethanolic dimethylamine (15 ml; 33%) and formalin 
(5 ml; 36%) were treated as in the preparation of compound 
(IV.19a). The crude product was purified by thin-layer 
chromatography (alumina; chloroform) and recrystallization 
from cyclohexane to give yellow crystals of 2,6-bis-
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(dimethylaminomethyl)-4-[21,7'-bis(trifluoromethyl)- 
quinolin-4'-ylamino]phenol (0.2 g), m.p. 199-200°
(Found: C, 57.1; H, 5.2; N, 11 4 C H F N 0 * * l23 24 6 4 requires
C, 56.8; H, 5.0; N, 11.5%) . XH n.m.r. (CDCl 3) : 6 2.32,
s, CH3; 3.58, s, CH2; 6.98, s, H 3’; 7.03, s , H 3,5; 7.25,
b, NH; 7.67, d, J5’,6’ * 68*5 HZ/ H 61; 8.07, d , J5 ',61 8-5
Hz, H 5’; 8.40, s, H 8’; 9.25, b, OH.
2.6- Bis(diethylaminomethyl)-4-[21, 7 '-bis(trifluoromethyl)- 
quinolin-41-ylamino]phenol (IV.23c)
4-[2',7'-Bis(trifluoromethyl)quinolin-4'-ylamino]- 
phenol (0.15 g) , diethylamine (3.0 ml), formalin (3.0 ml), 
and ethanol (10.0 ml) were allowed to react and the product 
purified as in the preparation of compound (IV.23b) to give
2.6- bis(diethylaminomethyl)-4-[21,71-bis(trifluoromethyl)-
quinolin-41-ylamino]phenol as a yellow oil which slowly
solidified. (Found: C, 59.9; H, 6.2; N, 10.5. ^27H32F6N4°
requires C, 59.8; H, 5.95; N, 10.3%). 1H n.m.r. (CDCl^):
6 1.09, t, J 7 Hz, CH3CH2; 2.63, q, J 7 Hz, CH3CH2; 3.72, 
s, CH2; 7.0, b, NH; 7.03, s, H 3'; 7.08, s, H 3,5; 7.71, q,
J , , 8.5 Hz, Jr, OI 1.5 Hz, H 6'; 8.05, d, J,, c , 8.5 Hz,
o j b O / O  O f t )
H 5'; 8.42, s, H 8'.
The hydrobromide, recrystallized from propan-2-ol, had 
m.p. 220° (Found: C, 42.5; H, 4.9; N, 7.4. C27H 32F6N4°‘ 2HBr. 
3H20 requires C, 42.75; H, 5.3; N, 7.4%).
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2,6-Bis(dipropylaminomethyl)-4-[2',71-bis(trifluoro- 
methyl)guinolin-4'-ylamino]phenol (IV.23d)
4 — [2 ' ,7'-Bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
(0.2 g), dipropylamine (3.0 ml), formalin (3.0 ml) and 
ethanol (10.0 ml) were treated as in the preparation of 
compound (IV.23b). The oily residue was subjected to 
column (alumina; chloroform) and thin-layer chromatography 
(silica; chloroform) to give 2,6-bis(dipropylaminomethyl- 
4-[21,71-bis(trifluoromethyl)quinolin-4'-ylamino]phenol as 
a yellow oil (Found: C, 62.2; H, 6.9; N, 9.3. C3pH4oF6N4° 
requires C, 62.2; H, 6.7; N, 9.4%). *H n.m.r. (CDCl^):
6 0.87, t, J 7 Hz, CH^; 1.49, complex, CH^CH^; 2.48, complex, 
CH2CH2CH3; 3.70, s, CH^N; 6.94, bs, NH; 6.98, s, H 3'; 7.09, 
s, H 3,5; 7.71, q, Jc, -, 8.5 Hz, Jr, OI 1.5 Hz, H 6'; 8.05,
3,0 0,0
d, J5, 6, 8.5 Hz, H 5'; 8.43, s, H 8'.
2,6-Bis(pyrrolidin-l"-ylmethyl)-4-[21,71-bis(trifluoro­
methyl) quinolin-41-ylamino]phenol (IV.23e)
4 — [2',7'-Bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
(0.2 g), pyrrolidine (3.0 ml), formalin (3.0 ml) and 
ethanol (10.0 ml) were treated as in the preparation of 
compound (IV.19d) except that trituration was with water 
(2 x 20 ml). The crude product was purified by thin-layer 
chromatography (alumina; chloroform) to give 2,6-bis- 
(pyrrolidin-ln-ylmethyl)-4-[2',71-bis(trifluoromethyl)- 
quinolin-4'-ylamino]phenol (0.2 g) as a yellow oil.
(Found: C, 60.4; H, 5.7; N, 10.5. C^H^F^N^O requires C, 
60.2; H, 5.2; N, 10.4%). lE n.m.r. (CDC13): 6 1.82, 
complex, H 3", 4"; 2.63, complex, H 2", 5"; 3.76, s, CH2;
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7.01, s, H 3’; 7.04, s, H 3,5; 7.25, bs, NH; 7.68, q,
J5’ ,6', 8.5 Hz, Jr, 0, 1.5b ,0 Hz, H 6'; 8.09, d, J5',6' 8,5
Hz, H 5*; 8.40, s, H 8’.
It did not give crystalline salts with ethanolic 
hydrogen bromide or picric acid.
2.6- Bis(piperidin-l"-ylmethyl)-4-[2 * ,7'-bis(trifluoro- 
methyl)guinolin-41-ylamino]phenol (IV.23f)
4-[2',7'-Bis(trifluoromethyl)quinolin-4'-ylamino]phenol
(0.2 g), piperidine (3.0 ml), formalin (3.0 ml) and ethanol
(10.0 ml) were treated and the product purified as in the
preparation of compound (IV.23e). The oil solidified on
standing and was recrystallized from aqueous ethanol to give
yellow crystals of 2,6-bis(piperidin-1"-ylmethyl-4-[21,71 -
bis(trifluoromethyl)quinolin-4'-ylamino]phenol (0.22 g),
m.p. 123-124° (Found: C, 57.6; H, 5.5; N, 9.3. Cn nH_„FrN .O.29 32 6 4
2H20 requires C, 57.8; H, 6.0; N, 9.3%). XH n.m.r.
(CDCl^): 6 1.55, complex, H 3",4",5"; 2.51, complex, H2",6"; 
3.62, s, CH2; 7.04, s, H 3,5; 7.15, s, H 3'; 7.4, bs, NH; 
7.69, q, J-, 8.5 Hz, J,, OI 1.5 Hz, H 6'; 8.05, d,« 3 / 0  \3 / O
J-. rI 8.5 Hz, H 5'; 8.42, s, H 8'.5 , 6
2.6- Bis (morpholin-lM-ylmethyl) -4-[2 ' , 7 1 -bis (trif luoro­
methyl) quinolin-4'-ylamino]phenol (IV.23g)
4 — [2',71-Bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
(0.2 g), morpholine (3.0 ml), formalin (3.0 ml) and ethanol 
(10.0 ml) were treated and the product purified as in the 
preparation of compound (IV.23e). The oil solidified on 
standing and was recrystallized from aqueous ethanol to give
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yellow crystals of 2,6-bis(morpholin-l"-ylmethyl)-4- 
[2',71-bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
(0.25 g), m.p. 194-195° (Found: C, 57.2; H , 5.1; N, 10.0.
C27H28F6N4°3 rec3u^res C ' 56.8; H, 4.9; N , 9.8%). * H n.m.r. 
(CDC13) : 6 2.57, complex, H 2", 6"; 3.68, s, CH2; 3.75, 
complex, H 3",5"; 6.99, s, H 3'; 7.10, s, H 3,5; 7.70, q,
Jr, c , 8.5 Hz, J,, OI 1.5 Hz, H 6'; 8.06, d, J_, c , 8.5 Hz,
3 / 0  O / O  Z D / U
H 5’; 8.42, s, H 8'.
2.6- Bis(diethylaminomethyl)-4-[21,81-bis(trifluoro­
methyl )quinolin-41-ylamino]phenol (IV.2 6)
4-Bromo-2,8-bis(trifluoromethyl)quinoline6 5 ( i v .24)
(0.4 g) , p-aminophenol hydrochloride (0.26 g) , ethanol 
(15.0 ml) and water (5.0 ml) were heated in an autoclave 
at 160° for 48 h. The reaction mixture was washed out with 
methanol and the crude product subjected to thin-layer 
chromatography (alumina; ethanol) to give presumably 4- 
[2',8'-bis(trifluoromethyl)quinolin-4'-ylamino]phenol 
(IV.25) (0.1 g) to which was added diethylamine (2.0 ml),
formalin (2.0 ml) and ethanol (5.0 ml) and this solution 
refluxed for 20 h. This mixture was evaporated to dryness 
and the product after thin-layer chromatography (alumina; 
chloroform and silica; methanol) gave, as a yellow oil,
2.6- bis(diethylaminomethyl)— 4 — [21,81-bis(trifluoromethyl)- 
quinolin-41-ylamino]phenol (0.06 g) (Found: C, 59.55; H,
5.9; N, 10.1. C27H32F6N4° rec3uires C ' 59.8; H, 5.9; N, 10.3%).
*H n.m.r. (CDC13): 6 1.09, t, J 7 Hz, CH3CH2; 2.63, q,
J 7 Hz, CH3CH2; 3.71, s, CH2; 6.3, b, NH; 7.02, s, H 3';
7.06, s, H 3,5; 7.49 - 8.15, multiplet, H 5',6,,7'.
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N-(21-Diethylaminoethyl)-2,7-bis(trifluoromethyl)- 
quinolin-4-amine (IV.28a)
4-Bromo-2,7-bis(trifluoromethyl)quinoline (IV.20)
(0.2 g) and 2-diethylaminoethylamine (0.7 g) in heptane 
(10.0 ml) were heated in an autoclave at 160° for 20 h.
The reaction mixture was washed out with methanol, the 
solvents evaporated and excess amine removed at c. 100°/
0.5 mm Hg. The product was subjected to thin-layer 
chromatography (alumina; chloroform) and recrystallized 
from aqueous methanol to give N-(2'-diethylaminoethyl-2,7- 
bis(trifluoromethyl)quinolin-4-amine (0.15 g), m.p. 98-99°. 
(Found, for sample dried at 70° and 0.2 mm Hg: C, 54.1;
H, 5.3; N, 10.8. C]_7 H]_9 FgN 3 requires C, 53.8; H, 5.05; N, 
11.1%). lU n.m.r. (CDCl3): 6 1.10, t, J 7 Hz, CH3CH2;
2.65, q, J 7 Hz, CH^CH^; 2.87, complex, CH^N; 3.31, complex, 
CH2NH; 6.6, b, NH; 6.74, s, H 3; 7.68, q, J5 ß 8.5 Hz,
Jr 0 1.5 Hz, H 6; 7.89, d, Jc , 8.5 Hz, H 5; 8.37, bs, H 8.u j Ö j  / O
N-(41 -Diethy1amino-11-methylbutyl)-2,7-bis(trifluoro­
methyl) quinolin-4-amine (IV.28b)
4-Bromo-2,7-bis(trifluoromethyl)quinoline (0.2 g) with 
5-diethylaminopentan-2-amine (1.0 g) in heptane as in the 
preparation of compound (IV.28a) gave, after thin-layer 
chromatography (alumina; chloroform), N-(41-diethylamino- 
1'-methylbutyl)-2,7-bis(trifluoromethyl)quinolin-4-amine 
(0.2 g) as a yellow oil. (Found: C, 57.0; H, 6.2; N, 10.0.
C20H25F6N3 rec3ui-res C, 57.0; H, 6.0; N, 10.0%). *H n.m.r. 
(CDC13): 6 1.02, t, J 7 Hz, CH3CH2; 1.35, d, J 6 Hz,
CH3CH; 1.74, complex, CH^CH^CH; 2.45, complex, CH2N; 2.54,
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q, J 7 Hz, CH^CH^; 3.80, complex, CH; 6.10, bd, J 6 Hz,
NH; 6.80, s, H 3; 7.62, q, Jc , 8.5 Hz, Jr 0 1.5 Hz, H 6;5 , b b , o
7.94, d, J, c 8.5 Hz, H 5; 8.37, bs, H 8.J / o
N-(21-Diethylaminoethyl)-2,8-bis(trifluoromethyl)- 
guinolin-4-amine (IV.27a)
4-Bromo-2,8-bis(trifluoromethyl)quinoline (IV.24)
(0.2 g), 2-diethylaminoethylamine (0.7 g) and heptane 
(10.0 ml) were heated and the product purified as in the 
preparation of (IV.28a) to give white crystals of N-(2'- 
diethylaminoethyl) -2,8-bis (trif luoromethyl)quinolin-4- 
amine (0.18 g), m.p. 55-56° (Found, for sample dried at 
30° and 0.2 mm Hg: C, 53.9; H, 5.3; N, 11.0. cq7Hi9F6N 3 
requires C, 53.8; H, 5.05; N, 11.1%). *H n.m.r. (CDCl^): 
6 1.09, t, J 7 Hz, CH3CH2; 2.63, q, J 7 Hz, CH3CH2; 2.85, 
complex, CH2N; 3.26, complex, CH2NH; 6.5, b, NH; 6.72, s,
H 3; 7.43 - 8.06, multiplet, H 5,6,7.
N-(41-Diethylamino-11-methylbutyl)-2,8-bis(trifluoro­
methyl) quinolin-4-amine (IV.27b)
4-Bromo-2,8-bis(trifluoromethyl)quinoline (0.2 g), 
5-diethylaminopentan-2-amine (1.0 g) and heptane (10.0ml) were 
heated and the product purified as in the preparation of 
compound (IV.27a) to give N-(4'-diethylamino-11-methyl- 
butyl )-2,8-bis(trifluoromethyl)quinolin-4-amine (0.22 g) as
a yellow oil. (Found: C, 56.7; H, 6.3; N, 9.8. ^20H25F6N3 
requires C, 57.0; H, 6.0; N, 10.0%). 1H n.m.r. (CDC13):
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6 1.01, t, J 7 
1.71, complex, 
J 7 Hz, CH3CH2 
6.78, s, H 3;
Hz, CH3CH2; 1.33, d, J 6.5 Hz, CH^CH;
CH CH2CH2; 2.45, complex, CH2N : 2.53, q, 
; 3.77, complex, CH; 5.92, d, J 7 Hz, NH; 
7.39 - 8.04, multiplet, H 5,6,7.
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CHAPTER V
BIOLOGICAL EVALUATION OF ANTIMALARIAL ACTIVITY
V-l Introduction to Antimalarial Testing
Adequate measures for the evaluation of candidate 
compounds in malaria chemotherapy are of paramount 
importance. Moreover, the choice of laboratory methods 
or screening procedures can be critical. The history of 
malaria chemotherapy shows many discrepancies between 
promising laboratory results and clinical utility although, 
occasionally, gratifying agreement is apparent. Several 
major problems may arise in an antimalarial drug evaluation 
programme. These include the variations in drug 
susceptibility among life cycle stages of parasites and the 
diversity of objectives. The latter, encompasses treatment 
of the acute attack, radical cure, suppression, prophylaxis 
and interrupting transmission.
Nevertheless various experimental models are now 
available to assess the activity of established and 
potential new antimalarial compounds. These include the 
use of avian, rodent and simian malarias and, more 
recently, the development of techniques for the continuous 
in vitro cultivation108 of Plasmodium falciparum which has 
provided unprecedented opportunities for advancing the 
search for new antimalarial drugs and for elucidating the 
mechanisms of action of existing drugs.
However, two of these screening procedures only, 
namely the in vivo blood schizontocide screen in rodent
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malaria and the in vitro method involving a semi- 
automated microdilution technique, will be discussed 
below.
V-l-A In Vivo Blood Schizontocide Screen
in Rodent Malaria
The numerous isolated species and subspecies of rodent 
malarias can be divided into two main series, the bergei 
group and the vinckei group. The former, consisting of 
P. bergei, P. yoelii, P. y. nigeriensis and other sub­
species is used in the majority of chemotherapy research 
projects. The vinckei group, containing P. vinckei,
P. chabaudi, and several subspecies is less used.
The rodent malaria models are often used as a primary 
and secondary screen before monkey malaria screens. 
Moreover, the correlation of data on compounds tested in 
rodent malaria systems with monkey malaria system is 
usually in agreement.109-111 Blood schizontocide screens 
in rodent malaria are usually performed in one or other of 
the following two ways:-
V-l-Ai Single-Dose Regimens
These comprise the Rane1s test112 and Fink and 
Kretschmar's test.113 The former test system is based on 
the use of mice, inoculated intraperitoneally with asexual 
blood parasites, and treated 3 days later with one 
subcutaneous injection of the test compound. Antimalarial 
activity is assessed by comparing survival times of treated
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mice with those of infected, but untreated controls.
The Fink and Kretschmar's test system assesses anti- 
malarial activity by determining the prolongation of 
survival of mice by 20% (UD20)* This procedure was 
developed as a simple test to save time (no blood films 
required) and to use a smaller amount of test compound.
Since the development of the Rane's test system, over
250.000 compounds have been tested with approximately
8.000 exhibiting some antimalarial activity.114 It is 
interesting to note that all compounds currently used in 
humans infected with malaria are active in the Rane1s test.
V-l-Aii Multiple-Dose Regimens
A great many multi-dose test systems for evaluating 
potential antimalarial agents have been designed and 
described in the past. These include the Early Test 
Procedures, Four-Day Test, Drug-Diet Methods and the Six- 
Day Test as summarized by Ager.114
Chemotherapy studies using rodent malaria are, however, 
diversified and the proper standardisation of a test system 
involves the close scrutiny of a large number of variables. 
For example, rodent strains vary tremendously in their 
susceptibility to malaria.115-117 Overall, the rodent 
malaria models have proven to be extremely valuable in 
assessing the activity of established and potential new 
antimalarial compounds.
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V-l-B In Vitro Evaluation of Potential
Antimalarial Drugs
The discovery of an efficient method of cultivating 
the blood stages of P. falciparum by Träger and Jensen10 8 
in 1976 was an event of major importance. Soon after, 
Desjardins et ad.118 described a rapid semiautomated 
technique for assessment of antimalarial drug activity 
using continuous cultures as a source of known resistant 
and susceptible isolates of P. falciparum. This 
technique, which employs standard microtitration equipment 
and radioisotope uptake as an indicator of parasite growth 
and multiplication, was designed with maximum efficiency 
and precision for use in an experimental antimalarial drug 
development programme. Analyses of the resulting data 
required application of non-linear curve fitting techniques. 
The data for each active compound were fitted to a 
generalised logistic-logarithmic function which included 
the ID50 (concentration of a drug causing 50% inhibition 
of the incorporation of radiolabelled nucleic acid precursor, 
3H-hypoxanthine) as one of its parameters. The output from 
the computer programme included a graph such as those in 
Figs. V .1 and V.2, which show the activity of chloroquine 
against a sensitive (African-Uganda I) and resistant 
(Vietnam-Smith) isolate of P. falciparum, respectively.
Also included in the output were the respective estimates 
of the ID5 0 and slope of the curve with corresponding 95% 
confidence limits. These estimates for chloroquine, 
amodiaquine, quinine, pyrimethamine, and mefloquine 
against two isolates of the parasite are shown in Table V.l 
(data from ref.119).
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Chloroquine vs Uganda I
10.25 (ng/ml)
10 100 
Concentration (ng/ml)
1000
Fig. V.l. A logistic-logarithmic analysis of the effect of 
chloroquine at various concentrations on the uptake of 
3H-hypoxanthine in vitro by erythrocytes parasitised with 
a chloroquine-sensitive isolate (African-Uganda I) of 
P. falciparum. After Desjardins et al. (ref. 118).
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Fig. V.2. A logistic-logarithmic analysis of the effect of 
chloroquine at various concentrations on the uptake of 
3H-hypoxanthine in vitro by erythrocytes parasitized with a 
chloroquine-resistant isolate (Vietnam-Smith) of P .falciparum. 
After Desjardins et al. (ref. 118) . -------------*
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V-2 Determination of Antimalarial Activity
of Compounds Synthesised during this Work 
Compounds synthesised in this work were screened for 
antimalarial activity by the following sequence of tests. 
Firstly each chemical was examined for toxicity in mice 
prior to the preliminary antimalarial screen. In this, 
mice were injected intraperitoneally with appropriate doses 
of the test chemical to establish dosages which would not 
cause acute toxic death among the test mice. Secondly, 
each chemical was evaluated in a preliminary screen for 
antimalarial activity in an in vivo test in mice infected 
with P. vinckei vinckei. Then potential antimalarial 
candidates from the preliminary screen were forwarded to 
the Army Malarial Research Unit, Ingleburn, N.S.W., 
Australia, for further in vitro evaluation against both 
chloroquine-sensitive (FCQ-27) and chloroquine-resistant 
(K-l) strains of P, falciparum.
V-2-A Toxicity Testing
Each chemical was tested for acute toxicity in three 
mice by injection intraperitoneally, each with a single dose 
in normal saline or peanut oil, at a dose level between 
100 to 200 mg/kg of body weight. Appropriate adjustment 
of the dosage was necessary in some cases until no 
detection of acute toxic death among the test mice.
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V-2-B Preliminary Antimalarial Screen
Mice were injected intraperitoneally with 106 
erythrocytes infected with P. vinckei vinckei which were 
obtained from an infected donor mouse. After 5 days 
(and daily thereafter) each mouse was examined for suitable 
parasitaemia levels (generally 10-20%). In this, thin 
blood smears were taken, slides were fixed with methanol, 
stained (Giemsa's Stain) and the mean percentage of 
parasite-infected red cells was determined as the average 
of two or more counts on each slide which varied by no 
more than ± 5% of the mean value.
At infection levels of preferably 10-20%, each test 
chemical at a dosage of 50, 100 or 200 mg/kg of body weight 
in 0.4 ml of normal saline or peanut oil was given intra­
peritoneally to three mice whose individual parasitaemia 
had just previously been determined. Thereafter thin 
blood smears were taken from each mouse at time intervals 
indicated in Tables (V.2-8) and the parasitaemia assessed 
as above. The results for the three mice were then 
averaged at each time point.
Control tests were made against peanut oil and normal 
saline, and reference tests run against primaquine and/or 
chloroquine (as diphosphates).
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V-2-C In Vitro Screen against two Isolates of 
Chloroquine-sensitive and Chloroquine- 
resistant Plasmodium falciparum 
The semiautomated microdilution technique as described 
by Desjardins et a_l. 1 1 8 with slight modification120 was 
employed for measuring the activity of potential anti- 
malarial agents [previously showing promise in the P. vinckei 
- mouse model (V-2-B)] against cultured intraerythrocytic 
asexual forms of Plasmodium falciparum. The two isolates 
of P. falciparum used in the in vitro screen were maintained 
routinely by the culture technique of Träger and Jensen10 8 
and are from the following sources:
FCQ-27 isolate from Dr G. Butcher (Royal Newcastle 
Hospital, Newcastle, Australia).
K-l isolate from Dr A. Saul (Queensland Institute of 
Medical Research).
These in vitro tests were carried out by Mr Haydn V. Scott 
of the Army Malaria Research Unit, Milpo, Ingleburn, New 
South Wales, Australia, and the results were recorded in 
Tables (V.9-11).
Peters et aJ.12 1 have derived chloroquine resistance 
indices of 1.4 and 6.9 for the FCQ-27 and K-l isolates 
respectively, from data reported earlier.122'123 Our 
results120 give an index of 0.4 for FCQ-27 and 10.7 for K-l; 
but would not be expected to yield the same numerical values 
as the earlier studies since different experimental 
procedures120 were employed. Knowles et ad..,124 from an 
examination of 18 isolates of P. falciparum ranked FCQ-27 
as the second most chloroquine sensitive and K-l the second 
most chloroquine resistant.
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V-3 Results of Antimalarial Tests
The compounds described in CHAPTER II, III and IV 
were screened for antimalarial activity in the preliminary 
in vivo tests against P. vinckei vinckei in mice and 
promising compounds were further evaluated in the in vitro 
tests against P. falciparum as described above. The 
in vivo results are recorded in Tables (V.2-8) and the 
in vitro results are in Tables (V.9-11).
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V-4 Discussion of Results
Although preliminary in vivo rodent screening results 
were obtained in full for all target chemicals synthesised 
in this work, only some of the candidate compounds selected 
for further in vitro tests against P. falciparum were 
evaluated in time to be included in this thesis.
Discussion of the results obtained is dealt with separately 
under two headings.
V-4-A In Vivo Screen against P. vinckei vinckei
4It is clear from Table V.2 that none of the N - 
substituted-2-methoxy (and 2-hydroxy)-1,5-naphthyridin-4- 
amines showed any significant antimalarial activity (as 
blood schizontocides) at a dosage of 100 mg/kg, as compared 
to the controls, chloroquine and primaquine. These 
observations are in contrast to the report of McCaustland 
and Cheng56 that "5-azapamaquine" (I.21b) and its chloro- 
analogue (I.21d) were active against P. bergei. The role 
of this series of 2,4-disubstituted 1,5-naphthyridin-4- 
amines (also considered as derivatives of 8-aminoquinolines) 
as potential prophylactic agents is yet to be evaluated in 
either the P. cynomolgi - rhesus monkey test system125'126 
or other appropriate avian, or rodent malaria models.
4The N -substituted-7-bromo (and chloro)-l,5- 
naphthyridin-4-amines (Table V.3) all showed blood 
schizontocidal activity in varying degree. Apparent cures 
were effected in the case of "5-azabromoquine" (II.33a) and 
compound (II.33b). Relative to "bromoquine"127 which has
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an LD50 of 72 mg/kg in mice127 for a single intra- 
peritoneal (i.p.) dose, "5-azabromoquine" is significantly 
less toxic, with no apparent ill effects at a dosage of 
200 mg/kg. It appears therefore that aza-substitution 
also decreases toxicity. Of the naphthyridines with 
terminal primary amino groups, the highest activity was 
shown by compound (II.33c) which decreased to no significant 
activity in (II.33g) at the test concentration of 200 mg/kg. 
The sulfide (11.35), unlike its nitrogen analogue (II.33b), 
showed no antimalarial activity which is consistent with 
Schönhöfer's hypothesis128'129 that a quinonoid system 
between the ring nitrogen and the amine side chain in 4-,
6-, or 8-aminoquinoline derivatives is required for anti- 
malarial activity. N,N'-Bis(7n-bromo-l",5"-naphthyridin- 
4"-yl)benzene-1,4-diamine (11.37) and 4-(7'-bromo-1’,5'- 
napthyridin-4'-ylamino)aniline (11.38) were also devoid of 
any activity against P. vinckei vinckei in mice.
All the mono- and di-Mannich bases (Table V.4) derived 
from 4-[7'-bromo (and chloro)-1',5'-naphthyridin-4'-ylamino]- 
phenols, were extremely effective as blood schizontocides. 
Parasitaemia in most cases was reduced to less than 1% 
within 24 to 48 h following a single i.p. dose of 100 to 
200 mg/kg of the test chemicals. This low level of 
parasitaemia was maintained in many instances, to and 
beyond 19 days of the test period. The pattern of an 
initial knockdown of parasite level by a test compound and 
then an upsurge followed by a decrease in parasitaemia 
again is the classical example of the involvement of host- 
immune response. The "unsymmetrical" di-Mannich base
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(11.42) also appeared to be an effective blood schizontocide 
in this P. vinckei vinckei - mouse model.
All of the 1,8-naphthyridine derivatives (Table V.5) 
including the 8 aza-analogue (III.34) of amodiaquine (I.5a) 
were found to be inactive as antimalarials. It appeared 
that 8 aza-substitution in the quinoline ring of amodiaquine 
destroys the antimalarial activity.
The mono- and di-Mannich bases (Table V.6) of 4-(7'- 
trifluoromethylquinolin-4'-ylamino)phenols all showed very 
significant antimalarial activity in a single i.p. dose of 
100 mg/kg [except for compound (IV.19i) which was toxic at 
100 mg/kg and was tested at 50 mg/kg]. Parasitaemia of test 
mice was reduced to less than 1% in all cases between 24 to 
48 h following treatment.
These observations were not repeated in the 4-[2',7'- 
and 2',8'-bis(trifluoromethyl)quinolin-4'-ylamino]phenols
4and N -substituted 2,7- (and 2,8-)bis(trifluoromethyl)- 
quinolin-4-amines reported in Tables V.7 and V.8. It 
appeared that insertion of the 2-trifluoromethyl substituent 
into compound (IV.19b) to give (IV.23c) eliminated the 
antimalarial activity shown by the former; and a shift 
of the trifluoromethyl substituents to the 2,8-positions 
gave (IV.26) which also reduced the antiplasmodial activity. 
Nevertheless, 2,7- and 2,8-bis(trifluoromethyl) substituents 
have been shown6 5 to be structural requirements for potent 
blood schizontocides in various quinolinemethanols 
including mefloquine.
167
V-4-B In Vitro Screen against P. falciparum
Among the few 7-bromo (and chloro)-1,5-naphthyridin- 
4-amines (Table V.9) selected for in vitro P. falciparum 
test, only compounds (II.33a) and (II.33b) approached the 
potency of chloroquine and mefloquine against the FCQ-27 
isolate, but seemed to show cross-resistance with 
chloroquine in the test against the K-l strain of P. 
falciparum.
However, when the 4-(7'-bromo-1',5'-naphthyridin-4'- 
ylamino)phenols (Table V.10) were examined for activity 
against P. falciparum, all except compound (II.41b) were 
highly active against the chloroquine-sensitive FCQ-27 
strain; and of these, compounds (II.41d-g) showed little 
or no cross-resistance with chloroquine against the K-l 
isolate. Moreover, the potency of the latter four 
compounds (as measured by their ID50 values) approached, 
and was not significatly different from, those of either 
mefloquine or amodiaquine.
The series of Mannich bases (Table V.ll) derived 
from 4-(7'-trifluoromethylquinolin-4'-ylamino)phenols 
appeared to be extremely active with ID50 values all well 
below 10 nmol/1 with both isolates of P. falciparum. 
Compound (IV.19e) in particular, is far superior to either 
chloroquine, amodiaquine or mefloquine and the ID50 of the 
former compound is essentially the same for the two 
strains of P. falciparum.
The in vitro results obtained in Tables V.10 and V.ll 
suggest that the Mannich bases (II.41d-g), (IV.17) and 
(IV.19a-h) are a series of antimalarial compounds worthy
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of further study, especially when earlier toxicity trials 
are taken into account130'131 (cf. the LD50 for a single 
i.p. dose of chloroquine, 68-78 mg/kg132). These compounds 
will be investigated further in in vivo studies by testing 
against chloroquine-sensitive and resistant lines of 
P. bergei produced in mice as well as by examining their 
antimalarial activity against P. falciparum in owl monkeys 
(Aotus trivirgatus).
Nevertheless, the work covered in this thesis is far 
from complete. Further work is envisaged to involve the 
synthesis of similar Mannich bases with quinazoline or 
pyrido[3,2-d]pyrimidine as the heterocyclic nucleus 
carrying suitable halogeno or trihalogenomethyl substituents, 
because the present work and various literature evidence 
suggest aza-substitution in the quinoline nucleus of anti- 
malarial agents reduces their intrinsic toxicity. It is 
therefore hoped that this further work will lead to an 
emergence of a new class of antimalarials in an attempt to 
overcome or alleviate the existing problem of drug
resistance.
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INDEX TO NEW COMPOUNDS
4 — (4'-Aminobutylamino)-1,5-naphthyridin-2-ol 6 2
N- (4 1-Aminobutyl)-2-methoxy-l,5-naphthyridin-
4-amine 58
4 — (6'-Aminohexylamino)-1,5-naphthyridin-2-ol 6 3
N- (6 '-Aminohexyl)-2-methoxy-l, 5-naphthyridin-
4-amine 59
4-(5'-Aminopentylamino)-1,5-naphthyridin-2-ol 62
N - (5'-Aminopentyl)-2-methoxy-l,5-naphthyridin-
4-amine 59
4-(3'-Aminopropylamino)-1,5-naphthyridin-2-ol 61
N-(3'-Aminopropyl)-2-methoxy-l, 5-naphthyridin-
4-amine 57
N ,N'-Bis(7"-bromo-1",5"-naphthyridin-4"-yl)-
benzene-1,4-diamine 72
2.6- Bis(diethylaminomethyl)— 4 — [2',7'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 130
2.6- Bis(diethylaminomethyl)-4-[2',8'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 133
2 .6- Bis(diethylaminomethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 123
2 , 6-Bis(dimethylaminomethyl)-4-[2',7'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 129
2 .6- Bis(dimethylaminomethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 122
2.6- Bis(3",5"-dimethylpiperidin-l"-ylmethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 126
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2.6- Bis(dipropylaminomethyl)-4-[2',7'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 131
2.6- Bis(dipropylaminomethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 123
2.6- Bis(4n-methylpiperazin-l"-ylmethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 127
2.6- Bis(2"-methylpiperidin-l"-ylmethyl) - 4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 125
2.6- Bis(morpholin-l"-ylmethyl)— 4 — [2',7'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 132
2.6- Bis(morpholin-l"-ylmethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 126
2.6- Bis(piperidin-l"-ylmethyl)-4-[2', 7 '-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 132
2.6- Bis(piperidin-l"-ylmethyl)-4-
(7'-trifluoromethylquinolin-41-ylamino)phenol 125
2.6- Bis(pyrrolidin-l"-ylmethyl)— 4 — [2 * ,7'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 131
2, 6-Bis(pyrrolidin-l"-ylmethyl)-4-
(7'-trifluoromethylquinolin-4'-ylamino)phenol 124
4-[2',1'-Bis(trifluoromethyl)quinolin-4'-
ylamino]phenol 128
3-Bromo-8-chloro-l,5-naphthyridine 64
7-Bromo-N-(4'-diethylaminobutyl)-1,5-
naphthyridin-4-amine 67
7-Bromo-N-(2'-diethylaminoethyl)-1,5-
naphthyridin-4-amine 66
7-Bromo-N-(41-diethylamino-1'-methylbutyl)-
1,5-naphthyridin-4-amine 65
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7-Bromo-N-(3'-diethylaminopropyl)-1,5-
naphthyridin-4-amine 66
7-Bromo-N-(3'-dimethylaminopropyl)-1,5-
naphthyridin-4-amine 69
7-Bromo-4-hydroxy-l,5-naphthyridine-3-
carboxylic acid 63
3- Bromo-8-methoxy-l,5-naphthyridine 71
7-Bromo-l,5-naphthyridin-4-ol 64
4 — (71-Bromo-1' , 5'-naphthyridin-4'-ylamino)-
aniline 72
4 — (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-
2.6- bis(diethylaminomethyl)phenol 77
4 — (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-
2.6- bis(dimethylaminomethyl)phenol 7 6
4 — (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-
2.6- bis(3",5"-dimethylpiperidin-l"-ylmethyl)-
phenol 80
4—  (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-
bis(dipropylaminomethyl)phenol 78
4 — (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-
bis(4 M-methylpiperazin-l"-ylmethyl)phenol 81
4-(71-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-
bis(2"-methylpiperidin-l"-ylmethyl)phenol 79
4 — (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-
bis(morpholin-4"-ylmethyl)phenol 81
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-
bis(piperidin-l"-ylmethyl)phenol 79
4-(71-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-
bis(pyrrolidin-l"-ylmethyl)phenol 78
172
4 — (7'-Bromo-1', 5'-naphthyridin-4'-ylamino)-
butylamine 67
4-(7'-Bromo-1',51-naphthyridin-4'-ylamino)-2-
diethylaminomethylphenol 73
4 — (7'-Bromo-1' , 5'-naphthyridin-4'-ylamino)-2-
dimethylaminomethylphenol 74
4-(7'-Bromo-1', 5 1-naphthyridin-4'-ylamino)-6- 
dimethylaminomethyl-2-pyrrolidin-l"-
ylmethylphenol 82
4- (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2-
dipropylaminomethylphenol 75
6- (7'-Bromo-11,5'-naphthyridin-4'-ylamino)-
hexylamine 68
5- (7'-Bromo-11,5'-naphthyridin-4'-ylamino)-
pentylamine 68
4 — (7 *-Bromo-11,5'-naphthyridin-4'-ylamino)-
phenol 74
4 — (7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2-
pyrrolidin-l"-ylmethylphenol 76
7- Chloro-N-(4'-diethylaminobutyl)-1,5-
naphthyridin-4-amine 70
7-Chloro-N- (2'-diethylaminoethyl) -1,5-
naphthyridin-4-amine 70
4 — (7'-Chloro-2'-methyl-1',8'-naphthyridin-4'-
ylamino)-2-diethylaminomethylphenol 107
4 — (71-Chloro-l',5'-naphthyridin-4'-ylamino)-
2.6- bis(diethylaminomethyl)phenol 84
4-(7'-Chloro-1',5'-naphthyridin-4'-ylamino)-
2.6- bis(dimethylaminomethyl)phenol 84
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4 — (7'-Chloro-1' , 5 '-naphthyridin-4'-ylamino)-
2.6- bis(dipropylaminomethyl)phenol 85
4-(7'-Chloro-1',5'-naphthyridin-4'-ylamino)-
2.6- bis(pyrrolidin-1"-ylmethyl)phenol 85
4 — (71-Chloro-1', 5'-naphthyridin-4'-ylamino)-
2-diethylaminomethylphenol 82
4-(7'-Chloro-1',8'-naphthyridin-4'-ylamino)-
2-diethylaminomethylphenol 106
4-(7'-Chloro-1', 5'-naphthyridin-4'-ylamino)-
phenol 83
2,5-Dichloro-l,8-naphthyridine 106
4-(2'-Diethylaminoethylamino)-1,5-naphthyridin-
2-ol 60
N - (2'-Diethylaminoethyl)-2,7-bis(trifluoromethyl)-
quinolin-4-amine 134
N-(2'-Diethylaminoethyl)-2,8-bis(trifluoromethyl)-
quinolin-4-amine 135
N-(2'-Diethylaminoethyl)-2-methoxy-l,5-
naphthyridin-4-amine 56
2-Diethylaminomethyl-4-[2',7'-bis(trifluoromethyl)-
quinolin-4'-ylamino]phenol 128
N - (4'-Diethylamino-1'-methylbutyl)-2,7-bis-
(trifluoromethyl)quinolin-4-amine 134
N-(4'-Diethylamino-1'-methylbutyl)-2,8-bis-
(trifluoromethyl)quinolin-4-amine 135
N-(4'-Diethylamino-1'-methylbutyl)-2,7-dimethyl-
1 ,8-naphthyridin-4-amine 104
N - (4'-Diethylamino-1'-methylbutyl)-7-methyl-
1f8-naphthyridin-4-amine 100
174
N-(4'-Diethylamino-1'-methylbutyl)-1, 8-
naphthyridin-4-amine 103
2-Diethylaminomethyl-4-(2', 7'-dimethyl-1 1,8'-
naphthyridin-4'-ylamino)phenol 103
2-Diethylaminomethyl-4-(2'-methoxy-1' , 5 ' -
naphthyridin-41-ylamino)phenol 55
2-Diethylaminomethyl-4-(7'-methyl-1' , 8 ' -
naphthyridin-4'-ylamino)phenol 99
2-Diethylaminomethyl-4-(11, 8 '-naphthyridin-
4'-ylamino)phenol 102
2-Diethylaminomethyl-4-(7'-trifluoromethyl-
quinolin-4'-ylamino)phenol 121
4 — (3 *-Diethylaminopropylamino-1,5-
naphthyridin-2-ol 60
N-(3'-Diethylaminopropyl)-2-methoxy-l,5-
naphthyridin-4-amine 56
N,N-Diethyl-2-(7'-bromo-1', 5'-naphthyridin-4'-
ylthio)ethylamine 71
2-Diisobutylaminomethyl-4-[2',7'-bis-
(trifluoromethyl)quinolin-4'-ylamino]phenol 129
6-Ethoxycarbonyl-5-hydroxy-l,8-naphthyridine-
2-carboxylic acid 100
4 — (7'-Trifluoromethylquinolin-4'-ylamino)phenol 121
175
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Potential Antimalarials. I 
1,8-Naphthyridines
Gordon B. Barlin and Weng-Lai Tan
Medical Chemistry Group, John Curtin School of Medical Research, 
Australian National University, P.O. Box 334, Canberra, A.C.T. 2601.
Abstract
A number of 1,8-naphthyridines including 8-aza analogues of chloroquine and amodiaquine, and 
similar 1,8-naphthyridines with 2- and 7-methyl substituents have been prepared. These compounds 
showed minimal antimalarial activity in a preliminary in vivo screen against Plasmodium vinckei 
vinckei.
Introduction
The acquired resistance of strains of malaria parasites to many of the known anti­
malarials1“4 has prompted the preparation of new structure types which incorporate 
other heterocyclic rings or variations to substituents in presently used heterocyclic 
nuclei to give compounds which may be more effective antimalarial agents.
McCaustland and Cheng'’ synthesized several 1,5-naphthyridine congeners of 
chloroquine (1; X = CH) and found that 7-chloro-/V-(4'-diethylamino-r-methyl- 
butyl)-l,5-naphthyridin-4-amine (1; X = N), ‘5-azachloroquine’, possessed very 
good antimalarial activity against Plasmodium berghei in mice. It was comparable 
to chloroquine in activity when screened for blood schizontocidal activity and was 
much less toxic than chloroquine. Other potential antimalarial l,5(and l,8)-naph- 
thyridines have been synthesized by Adams et a!. , 6 and Goldberg et al.1
Chien and Cheng8 have also prepared a number of 1,7-naphthyridines in which 
the electron-withdrawing chloro substituent of chloroquine and amodiaquine was
1 Bruce-Chwatt, L. J., et al., (Eds), ‘Chemotherapy of Malaria’ 2nd Edn, p. 102 (World Health 
Organization: 1981).
2 Peters, W., ‘Malaria’ (Ed. J P. Kreier) Vol. 1, p. 145 (Academic Press: New York 1980).
3 Rollo, I. M., in Goodman and Gilman’s ‘The Pharmacological Basis of Therapeutics’ (Eds A. G. 
Gilman, L. S. Goodman and A. Gilman) 6th Edn, p. 1041 (Macmillan: New York 1980).
4 Peters, W., ‘Chemotherapy and Drug Resistance in Malaria’ p. 364 (Academic Press: London 
1970).
5 McCaustland, D. J., and Cheng, C. C., J. Heterocycl. Chem., 1970, 7, 467.
6 Adams, J. T., Bradsher, C. K., Breslow, D. S., Amore, S. T., and Hauser, C. R., J. Am. Chem. Soc., 
1946, 68, 1317.
7 Goldberg, A. A., Theobald, R. S., and Williamson, W., J. Chem. Soc., 1954, 2357.
8 Chien, P.-L., and Cheng, C. C., J. Med. Chem., 1968, 11, 164.
0004-9425/84/051065S02.00
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replaced by a doubly bound ring nitrogen atom. yV-(4'-Diethylamino-r-methylbutyl)- 
l,7-naphthyridin-4-amine (2) and 2-diethylaminomethyl-4-(T,7,-naphthyridin-4'-yl- 
amino)phenol produced only a slight extension in survival time of mice infected with 
P. berghei compared to untreated controls. Neither of these compounds approached 
the potency of chloroquine.
The effect on antimalarial activity when the chloroquine molecule was modified 
by the addition of (a) ring nitrogens, (b) exocyclic groups containing electron-rich 
centres, and (c) groups capable of hydrophobic bonding to the quinoline ring has 
been examined by Temple, Rose, Elliott and Montgomery.9,10 They synthesized a 
large series of substituted pyrido[2,3-/>]pyrazines and found the most potent, when 
screened in the P. berghei!mouse model for blood schizontocidal activity, to be 
8-(4'-diethylamino-r-methylbutyl)amino-3-/?-(trifluoromethyl)phenylpyrido[2,3-6]pyr- 
azin-6-amine (3). It gave 100% cures at a dose of 640 mg/kg, and was less acutely 
toxic and much superior to chloroquine in this model.
9 Temple, C., Rose, J. D., Elliott, R. D., and Montgomery, J. A., J. Med. Chem., 1968, 11, 1216.
10 Temple, C., Rose, J. D., Elliott, R. D., and Montgomery, J. A., J. Med. Chem., 1970, 13, 853.
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We have commenced a study of potential antimalarial substances, and in this 
paper report on the synthesis and testing of a series of 1,8-naphthyridines (8-aza- 
quinolines) (4)-(6).
Synthesis
The synthesis of the 1,8-naphthyridines in this work commenced from pyridine- 
amines. 6-Methylpyridin-2-amine (7; R = Me) with diethyl ethoxymethylene- 
malonate (8) gave diethyl (6'-methylpyridin-2'-yl)aminomethylenemalonaten (9) 
which refluxed in diphenyl ether gave ethyl 4-hydroxy-7-methyl-l,8-naphthyridine- 
3-carboxylate11 12 (10; R1 = Me, R2 = OH, R3 = COOEt). The latter, hydrolysed 
in aqueous potassium hydroxide, and the acid13 (not isolated) decarboxylated in 
refluxing quinoline to 7-methyl-l,8-naphthyridin-4-ol12,13 (10; R1 = Me, R2 = OH, 
R3 = H). The last-named compound was converted as described by Brown12 into 
5-chloro-2-methyl-l,8-naphthyridine and displacement of the chloro substituent 
occurred with 4-amino-2-diethylaminomethylphenol at 100° and 5-diethylamino- 
pentan-2-amine at 160° to give (5) and (6) (R1 = Me, R3 = H) respectively.
Ethyl 4-hydroxy-7-methyl-l,8-naphthyridine-3-carboxylate (10; R1 = Me, R2 = 
OH, R3 = COOEt) was oxidized by selenium dioxide in good yield to 6-ethoxy- 
carbonyl-5-hydroxy-l,8-naphthyridine-2-carboxylic acid (10; R1 = COOH, R2 = 
OH, R3 = COOEt) which hydrolysed in alkali and the diacid decarboxylated in 
quinoline to l,8-naphthyridin-4-ol (10; R1 = R3 = H, R2 = OH). Direct bromina- 
tion of the latter with phosphoryl bromide gave 4-bromo-l,8-naphthyridine which 
had previously been prepared from 2,4-dibromo-l,8-naphthyridine.14 4-Bromo-
1.8- naphthyridine reacted with 4-amino-2-diethylaminomethylphenol and 5-diethyl- 
aminopentan-2-amine under similar conditions to those described above to give (5) 
and (6) (R1 = R2 = H) respectively.
4-Chloro-2,7-dimethyl-l,8-naphthyridine1:’ (4; R1 = R3 = Me, R2 = Cl) was 
prepared from 6-methylpyridin-2-amine (7; R = Me) through 2,6-dimethylpyrido- 
[l,2-a]pyrimidin-4-one (11) and 2,7-dimethyl-l,8-naphthyridin-4-ol1:' (4; R1 = R3 = 
Me, R2 = OH), and it reacted with amines to give the desired potential antimalarials.
l,8-Naphthyridine-2,5-diol was prepared from 6-aminopyridin-2-ol (7; R = OH) 
and diethyl ethoxymethylenemalonate at 100° followed by hydrolysis of the ester 
(10; R1 = R2 = OH, R3 = COOEt) to the acid which was decarboxylated by 
refluxing in diphenyl ether for 9 h. This compound has also been prepared from 
7-amino-ES-naphthyridin^-ol16 and reported by Hermecz et a l}1 2,5-Dichloro-
1.8- naphthyridine, prepared from the dihydroxy compound by chlorination with 
phosphoryl chloride, reacted with 4-amino-2-diethylaminomethylphenol dihydro­
chloride in water by replacement of the 5-chloro substituent to give 4-(7'-chloro- 
r,8'-naphthyridin-4'-ylamino)-2-diethylaminomethylphenol in which the site of sub-
11 Lappin, G. L., J. Am. Chem Soc., 1948, 70, 3348.
12 Brown, E. V., J. Org. Chem., 1965, 30, 1607.
13 Möller, K., and Siis, O., Justus Liebigs Ann. Chem., 1957, 612, 153.
14 Czuba, W., and Wozniak, M., Synthesis, 1974, 809.
15 Chandler, C. J., Deady, L. W., Reiss, J. A., and Tzimos, V., J. Heterocycl. Chem., 1982, 19, 1017. 
16Carboni, S., Da Settimo, A., Bertini, D., Ferrarini, P. L., Livi, O., Mori, C., and Tonetti, I., 
Gazz. Chim. Ital., 1972, 102, 253.
17 Hermecz, I., Meszäros, Z., Vasväri-Debreczy, L., Horvath, A., Horvath, G., and Pongor-Csäkväri, 
M., J. Chem. Soc., Perkin Trans. 1, 1977, 789.
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stitution was established by catalytic dechlorination to the pre-prepared 2-diethyl- 
aminomethyl-4-(r,8'-naphthyridin-4'-ylamino)phenol. 2,5-Dichloro-l,8-naphthyri- 
dine also reacted with 5-diethylaminopentan-2-amine alone to give monosubstitution 
but removal of excess 5-diethylaminopentan-2-amine was difficult. The absence of 
disubstitution is probably associated with relative deactivation of the chloro sub­
stituent in the monoamino monochloro product.
Table 1. Preliminary antimalarial screening results against Plasmodium vinckei vinckei in mice
For details of test procedure see Experimental section
Com- Dose Mean (%) of parasite infected red cells
pound (mg/kg) Pre­
treatment
Time from administration of dose 
3 h 6 h 12 h 20 h 22 h 24 h
(5; R ‘ =  R 3 =  H) 10 24 45 A
20 25 32 34 A
50 40 40 A
(6; R 1 =  R 3 =  H) 10 24 26 A
20 28 A
50 35 A
(5; R 1 =  Me, R 3 =  H) 10 31 41 38
20 25 35 35 31 A
50 43 43 A
(6; R 1 =  Me, R 3 =  H) 10 34 44 A
20 43 63 65 68 A
50 50 A
(5; R 1 =  R 3 =  Me)B 50 40 40 55
(6; R1 =  R3 =  Me) 10 28 29 40
20 36 36 46
30 23 29 30 34 60
50 40 A
(5; R1 -  Cl, R3 =  H) 10 29 39 45 41 A
(5; R 1 =  Cl, R3 =  Me) 10 19 27 29 A
Control 28 40 38 52 58
A Toxic death. 
b 2HC1.2H20 .
7-Amino-2-methyl-l,8-naphthyridin-4-ol (4; R1 = NH2, R2 = OH, R3 = Me) 
was prepared by condensation of pyridine-2,6-diamine (7; R = NH2) with ethyl 
acetoacetate in diphenyl ether. The desired product was separated from the mixture 
containing the isomeric 2-hydroxy-4-methyl compound by the preferential solubility 
of the former in ethanol. Carboni et al2 6 have reported the preparation of 7-amino- 
2-methyl-l,8-naphthyridin-4-ol from pyridine-2,6-diamine and ethyl acetoacetate 
through a series of intermediates, but the preparation reported by Hauser and Weiss18 
is in error.16
4,7-Dichloro-2-methyl-l,8-naphthyridine19 (4; R1 = R2 = Cl, R3 = Me) (pre­
pared from 7-amino-2-methyl-l,8-naphthyridin-4-ol19 through 2-methyl-1,8-naph- 
thyridine-4,7-diol)19 reacted with 4-amino-2-diethylaminomethylphenol (dihydro­
chloride) in water at 100°, and the structure of the monosubstitution product, 4-(7'- 
chloro-2'-methyl-1,8-naphthyridin-4'ylamino)-2-diethylaminomethylphenol, was as­
signed from the similar reaction of 2,5-dichloro-l,8-naphthyridine described above.
18 Hauser, C. R., and Weiss, M. J., J. Org. Chem., 1949, 14, 453.
19 Carboni, S., Da Settimo, A., Pirisino, G., and Segnini, D., Gazz. Chim. Ital., 1966, 96, 103.
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Biological Activities
In vivo evaluation for antimalarial activity against Plasmodium vinckei vinckei in 
preliminary screening in rodents was examined, and the results are summarized in 
Table 1. Minimal antimalarial activity was detected in the compounds examined 
when compared to the progressive increase in mean percentage of parasite infected 
red cells of the control sample.
More refined test results will be presented in a forthcoming publication.
Experimental
Solids for analysis were dried at 100° (unless otherwise specified), and melting points were taken 
in Pyrex capillaries. Analyses were performed by the Australian National University Analytical 
Services Unit. 'H n.m.r. spectra were recorded at 90 MHz and 30’ with a jeol FX90Q Fourier 
transform spectrometer with tetramethylsilane (in CDC13 and CD3SOCD3) and sodium 3-tri- 
methylsilylpropanesulfonate (in D20) as internal standards.
Ethyl 4-Hydroxy-7-methyl-l,8-naphthyridine-3-carboxylate (10; R' — Me, R2 — OH, R3 = COOEt)
This compound was prepared from 6-methylpyridine-2-amine by reaction with diethyl ethoxy- 
methylenemalonate at 110° to give diethyl (ö'-methylpyridin^'-yOaminomethylenemalonate11 
followed by ring closure by repeated refluxing in diphenyl ether11,12 for 10 min. The product,11 
recrystallized from ethanol, had m.p. 271-272° (lit.11 278-280°). !H n.m.r. CD3SOCD3: ö 1-28, 
t, J 1  Hz, CH3CH2; 2-60, s, 7-Me; 4-21, q, J  7 Hz, CH3CH2; 7-70, d, 8-40, d, J  10-5 Hz, H5,6; 
8-48, s, H 2.
7-Methyl-1,8-naphthyridin-4-ol (10; R l — Me, R2 — OH, R3 = H)
A mixture of ethyl 4-hydroxy-7-methyl-l,8-naphthyridine-3-carboxylate (2 0 g) and potassium 
hydroxide (3 0 g) in water (20 ml) was heated on a steam bath for 1 -75 h, cooled and adjusted with 
5 m hydrochloric acid to pH c. 3-5. The free acid separated as a dense yellowish precipitate (1 -2 g) 
which was filtered off, washed with water and dried. This product was refluxed in quinoline (40 ml) 
for 2 - 5 h, excess solvent removed under reduced pressure, the residue dissolved in 1 m sodium hydrox­
ide and extracted with a small volume of ether to remove the last traces of quinoline. The aqueous 
solution was neutralized with 1 m hydrochloric acid, and the dense precipitate filtered off and recrystal­
lized from water to give 7-methyl-l,8-naphthyridin-4-ol (0-83 g), m.p. 231-232° (lit.12,13,20 236-237°, 
238-240°) (Found: C, 66-5; H, 4 9; N, 171. Calc, for C9H8N20 : C, 66-7; H, 5 1 ;  N, 17-3%). 
‘Hn.m.r. (CDC13): S 2-66, s, 7-Me; 6-36, d, J  8 Hz, H 3; 7-17, d, 8-61, d, J 11 Hz, H 5,6; 7-71, 
m, H 2.
5-Chloro-2-methyl-l,8-naphthyridine (10; R' = Me, R2 = Cl, R3 — H)
7-Methyl-l,8-naphthyridin-4-ol (l-5g) was chlorinated with phosphoryl chloride (10 0 ml) as 
described by Brown.12 The product recrystallized from light petroleum (b.p. 60-80°) with charcoal 
filtration gave pink needles of 5-chloro-2-methyl-l,8-naphthyridine (1-45 g), m.p. 116-118° (lit.12 
121-122°) (Found, for sample dried at 20° and 20 mmHg: C, 60-6; H ,4-0; Cl, 19-6; N, 15-9. 
Calc, for G ,H 7C1N2: C, 60-5; H, 3-95; Cl, 19-8; N, 15-7%). ‘H n.m.r. (CDC13): S 2-83, s, 
7-Me; 7-46, d, J  8 Hz, H 2; 7-50, d, 8-95, d, J  4-5 Hz, H 5,6; 8-46, d, J  8 Hz, H 3.
2-DiethylaminomethyI-4-(7'-methyl-1',8'-naphthyridin-4'-ylamino)phenol (5; R' — Me, R3 — H)
5-Chloro-2-methyl-l,8-naphthyridine (0-447g, 0-0025 mol), 4-amino-2-diethylaminomethyl- 
phenol dihydrochloride (0 -668 g, 0-0025 mol) and water (15 ml) were heated on a steam bath for 
2 h. The cooled solution was made alkaline with aqueous ammonia and extracted with chloroform 
(4x). The chloroform extract was washed with sodium chloride solution, dried (Na2S 04) and 
evaporated to give a yellow product (1 -0 g). This product was recrystallized from ethyl acetate to
20 Bowie, R. A., Mullan, M. J. C., and Unsworth, J. F., J. Chem. Soc., Perkin Trans. 1, 1972, 1106.
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give 2-diethylaminomethyl-4-(7'-methyl-l',8,-naphthyridin-4'-ylamino)phenol (0-6g), which decom­
poses above 186° (Found: C, 71-4; H, 7-3; N, 16-6. C20H24N4O requires C, 71-4; H, 7-2; 
N, 16-7%). ‘H n.m.r. (CDCI3): 8 1 ■ 13, t, 7 7-5 Hz, CH3CH2; 2-65, q, 7 7-5 Hz, CH3CH2;
3- 76, s, CH2N; 6-62, d, 7 5-5 Hz, H 3; 6 -88, complex, HAr; 7-24, d, 7 8-5 Hz, H 6; 8-23, d, 
7 8-5 Hz, H5; 8-58, d, 7 5-5 Hz, H2.
N -{4'-Diethylamino-l'-methylbutyl)-7-methyl-l,8-naphthyridin-4-amine (6\ R' — Me, R3 = H)
5-Chloro-2-methyl-l,8-naphthyridine (l-0g , 0 0056 mol) and 5-diethylaminopentan-2-amine 
(4 ■ 4 g, 0 • 0278 mol) were heated in an autoclave at 160° for 9 h. The reaction mixture was evaporated 
under reduced pressure, made alkaline with 2 m sodium hydroxide and extracted with chloroform. 
The product was subjected to column and thin-layer chromatography (alumina; ethyl acetate) to 
give N-{4’-diethylamino-1'-methylbutyl )-7-methyl-1,8-naphthyridin-4-amine (0-7g) as a yellow oil 
(Found: C, 71-6; H ,9 4; N, 18-4. C18H28N4 requires C, 71-95; H, 9-4; N, 18-6%). JH n.m.r. 
(CDC13): 8 0-99, t, 7 7-5 Hz, CH3CH2; 1-30, d, 7 6-5 Hz, F-Me; 1-65, complex, 2-42, complex, 
CH22,,3,,4'; 2-51, q, 7 7-5 Hz, CH3CH2; 2-71, s, 7-Me; 3-71, complex, H 1'; 5-45, d, 7 7 Hz, 
NH; 6-42, d, 75-5 Hz, H3; 7-16, d, 78-5 Hz, H 6; 8 09, d, 7 8 -5 Hz, H 5; 8-63, d, 7 5 • 5 Hz, H 2.
6-Ethoxycarbonyl-5-hydroxy-l,8-naphthyridine-2-carboxylic Acid (10; R l — COOH, R2 = OH,
R3 =  COOEt)
Ethyl 4-hydroxy-7-methyl-l,8-naphthyridine-3-carboxylate (4-64 g, 0 02 mol), selenium dioxide 
(5-31 g, 0 048 mol), water (10 0 ml) and pyridine (20 ml) were refluxed with stirring for 10 h. The 
mixture was diluted with pyridine (50 ml), boiled to dissolve the yellow crude product, filtered and 
evaporated. The residue was recrystallized from pyridine and the product washed with acetone to 
give 6-ethoxycarbonyl-5-hydroxy-l,8-naphthyridine-2-carboxylic acid (4 ■ 7 g), m.p. >279° (dec.) 
(Found: C ,54-1; H ,3-8; N, 10 5. C u H ^ N jOj requires C, 54-9; H ,3-8; N, 10-7%). ‘H 
n.m.r. (CD3SOCD3): 8 1 -29, t, 7 7 Hz, CH3CH2; 4-23, q, 7 7 Hz, CH3CH2; 8 05, d, 8-67, d,
7 8 Hz, H 5,6; 8-57, b ,H 2 ; 13• 12, b, COOH.
4- Bromo-l,8-naphthyridine (10; R l = R3 = H, R2 = Br)
A mixture of 6-ethoxycarbonyl-5-hydroxy-l,8-naphthyridine-2-carboxylic acid (9-0 g), potassium 
hydroxide (13 0 g) and water (90 ml) were heated on a steam bath for 1 -75 h. The cooled solution 
was adjusted with 5 m hydrochloric acid to pH c. 2-5, and the dense light yellow precipitate of the 
acid filtered off, washed with water and dried. This solid was refluxed with quinoline (120 ml) for
8 h, excess quinoline removed under reduced pressure, and the solid remaining dissolved in the 
minimum volume of 1 m sodium hydroxide and extracted with chloroform to remove remaining 
traces of quinoline. The aqueous solution was adjusted with 1 m hydrochloric acid to pH c. 7 but 
the hydroxy compound did not precipitate. The aqueous solution was evaporated to dryness to 
give crude hydroxy compound (4 0 g) [1H n.m.r. (CD3OD): 8 6-35, d, 7 7-5 Hz, H3; 7-59, q, 
78-5 Hz, 74-5 Hz, H 6; 8 05, d. 7 7-5 Hz, H 2; 8-63, q, 7 2 Hz, 7 8 ■ 5 Hz, H 5; 8-71, q, 7 2 Hz, 
7 4-5 Hz, H7] which was brominated directly.
The crude hydroxy compound (4 0 g) and phosphoryl bromide (20-0 g) were heated in an oil 
bath at 140-150° for 0-75 h. Ice was added carefully with stirring to the cooled mixture, and the 
resulting solution adjusted with sodium hydrogen carbonate solution to pH c. 6-5, and extracted 
with chloroform (4 x ). The extract was dried (Na2S 04) and evaporated under vacuum and the 
product recrystallized from light petroleum (b.p. 60-80°) to give colourless plates of 4-bromo- 
1,8-naphthyridine (3 -3 g), m.p. 78-79°(lit.,14 72-73°) (Found, for material dried at 20° and 20 mmHg: 
C, 45•9; H, 2-4; Br,38-3; N, 13- 4 . Calc, for C8H5BrN2: C,46-0; H ,2-4; Br,38-2; N, 13-4%). 
‘H n.m.r. (CDCI3): <5 7-59, q, 7 4 Hz, 7 8-5 Hz, H 6 ; 7-78, d, 7 5 Hz, H 3; 8-56, q, 7 2 Hz, 7 
8-5 Hz, H5; 8-92, d, 7 5 Hz, H 2; 9-17, q, 7 4 Hz, 7 2 Hz, H 7.
2-Diethylaminomethyl-4-(l',8'-naphthyridin-4'-ylamino)phenol (5; R1 = R3 — H)
4-Bromo-l,8-naphthyridine (0-42 g, 0-002 mol) and 4-amino-2-diethylaminomethylphenol dihy­
drochloride (0 -534 g, 0 -002 mol) in water (15 ml) were heated on a steam bath for 2 h. The reaction 
mixture was worked up as described above for the reaction of 4-chloro-7-methyl-l,8-naphthyridine 
with the same amine. The chloroform extract gave a crude product (0-84g) which recrystallized
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from toluene to give yellow crystals of 2-diethylaminomethyl-4-(V ,8'-naphthyridin-4' -ylamino) phenol 
(0-5 g), m.p. 174° (dec.)(Found: C, 71-2; H, 6-9; N, 17-4. C19H22N40  requires C, 70-8; H, 6-9; 
N, 17-4%). 'H n.m.r. (CD3OD): <5 1 • 14, t, J 7-5 Hz, CH3CH2; 2-69, q, J 7-5 Hz, CH3CH2;
3- 83, s, CH2N; 6-67, d, J 6 Hz, H 3; 7 08, complex, ArH; 7-50, q, J 4 Hz, J 8 Hz, H6; 8-46, 
d, 7 6 Hz, H2; 8-75, q, J 8 Hz, J 2 Hz, H 5; 8-93, q, J 2 Hz, J 4 Hz, H 7.
N-(4'- Diet hylamino-1'-met hylbuty I)-1,8-naphthyridin-4-amine (6; R l — R3 =  H )
4-Bromo-l,8-naphthyridine (1 05 g, 0 005 mol) and 5-diethylaminopentan-2-amine (3• 95 g, 
0-025 mol) were heated in an autoclave at 160° for 9 h. The reaction mixture was worked up as de­
scribed above for the reaction of 4-chloro-7-methyl-l,8-naphthyridine with 5-diethylaminopentan- 
2-amine. The dried chloroform extracts (Na2S 0 4) were evaporated to a viscous brown oil which 
was subjected to column chromatography (alumina; methanol). The product was washed by 
decantation with light petroleum (b.p. 60-80°) to remove remaining traces of 5-diethylaminopentan- 
2-amine, and dried at 20° and 20 mmHg to give N-(4'-diethylamino-]'-methylbutyl)-l ,8-naphthyridin-
4- amine (1 • 1 g) (Found: N, 19-4. C i7 H26N 4 requires N, 19-6%). ‘H n.m.r. (CDC13): <5 0-99, t, 
J 7 Hz, CH3CH2; 1 -31, d, J 6 Hz, F-Me; 1 -67, complex, 2-44, complex, CH22/,3',4'; 2-52, q, 
J 1 Hz, CH3CH2; 3-73, complex, H F; 5 -68, d, J 7 Hz, NH; 6-48, d, J 5 -5 Hz, H 3; 7-28, q, 
J  8-5 Hz, J 5 Hz, H 6; 8-27, q, J  2 Hz, J  8-5 Hz, H5; 8-69, d, J 5-5 Hz, H2; 9-97, q, J 2 Hz, 
J  5 Hz, H 7.
4-Chloro-2,7-dimethyl-1,8-naphthyridine (4 ; R' =  R3 =  Me, R2 =  Cl)
This compound was prepared from 6-methylpyridin-2-amine and ethyl acetoacetate through 
2,6-dimethylpyrido[l,2-«]pyrimidin-4-one15 and 2,7-dimethyl-l,8-naphthyridin-4(l//)-one15 [‘H 
n.m.r. (CDCI3): <5 2 41, s, 2-Me; 2-61, s, 7-Me; 6-14, s ,H  3; 7-15, d, 8-50, d, J 8 Hz, H5,6] 
followed by chlorination with phosphoryl chloride.15 The 4-chloro-2,7-dimethyl-1,8-naphthyridine 
had m.p. 84-86° (lit.15 83).
2-Diethylaminomethyl-4-(2',7'-dimethyl-1',8'-naphthyridin-4'-ylamino)phenol (5; R l =  R3 =  Me)
4-Chloro-2,7-dimethyl-l,8-naphthyridine (0-1 g, 0-0005 mol) and 4-amino-2-diethylaminomethyl- 
phenol dihydrochloride (0 -134 g, 0-0005 mol) in water (3 -0 ml) were heated on a steam bath for 
2 h. The reaction mixture was worked up as described above. The product was subjected to t.l.c. 
(alumina; ethyl acetate), treated with 20% ethanolic hydrogen chloride, the mixture evaporated to 
dryness and the solid recrystallized from t-butyl alcohol to give yellow crystals of 2-diethylaminomethyl- 
4-{2',7'-dimethyl-V,8'-naphthyridin-4'-ylamino)phenol dihydrochloride (0-12 g), which sublimed at 
temperatures greater than 175° (Found: C ,54-6; H ,7-2; Cl, 15-3; N , l l - 7 .  C2iH26N40.2HC1.- 
2H20 :  C, 54-9; H, 7-0; Cl, 15-4; N, 12-2%). *H n.m.r. (D 20): <5 1 -36, t, J  7-5 Hz, CH3CH2; 
2-58, s, 2-Me; 2-76, s, 7-Me; 3-26, q, J  7-5 Hz, CH3CH2; 6 61, s, H3; 7-41, complex, ArH; 
7-64, d, 8-66, d, J  9 Hz, H 5,6.
~N-(4'-Diethylamino-I'-methylbutyl)-2,7-dimethyl-l,8-naphthyridin-4-amine (6; R' =  R3 =  Me)
4-Chloro-2,7-dimethyl-l,8-naphthyridine (1-Og) and 5-diethylaminopentan-2-amine (4-11 g) 
were heated in an autoclave at 160° for 9 h. The mixture was worked up as described above. The 
chloroform extract gave a viscous brown oil which was purified by column chromatography and 
t.l.c. (alumina; ethyl acetate) to give oily N-(4'-diethylamino-l'-methylbutyl)-2,7-dimethyl-l ,8-naph- 
thyridin-4-amine (0-64 g) (Found, for material dried at 20° and 20 mmHg: C ,72-4; H ,9-9; N, 17-8. 
C 19H30N 4 requires C, 72-6; H, 9-6; N, 17-8%). JH n.m.r. (CDC13): <5 0-99, t, J 1 Hz, CH3CH2; 
1 -29, d, J 6-5 Hz, F-Me; 1 -63, complex, 2-40, complex, CH22',3,,4'; 2 51, q, /  7 Hz, CH3CH2; 
2-61, s, 2-Me; 2-68, s, 7-Me; 3-70, complex, H F; 5-23, d, J  1 Hz, N H ; 6-32, s ,H 3 ;  7-11, d, 
7-98, d, J  8-5 Hz, H 5,6.
1,8-Naphthyridine-2,5-diol (10; Rl =  R2 =  OH, R3 =  H)
6-Aminopyridin-2-ol ( 4 0 g ,  0-036 mol) and diethyl ethoxymethylenemalonate (7-86 g, 0-036 
mol) were heated in an oil bath at 110° for 1-5 h. The cooled reaction mixture was dissolved in 
ethanol (c. 100 ml), filtered, and the filtrate evaporated to give a dark yellow oil. This oil was heated 
on a steam bath with sodium hydroxide (3-0g) in water (100 ml) for 1-75 h, adjusted to pH 2-5
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and the solid filtered off. This solid was added to diphenyl ether (200 ml) and the mixture refluxed 
for 9 h, cooled as rapidly as possible, and diluted with light petroleum (b.p. 60-80") (1000 ml). The 
yellow precipitate (2-5 g) was filtered off, washed with light petroleum (b.p. 60-80°) and dried. A 
sample of this material was recrystallized from a large volume of methanol to give 1,8-naphthyridine-
2.5- diol, m.p. 355-357° (lit.16-17 >320°, >360°) (Found: C,59-2; H ,3-2; N, 17-9. Calc, for 
C8H6N20 2: C, 59-3; H, 3-7; N, 17-3%). ‘H n.m.r. (1 m NaOD): Ö 6-30, d, J  6 Hz, H3; 
6-50, d, 8• 18, d, 7 9 Hz, H5,6; 8 07, d, 7 6 Hz, H2.
2.5- Dichloro-l,8-naphthyridine (/0; R' — R2 = Cl, R3 = H)
Crude l,8-naphthyridine-2,5-diol (1 0 g )  and phosphoryl chloride (10 0 ml) were heated in an 
oil bath at 120° for 0-75 h. The cooled reaction mixture was cautiously poured onto ice, and adjusted 
with aqueous sodium hydrogen carbonate to pH c. 5 • 5. This mixture was extracted with chloroform, 
the extract dried (Na2S 04), solvent evaporated, and the product recrystallized from light petroleum 
(b.p. 60-80°) to give 2,5-dichloro-l,8-naphthyridine (0• 8 g), m.p. 131-132° (Found: C, 48 • 1; H, 2 • 1; 
N, 141. C8H4C12N2 requires C, 48 -3; H, 2 0; N, 141%). >H n.m.r. (CDC13): S 7-58, d, J 9 Hz, 
H 3; 7-59, d, 9 00, d, J 5 Hz, H5,6; 8-54, d, J  9 Hz, H2.
4-{T -Chloro-1' ,8'-naphthyridin-4' -ylamino)-2-diethylaminomethylphenol (5; R' = Cl, R3 = H)
A mixture of 2,5-dichloro-l,8-naphthyridine (012g , 0-0006 mol) and 4-amino-2-diethylamino- 
methylphenol dihydrochloride (0-16g, 0 0006 mol) in water (10 ml) were heated on a steam bath 
for 2 h. After cooling, the reaction mixture was made alkaline with 14 m ammonium hydroxide, 
and gave a dense yellow precipitate. This product was collected and recrystallized from toluene to 
give 4-(J'-chloro-r,8'-naphthyridin-4'-ylamino)-2-diethylaminomethylphenol (0 15 g), m.p. >360° 
(Found: C, 63-3; H, 6 1 ;  Cl, 9 95; N, 15-4. C19H21C1N40  requires C, 63-9; H, 5-9; Cl, 9-9; 
N, 15-7%). ‘H n.m.r. (CD3OD): ö 1 • 14, t, J 1 Hz, CH3CH2; 2-67, q, J 1 Hz, CH3CH2; 3• 83, 
s, CH2N; 6-67, d, J  6 Hz, H3; 7 07 complex, ArH; 7-47, d, 8-69, d, J  8 Hz, H 5,6; 8 -42, d, 
y 6 Hz, H 2.
Dechlorination o f 4-(J’ -Chloro-V ,8'-naphthyridin-4' -ylamino)-2-diethylaminomethylphenol to 2-Diethyl- 
aminomethyl-4-(r,8'-naphthyridin-4'-ylamino)phenol (5; R' = R3 — H )
A mixture of 4-(7'-chloro-l',8'-naphthyridin-4'-ylamino)-2-diethylaminomethylphenol (0 036 g), 
magnesium oxide (0-5 g), ethanol (30 ml) and 10% palladium-charcoal (0 05 g) were hydrogenated 
at room temperature and pressure until hydrogen uptake ceased. This mixture was filtered through 
Celite, the filtrate evaporated to dryness, and the solid subjected to t.l.c. (silica; methanol). The 
product was dissolved in methanol, the solution diluted with light petroleum (b.p. 80-100°), and the 
mixture concentrated to give a yellow precipitate of 2-diethylaminomethyl-4-(^,8/-naphthyridin-4,- 
ylamino)phenol, m.p. 174° (dec.), not depressed on admixture with authentic material prepared 
above. The ‘H n.m.r. and i.r. spectra were also identical with authentic compound.
Reaction of 2,5-Dichloro-l ,8-naphthyridine with 5-Diethylaminopentan-2-amine
2,5-Dichloro-l,8-naphthyridine (0-4 g, 0-002 mol) and 5-diethylaminopentan-2-amine (1 -58 g, 
0 01 mol) were heated in an autoclave at 160° for 9 h. The mixture was dissolved in methanol, the 
solvent evaporated, and the residue treated with water (20 ml) and 2 m sodium hydroxide (1 0  ml) 
and extracted with chloroform (4 x ). The chloroform extracts were dried (Na2S04), evaporated 
and the product subjected to t.l.c. (alumina and silica; chloroform), extracted with light petroleum 
(b.p. 60-80 ) to remove excess amine reactant and dried at 130° and 1 mmHg (Found: N, 17-7. 
C17H25C1N4 requires N, 17-5%). The ‘H n.m.r. (CDC13) [J 0-99, t, J 1 Hz, CH3CH2; 1 -28, d, 
y 6-5 Hz, F-Me; 1 -56, complex, 2-40, complex, CH22',3',4'; 2-50, q, J 7 Hz, CH3CH2; 3-67, 
complex, HI ' ;  5 • 16, d, J 8 Hz, N H ; 6-24, d, J 6 Hz, H 3; 6-48, d, 7-84, d, J 9 Hz, H 5,6; 8-41, 
d, y 6 Hz, H2] also showed traces of 5-diethylaminopentan-2-amine.
7-Amino-2-methyl-l,8-naphthyridin-4-ol (4; R' — NH2, R2 = OH, R3 = Me)
A  mixture of pyridine-2,6-diamine (22 g, 0 • 2 mol; commercial), ethyl acetoacetate (39 g, 0 • 3 mol) 
and diphenyl ether (500 ml) was stirred and heated in an oil bath at 130° for 0-5 h, then refluxed
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for 2 h. After cooling, the yellow precipitate was filtered off, washed with light petroleum (b.p. 
80-100°) and dried. It was recrystallized from ethanol, and the product washed with ethyl acetate 
to give 7-amino-2-methyl-l,8-naphthyridin-4-ol (8-0 g), m.p. 268-270° (lit. 19 282-284°) (Found: 
C, 61-8; H, 5-4; N, 34-4. Calc, for C9 HQN .,0: C, 61-7; H, 5 2; N, 34 0%). 'H n.m.r. (CD3- 
SOCD3): Ö 2-23, s, 2-Me; 5 -72, s ,H 3 ; 6-42, d, 7-95, d, J 8-5 Hz, H 5,6; 6-67, bs, N H 2; 11-21, 
bs, OH (?). This product was clearly different (m.p., 'H n.m.r. and i.r.) from the isomeric 7-amino- 
4-methyl-l,8-naphthyridin-2-ol, prepared as described by Brown12 (Method D) and purified according 
to Seide, 21 which had m.p. >360° (lit. 21 darkening from 340 and decomposing about 405°) and 
!H n.m.r. (CD 3SOCD3): Ö 2-67, s, 4-Me; 5-99, bs, H3; 6-34, d, 7-69, d, J 9 Hz, H 5,6 ; 6-58, 
bs, N H 2. The i.r. spectra of both isomers are consistent with those obtained by Carboni and co­
workers. 1 9 ’2 2
4,7 -Dichloro-2-methyl-l ,8-naphthyridine (4 ; Rl =  R2 — Cl, R3 =  Me)
This compound was prepared from 7-amino-2-methyl-l,8-naphthyridin-4-ol through 2-methyl- 
1,8-naphthyridin-4,7-diol ['H n.m.r. (1 m NaOD): Ö 2-35, s, 2-Me; 6  19, s, H3; 6-45, d, 8-11, 
d, J 9 Hz, H 5,6] by chlorination with phosphoryl chloride as described by Carboni et al.19 It was 
recrystallized from light petroleum (b.p. 60-80 ) and had m.p. 178-180° (lit. 19 180°). ‘H n.m.r. 
(CDCI3): Ö 2-77, s, 2-Me; 7-46, s ,H  3; 7-50, d, 8-44, d, J 9 Hz, H 5,6 .
4-(7'-Chloro-2’-methyl-1',8'-naphthyridin-4'-ylamino)-2-diethylaminomethylplienol (5; Rl — Cl,
R3 =  Me)
4,7-Dichloro-2-methyl-1,8-naphthyridine (0-213 g, 0 001 mol) and 4-amino-2-diethylamino- 
methylphenol dihydrochloride (0 -267 g, 0-001 mol) in water (15 ml) were heated on a steam bath 
for 2 h. The mixture was worked up as described above and the yellow precipitate was recrystallized 
from cyclohexane to give 4-(7'-chloro-2'-methyl-1',8'-naphthyridin-4'-ylamino)-2-diethylaminomethyl- 
phenol (0-3g), m.p. 174-176° (Found: C ,6 5 -l;  H ,6-4; C l,9-55; N, 14-9. C2 oH 2 3 C1N40
requires C, 64-8; H, 6-3; Cl, 9 6 ; N, 15-1%). ‘H n.m.r. (CDCI3): S 1 • 14, t, J 1 Hz, CH3CH2; 
2-54, s, 2-Me; 2-66, q, J 7 Hz, CH3CH2; 3-78, s, CH2 N; 6-55, s, H3; 6-91, complex, ArH; 
7-31, d, 8-15, d, 7 8-5 Hz, H 5,6.
Preliminary Antimalarial Screen
Mice were injected intraperitoneally with 106 erythrocytes infected with Plasmodium vinckei 
vinckei 6  days prior to administration of the chemical. Each dosage of the chemical (in 0-2 ml of 
50% dimethylformamide with normal saline) was given intraperitoneally at concentrations of 10, 
20, 30, and 50 mg/kg of body weight to three mice at each test concentration. Thin blood smears 
were taken at various time intervals while a minimum of two mice survived from each test group. 
Slides were fixed, stained (Giemsa’s stain) and the mean percentage of parasite-infected red cells 
determined. The results for each chemical at the various dose levels are recorded in Table 1 and were 
discontinued (Table entry as toxic death) at the death of the second mouse of each test group due 
either to the toxicity of the chemical or the malarial infection.
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Abstract
Several new A4-substituted 2-methoxy(and 2-hydroxy)-l,5-naphthyridin-4-amines have been 
prepared from ethyl 3-aminopyridine-2-carboxylate. 2,4-Dichloro-l,5-naphthyridine with methanolic 
sodium methoxide gave 4-chloro-2-methoxy-l,5-naphthyridine but with methanolic hydrogen 
chloride afforded 4-chloro-l,5-naphthyridin-2-ol.
The A4-substituted l,5-naphthyridin-4-amines showed no significant antimalarial activity 
compared to chloroquine or primaquine in a preliminary in vivo screen against Plasmodium vinckei 
vinckei in mice.
Introduction
In an earlier publication1 we reported the synthesis and preliminary antimalarial 
screening of a series of 1,8-naphthyridines (1) and (2) against Plasmodium vinckei 
vinckei in mice. We now report the preparation of a series of new 1,5-naphthyridines 
(3) and the testing, by a more refined test procedure, of these compounds and of the 
previously described 1,8-naphthyridines.1
McCaustland and Cheng2 synthesized several 1,5-naphthyridines and found that
7- chloro-7V-(4'-diethylamino-r-methylbutyl)-l,5-naphthyridin-4-amine (4), ‘5-aza- 
chloroquine’, possessed very good antimalarial activity against Plasmodium berghei 
in mice. It was comparable to chloroquine in activity when screened for blood 
schizontocidal activity and was much less toxic than chloroquine and the 4- and
8- aminoquinoline drugs. Other potential antimalarial 1,5-naphthyridines have been 
synthesized by Adams et air’ and Goldberg et a l4
Schmidt5,6 has reported significant radical curative activity by many 8-amino- 
quinolines3-4 and also some evidence in derivatives of 4-amino-l,5-naphthyridin-2-ols6 
in tests against Plasmodium cynomolgi in Rhesus monkeys.
In a search for curative activity, and because of the obvious similarity of the 
l,5-naphthyridin-4-amines to the quinolin-8-amines, we have prepared a number of
* Part I, Aust. J. Chem., 1984, 37, 1065.
1 Barlin, G. B., and Tan, W.-L., Aust. J. Chem., 1984, 37, 1065.
2 McCaustland, D. J., and Cheng, C. C., J. Heterocycl. Chem., 1970, 7, 467.
3 Adams, J. T., Bradsher, C. K., Breslow, D. S., Amore, S. T., and Hauser, C. R., J. Am. Chem. 
Soc., 1946, 68, 1317.
4 Goldberg, A. A., Theobald, R. S., and Williamson, W., J. Chem. Soc., 1954, 2357.
5 Schmidt, L. H., Antimicrob. Agents Chemother., 1983, 24, 615.
6 Schmidt, L. H., Am. J. Trop. Med. Hyg., 1983, 32, 231.
0004-9425/84/122469502.00
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derivatives of l,5-naphthyridin-4-amines for testing for antimalarial activity. The 
various amine side chains incorporated in these new compounds were selected from 
those present in substances which had previously shown activity5,7 in animal screening 
experiments and also in clinical use, for example, Amodiaquine.
NHCHXH,-------
Synthesis
The 1,5-naphthyridines in this work were prepared initially from ethyl 3-amino- 
pyridine-2-carboxylate which with diethyl malonate, under conditions modified 
from those described by Oakes and Rydon,7 8 and without isolating the intermediate, 
gave l,5-naphthyridine-2,4-diol8 (3; R1 = R2 = OH). Treatment of the latter with 
phosphoryl chloride afforded 2,4-dichloro-l,5-naphthyridine8 (3; R1 = R2 = Cl) 
which with methanolic sodium methoxide at reflux gave 4-chloro-2-methoxy-l,5-naph- 
thyridine (3; R1 = OMe, R2 = Cl) whose structure was established as described 
below. The reaction of 2,4-dichloro-l,5-naphthyridine with methanolic hydrogen 
chloride at reflux to give 4-chloro-2-methoxy-l,5-naphthyridine as described by 
McCaustland and Cheng2 proved unsatisfactory in our hands. Instead it gave 
4-chloro-l,5-naphthyridin-2-ol (3; R1 = OH, R2 = Cl) which was also prepared 
by hydrolysis of 2,4-dichloro-l,5-naphthyridine with 5 m  hydrochloric acid in dioxan,8 
as well as by hydrolysis of 4-chloro-2-methoxy-l,5-naphthyridine with 5 m  hydro­
chloric acid in dioxan. The product from the last reaction was dechlorinated with 
/j-toluenesulfonylhydrazide8 to l,5-naphthyridin-2-ol (3; R1 = OH, R2 = H). 
The methoxy compound was therefore 4-chloro-2-methoxy-l,5-naphthyridine.
4-Chloro-2-methoxy-l,5-naphthyridine reacted with 4-amino-2-diethylamino- 
methylphenol in aqueous solution at 100° to give 2-diethylaminomethyl-4-(2'-methoxy- 
r,5'-naphthyridin-4'-ylamino)phenol (5; R 1 = OMe) and with a series of amines 
(namely 2-diethylaminoethylamine, 3-diethylaminopropylamine, propane-1,3-diamine, 
butane-1,4-diamine, pentane-1,5-diamine and hexane-1,6-diamine) together with
7 Wiselogle, F. Y., ‘A Survey of Antimalarial Drugs 1941-1945’ (J. W. Edwards: Ann Arbor, 
Michigan, 1946).
8 Oakes, V., and Rydon, H. N., J. Chem. Soc., 1958, 204.
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one equivalent of sodium carbonatein n-heptane in an autoclave at 160° for 20 h 
by replacement of the 4-chloro substituent and formation of the corresponding 
jV4-substituted 2-methoxy-l,5-naphthyridin-4-amines [e.g. (3); R1 = OMe, R2 = 
NHCH2CH2NEt2].
Brown and Lee9 have studied the thermal rearrangement of 2- and 4-alkoxy- 
pyrimidines to their A-alkyl isomers and McCaustland and Cheng2 have observed 
O to N  rearrangement in the aminolysis of 4-chloro-2-methoxy-l,5-naphthyridine 
(3; R1 = OMe, R2 = Cl) with novaldiamine but McCaustland and Cheng2 found 
that in excess amine with one molar equivalent of potassium carbonate no significant 
rearrangement took place. In our reactions in the presence of one equivalent of 
sodium carbonate no sign of rearranged product was detected. The 'H  n.m.r. of the 
neutral molecules in deuterochloroform showed the methoxy group at 5 4-01-4-02, 
and should be compared with that of 4-chloro-2-methoxy-l,5-naphthyridine at 
4-07; and the 13C n.m.r. spectrum of the products from reaction of 4-chloro-2-meth- 
oxy-l,5-naphthyridine with 2-diethylaminoethylamine and propane-1,3-diamine, 
as dihydrobromides in deuterium oxide, showed resonances at <5 58-40 and 58-28, 
respectively which are indicative of methoxy groups.10 The resonance signal due to 
the carbon of the methoxy group has been found in a variety of heterocycles to occur 
in the range from S 53-20 to 61 -87 and that of the iV-methyl group in the range from 
34-29 to 49-62.10
4-Chloro-l,5-naphthyridin-2-ol (3; R1 = OH, R2 = Cl) also reacted with the 
same series of aliphatic amines as its 2-methoxy analogue but at 180° to give the 
4-(jV-substituted)amino-l,5-naphthyridin-2-ols [e.g. (3); R1 = OH, R2 = NHCH2- 
CH2NEt2].
Ledöchowski and Chimiak11 report that 9-chloroacridine with butane-1,4-diamine 
(hydrochloride) in phenol at 200° gave jV,/V'-di(acridin-9-yl)butane- 1,4-diamine (6); 
and 3-chloro-7-methoxy-9-phenoxyacridine with the same reagents but at 100° gave 
both the mono- and bis-acridinyl derivatives. In our reactions, no bis(l,5-naphthyridin- 
4-yl) compounds were obtained: analyses, integration of the *H n.m.r. and mass 
spectra gave no indication of these products.
4-Chloro-l,5-naphthyridin-2-ol failed to react with 4-amino-2-diethylaminophenol 
in water at 100°.
Biological Activities
Compounds first reported in this paper and others reported previously were 
evaluated by a new test procedure for antimalarial activity against Plasmodium 
vinckei vinckei in rodents as described in the Experimental section.
The compounds, already tested for toxicity and safe dosage levels on three mice 
for each compound and dosage, were administered intraperitoneally to three mice 
[generally at 10-20% parasitaemia (the mean percentage of parasite-infected red cells)] 
in normal saline or peanut oil and controls were run against the widely used anti­
malarials, chloroquine and primaquine, and against the solvents normal saline and 
peanut oil. Blood counts were made then at various time intervals to determine 
parasitaemia levels.
9 Brown, D. J., and Lee, T.-C., Aust. J. Chem., 1968, 21, 243.
10 Barlin, G. B., Brown, D. J., and Fenn, M. D., Aust. J. Chem., 1984, 37, 2391.
11 Ledöchowski, Z., and Chimiak, A., Rocz. Chem., 1959, 33, 1207.
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In earlier experiments1 the compounds were administered in 50% dimethyl- 
formamide in normal saline to more highly infected mice and tests were thus made 
over shorter time spans. This was discontinued due to the toxicity of the dimethyl- 
formamide, and to the desirability of taking blood counts on mice over a longer 
time period thus requiring commencement of the tests at lower infection levels.
No significant antimalarial activity was detected in either the 1,5- or 
1,8-naphthyridines tested when compared to the progressive increase in the mean 
percentage of parasite-infected red cells of the control samples injected with normal 
saline or peanut oil, or when compared to the significant effects of lower dosages 
of primaquine or chloroquine.
Representative results of the tests on the 1,5-naphthyridines reported in this 
paper and some 1,8-naphthyridines reported previously1 are given in Table 1.
Table 1. Preliminary antimalarial screening results against Plasmodium vinckei vinckei in mice
For details of test procedures see Experimental section
Com- Sol- Dose Mean (%) of infected red cells
pound ventA (mg/kg) Pre- Time from dose
treatment 6  h 24 h 48 h
(3; R 1 =  OH, R 2 =  N H (C H 2)3N E t2) PO 1 0 0 18 27 56 85
(3; R 1 =  OH, R 2 =  NH(CH 2 )6 N H 2) NS 1 0 0 1 0 14 28 67
(5; R 1 =  OMe) PO 1 0 0 16 25 41 73
(3; R 1 =  OMe, R 2 =  N H(CH 2)2 N Et2)B NS 1 0 0 13 25 44 80
(3; R 1 =  OMe, R 2 =  N H(CH 2)4 N H 2)B NS 1 0 0 2 0 38 61 87
(1; R 1 =  R 2 =  H) PO 1 0 0 14 27 53 87
(2; R 1 =  R 2 =  H) PO 50 19 34 54 85
(1; R 1 =  Me, R 2 =  H) PO 1 0 0 11 18 31 6 8
(1; R 1 =  Cl, R 2 =  H) PO 1 0 0 1 2 16 42 76
(2; R 1 =  Cl, R 2 =  Me) PO 1 0 0 6 13 34 71
Normal saline — — 14 19 47 80
Peanut oil — — 24 33 63 77
Primaquinec NS 30 9 8 4 2
Chloroquinec NS 2 0 16 18 8 1
A po, peanut oil; ns, normal saline. 
B 2HBr. 
c Diphosphate.
Experimental
Solids for analysis were dried in an oven at 100° (unless otherwise specified), and melting points 
were taken in Pyrex capillaries. Analyses were performed by the Australian National University 
Analytical Services Unit. JH and 13C spectra were recorded at 90 MHz and 30° with a jeol FX90Q 
Fourier transform spectrometer with digital resolution of 0 -12 Hz with tetramethylsilane in CDC13 
or CD 3 SOCD 3 and sodium 3-trimethylsilylpropanesulfonate (in D2 0 ) as internal standards. Mass 
spectra were recorded on an Incos data system attached to a VG Micro Mass 7070F spectrometer 
with perfluorokerosene as standard.
1,5-Naphthyridine-2,4-diol (3 ; R' =  R 2 — OH)
l,5-Naphthyridine-2,4-diol was prepared in improved yield as described below from quinolinic 
acid through quinolinic acid imide, 12 3-aminopyridine-2-carboxylic acid13 and its ethyl ester13
12 Sucharda, E., Ber. Dtsch. Chem. Ges., 1925, 58 , 1727.
1 3  Oakes, V., Pascoe, R., and Rydon, H. N., J. Chem. Soc., 1956, 1045.
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['H n.m.r. (CDCI3): <5 1 -45, t, J 7 Hz, CH3CH2; 4-46, q, J 7 Hz, CH2CH3; 5-6, b, N H 2; 7 02, 
q, y4,5 8-5 Hz, 7 4 ,6  1-5 Hz, H4; 7 1 6 , q, / 4>5 8-5 Hz, Js,6 4-OHz, H5; 8 08, q, J 5,6 4-0 Hz, 
y4 6 1 -5 Hz, H 6] by a modification of the literature8 procedure which proved troublesome.
Ethyl 3-aminopicolinate (6 0 g) was added in portions over 15 min to diethyl malonate (45 ml) 
stirred in an open flask at 120° and maintained at that temperature for 5 h. Excess malonic ester 
was removed under reduced pressure, and the residue refluxed with ethanolic sodium ethoxide 
(from 1 05 g sodium and 90 ml ethanol) for 5 h, then evaporated to half volume, and diluted with 
ether (45 ml).
The solid was filtered off, dried, powdered, suspended in water (9-0 ml) and refluxed with 10 m 
sodium hydroxide (21 ml) until effervescence ceased. Boiling water was then added dropwise to 
give an almost clear solution which was filtered, and the filtrate adjusted to pH c. 5-5 with acetic 
acid. The dense yellow precipitate was filtered off, washed with water and dried to give 1,5-naph- 
thyridine-2,4-diol (5-7 g), m.p. >360° (lit.8 >360°). ]H n.m.r. (CD3SOCD3): <5 5-91, s, H 3; 
7-53, q, y7i8 8-5 Hz, / 6>7 4-0 Hz, H7; 7-67, q, J7,8 8-5 Hz, / 6>8 2 Hz, H8; 8-44, q, / 6,7 4 Hz, 
y6>8 2 Hz, H 6.
2,4-Dichloro-l ,5-naphthyridine (3 ; Rl =  R2 =  Cl)
2.4- Dichloro-l,5-naphthyridine was prepared from l,5-naphthyridine-2,4-diol (3-0 g) with 
phosphoryl chloride as described by Oakes and Rydon.8 The crude product was recrystallized from 
light petroleum (b.p. 60-80°) to give the dichloro compound as white crystals (2-7 g), m.p. 138-140 
(lit.8 140°). 'H n.m.r. (CDC13): Ö 7-71, q, J7t8 8-5 Hz, J6<7 4 0 Hz, H 7; 7-73, s ,H 3 ;  8-32, q, 
y7,8 8-5 Hz, J6 s 1-5 Hz, H 8; 9 05, q, J6,7 4 0 Hz, J6,8 1 -5 Hz, H 6.
4-Chloro-2-methoxy-l ,5-naphthyridine (3 ; R1 — OMe, R2 =  Cl)
2.4- Dichloro-l,5-naphthyridine (4 0 g) and methanolic sodium methoxide (from 0-6 g sodium 
and 180 ml methanol) were refluxed for 1 h. Excess methanol was removed under reduced pressure, 
and the product purified by column chromatography in ether over silica to give 4-chloro-2-methoxy-
1,5-naphthyridine (2-5 g), m.p. 113-114° (lit.2 114-115°). ‘H n.m.r. (CDC13): S 4-07, s, MeO; 
7-27, s ,H 3 ;  7-59, q, 77,8 8-5 Hz, Jb%7 4-5 Hz, H7; 8• 16, q, / 7>8 8• 5 Hz, / 6i8 2 Hz, H 8; 8-87, 
q, / 6>7 4 • 5 Hz, y6,8 2 Hz, H 6.
4-Chloro-l,5-naphthyridin-2-ol (3; R' = OH, R2 =  Cl)
(a) This compound was prepared in quantity from 2,4-dichloro-l,5-naphthyridine as described 
by Oakes and Rydon.8 It had m.p. 263° (lit.8 263°). *H n.m.r. (CDC13): Ö 7-13, s, H 3; 7-53, 
q, 77i8 8-5 Hz, / 6>7 4-5 Hz, H7; 7-81, q, 77,8 8-5 Hz, / 6.8 1-5 Hz, H8; 8-71, q, 76>7 4-5 Hz, 
J6,8 1-5 Hz, H 6.
(b) 4-Chloro-2-methoxy-l,5-naphthyridine (0-4 g), 5 m hydrochloric acid (5 0 ml) and dioxan 
(5 • 0 ml) were refluxed for 1 h. The mixture was diluted with water, made basic with sodium carbonate, 
and evaporated to dryness. The residue was boiled with chloroform (3 x 50 ml), and the product 
extracted was recrystallized from ethyl acetate to give white crystals of 4-chloro-l,5-naphthyridin- 
2-ol (0-22 g), m.p. 262-263°, not depressed on admixture with the product from (a), and had the 
same 'H n.m.r. as the product from (a).
This product obtained in (b) was also dechlorinated with /7-toluenesulfonylhydrazide as described 
by Oakes and Rydon8 to give l,5-naphthyridin-2-ol, m.p. 256-258° (lit. 258°,8 259°14). 1,5-Naph- 
thyridin-4-ol is reported to have m.p. 340°.15
2-Diethylaminomethyl-4-{2'-methoxy-V,5'-naphthyridin-4’-ylamino)phenol [5; Ri =  OMe]
4-Chloro-2-methoxy-l,5-naphthyridine (1-0 g), 4-amino-2-diethylaminomethylphenol dihydro­
chloride (1 -37 g), water (20 ml) and ethanol (10 ml) were heated in an oil bath with stirring at 100° 
for 4 h. The mixture was evaporated under reduced pressure and evaporated three times with water 
(3 x 20 ml) to remove unchanged chloro compound. The residue was diluted with water (20 ml), 
adjusted to pH c. 7-3 with aqueous ammonia and extracted with chloroform. The extract was dried
14 Petrow, V., and Sturgeon, B., J. Chem. Soc., 1949, 1157.
15 Hart, E. P., J. Chem. Soc., 1954, 1879.
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(Na2S 04) and evaporated to give an oil which was subjected to column and t.l.c. chromatography 
in chloroform over alumina to give, as a yellow oil, 2-diethylaminomethyl-4-{2'-methoxy-1' ,5'-naph- 
thyridin-4'-ylamino)phenol (0-85 g) (Found: for a sample dried at 20° under vacuum, C, 68-3; 
H, 6-9. C20H24N4O2 requires C, 68-2; H, 6-9%). M 352. ‘Hn.m.r. (CDC13): 8 1 • 11, t, J 7 Hz, 
CH3CH2; 2 -63, q, y 7 Hz, CH2CH3; 3-75, s, CH2N; 3-99, s, MeO; 6-37, s ,H 3 ';  6-83, d, J5 6 
8-5 Hz, H 6; 6-96, d, y 3 , 5 2-5 Hz, H 3; 7-15, q, / 3,5 2-5 Hz, / 5>6 8-5 Hz, H 5; 7-48, q, J, ,8. 
8 5 Hz, y6-,7. 4-5 Hz, H7; 8-03, q, Jy.s- 8-5 Hz, / 6- 8- 1-5 Hz, H 8'; 8-56, q, J„. 7. 4-5 Hz, 
/ 6.i8. 1-5 Hz, H 6 '; 9-5, b, NH.
The dipicrate, prepared in ethanol, had m.p. 200-201° (Found, for sample dried at 100° for 1 h: 
C, 47-7; H, 3-8; N, 17-1. C32H30N 10O16 requires C, 47-4; H, 3-7; N, 17-3%).
~N-(2'-Diethylaminoethyl)-2-methoxy-l,5-naphthyridin-4-amine 
[i; R1 — OMe, R2 = NHCH2CH2NEt2\
4-Chloro-2-methoxy-l,5-naphthyridine (1*0 g), 2-diethylaminoethylamine (3 0 g), anhydrous 
sodium carbonate (0-54g) and n-heptane (20 ml) were heated in an autoclave at 160’ for 20 h, 
then the solvent and excess amine removed under vacuum, and the remaining oil chromatographed 
in chloroform over alumina.
The product was treated with ethanolic hydrogen bromide and the precipitate recrystallized 
from ethanol to give white crystals of N-(2'-diethylaminoethyl)-2-methoxy-l,5-naphthyridin-4-amine 
dihydrobromide (1-5 g), m.p. 169-170° (Found: C, 41-5; H, 5-7; Br, 36-6; N, 12-9.
C15H24Br2N40  requires C, 41-3; H, 5-6; Br, 36-6; N, 12-8%). *H n.m.r. (free base in CDC13): 
<51-04, t,7  7Hz, CH3CH2; 2 • 58, q, J 7 Hz, CH2CH3; 2 • 76, t, J 5 ■ 5 Hz, CH2NEt2; 5 • 62, complex, 
CH2NH; 4-01, s, MeO; 5-97, s ,H 3 ; 6-81, b, NH; 7-40, q, J 7,8 8• 5 Hz, J 6,7 4-0 Hz, H 7; 7-97, 
q, / 7.8 8-5 Hz, y6 i 8  1 • 5 Hz, H 8; 8 • 50, q, y6 > 7 4 • 5 Hz, y 6 . 8 1-5 Hz, H6.
13C n.m.r. (dihydrobromide in D20 ): <5 8 • 15, CH3CH2; 37-46, 49-38, CH2CH2NEt2; 47-86, 
CH2CH3; 58-40, CH30 ;  82-67, C3; 126-85, C7; 128-50, C8; 129-88, C4; 132-10, C8a; 
148-14, C6; 156-70, C4a; 162-03, C2.
~H-(3'-Diethylaminopropyl)-2-methoxy-l ,5-naphthyridin-4-amine 
[J; R1 = OMe, R2 = NH(CH2)3NEt2\
4-Chloro-2-methoxy-l,5-naphthyridine (0-5 g), 3-diethylaminopropylamine (1 -675 g), anhydrous 
sodium carbonate (0-275 g) and n-heptane were heated at 160° for 20 h as described above. The 
product was subjected to chromatography in ether over alumina (8 cm) and after elution with ether, 
the product was eluted with ethanol which was evaporated to give a light yellow oil (0-51 g). M 288. 
■H n.m.r. (CDC13): <5 1 -03, t, J 7 Hz, CH3CH2; 1 -85, complex, CH2CH2CH2; 2-53, q, J 1 Hz, 
CH2CH3; 2-57, complex, CH2NEt2; 3-32, complex CH2NH; 4-01, s, MeO; 5-97, s ,H 3 ; 7-0, 
b, NH; 7-42, q, y 7>8 8-5 Hz; y6>7 4-5 Hz, H7; 7-98, q, y 7>8 8-5 Hz, y6 . 8 1-5 Hz, H 8; 8-49, q, 
y6 i 7  4-5 Hz, y6 . 8 1-5 Hz, H 6.
A sample of this oil was treated with ethanolic picric acid, and the product recrystallized from 
ethanol to give N-(3'-diethylaminopropyl)-2-methoxy-l ,5-naphthyridin-4-amine dipicrate, m.p. 
185-187°(Found: C, 44-7; H, 4-0; N, 18-4. C28H30N 10O15 requiresC, 45-0; H ,4-0 ; N, 18-8%).
’N-(3'-Aminopropyl)-2-methoxy-l,5-naphthyridin-4-amine [3\ Rl — OMe, R2 = NH(CH2)3NH2\
4-Chloro-2-methoxy-l,5-naphthyridine (0-50 g), propane-1,3-diamine (1 -9 g), anhydrous sodium 
carbonate (0-27 g) and n-heptane (10-0 ml) were heated at 160° for 20 h. Column and thin-layer 
chromatography (alumina; chloroform) gave a light yellow oil (0-32 g). ‘H n.m.r. (CDC13): 
<5 1-85, complex, CH2CH2CH2; 2-86, t, CH2NH2; 3-34, complex, CH,NH; 4-01, s, MeO; 
5-98,s,H 3 ; 6-6, b ,N H ; 7-43, q, y 7>8 8-5 Hz, y6 > 7 4 0 Hz, H 7; 7-99, q, y 7 . 8 8-5 Hz, y6 , 8  1-5 Hz, 
H 8; 8-50, q, y6 > 7 4-0 Hz, y6 , 8 1-5 Hz, H6.
This oil with ethanolic hydrogen bromide gave bright yellow crystals of N-(3'-aminopropyl)- 
2-methoxy-l,5-naphthyridin-4-amine dihydrobromide (0-45 g) (from ethanol), m.p. >169° (dec.) 
(Found: C, 36-5; H, 4-7; Br, 40-3; N, 14-0. C12H 18Br2N40  requires C, 36-6; H, 4-6; Br, 40-5; 
N, 14-2%).
13C n.m.r. (D20): <5 25-54, CH2CH2CH2; 37-05, 39-76, CH2CH2CH2; 58-28, CH30 ;  81-50, 
C3; 126-39, C7; 128-28, C8; 129-45, C4; 131-70, C8a; 137-76, C6; 156-32, C4a; 161-44, C2.
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N-(4'-Aminobutyl)-2-methoxy-l,5-naphthyridin-4-amine [3\ R' = OMe, R2 =  NH(CH2)4NH2\
4-Chloro-2-methoxy-l,5-naphthyridine (0-5 g), butane-l,4-diamine (3 0g), anhydrous sodium 
carbonate (0-275 g) and n-heptane (10-0 ml) were heated at 160° for 20 h. Column and thin-layer 
chromatography (alumina; methanol) gave a light yellow oil (0-4g). ‘H n.m.r. (CDC13): <5 1-67, 
complex, CH2CH2CH2CH2; 2-74, t, CH2NH2; 3-27, complex, CH2NH; 4-01, s, MeO; 5-97, 
s, H 3; 6-5, b, NH; 7-44, q, / 7,8 8-5 Hz, y6>7 4 0 Hz, H7; 7-99, q, / 7>8 8-5 Hz, y6>8 1 -5 Hz, H 8; 
8-50, q, y6,7 4 0 Hz, y6>8 1-5 Hz, H6.
This oil was treated with ethanolic hydrogen bromide and the product recrystallized from 
isopropyl alcohol (charcoal) to give N-(4'-aminobutyl)-2-methoxy-1,5-naphthyridin-4-amine dihydro­
bromide (0-5 g), which decomposed above 166° (Found: C, 38-6; H, 5 -3; N, 13-7. C13H20Br2N4O 
requires C, 38-3; H ,4 9; N, 13-7%).
N-(5'-Aminopentyl)-2-methoxy-l,5-naphthyridin-4-amine [5; R 1 — OMe, R2 = NH(CH2)SNH2]
4-Chloro-2-methoxy-l,5-naphthyridine (0-5 g), pentane-1,5-diamine (3 0 g), anhydrous sodium 
carbonate (0-275 g) and n-heptane (10-0 ml) were heated at 160° for 20 h. Column and thin-layer 
chromatography (alumina; methanol) gave a yellow oil (0-45 g). 'H  n.m.r. (CDC13): ö 1-57, 
complex, CH2(CH2)3CH2; 2-68, complex, CH2NH2; 3-25, complex, CH2NH; 4-01, s, MeO; 
5-96,s ,H 3 ; 6 -5 ,b ,N H ; 7-44, q, y7,8 8-5 Hz, y6.7 4-5 Hz, H7; 7-99, q, y7.8 8-5 Hz, y6>8 1-5 Hz, 
H 8; 8-50, q, y6>7 4-5 Hz, y6,8 1 -5 Hz, H 6.
This oil with ethanolic hydrogen bromide gave a precipitate which was recrystallized from ethanol 
(charcoal) to give N-(5'-aminopenty\)-2-methoxy-l,5-naphthyridin-4-amine dihydrobromide (0-6g) 
which decomposed above 164° (Found, for product dried at 100° under vacuum: C, 40-1; H, 5-4; 
N, 13 -4. C14H22Br2N40  requires C, 39-8; H, 5-3; N, 13-3%).
Ei-(6'-Aminohexyl)-2-methoxy-l ,5-naphthyridin-4-amine [i; R l = OMe, R2 = NH(CH2)6NH2]
4-Chloro-2-methoxy-l,5-naphthyridine (0-5 g), hexane-1,6-diamine (3-0 g), anhydrous sodium 
carbonate (0-275 g) and n-heptane (10 ml) were heated at 160J for 20 h. Column and thin-layer 
chromatography (silica; methanol) gave a yellow oil (0-54 g). *H n.m.r. (CDC13): ö 1-44, b, 
CH2(CH2)4CH2; 2-69, complex, CH2NH2; 3-28, complex, CH2NH; 4-02, s, MeO; 5-98, s, 
H 3; 6-4, b, NH; 7-45, q, y7>8 8-5 Hz, y6>7 4-0 Hz, H7; 8-00, y7>8 8-5 Hz, y6>8 1-5 Hz, H 8; 
8-51, q, y6i7 4 0 Hz, y6>8 1-5 Hz, H6.
The free base was treated with ethanolic hydrogen bromide and the yellow solid recrystallized 
from ethanol (charcoal) to give N-(6'-aminohexyl)-2-methoxy-l,5-naphthyridin-4-amine dihydro­
bromide (0-65 g) which decomposed above 163° (Found, for sample dried at 100° under vacuum: 
C, 41 0; H, 5-7; N, 12-9. C15H24Br2N40  requires C, 41-3; H, 5-6; N, 12-9%).
4-(2'-Diethylaminoethylamino)-l,5-naphthyridin-2-ol [3; R' = OH, R2 =  NHCH2CH2NEt2\
4-Chloro-l,5-naphthyridin-2-ol (0-5 g), 2-diethylaminoethylamine (1-675 g), anhydrous sodium 
carbonate (0- 3 g) and n-heptane (10-0 ml) were heated in an autoclave at 180° for 20 h. The product 
was subjected to chromatography in methanol over alumina and recrystallized from ethyl acetate to 
give white crystals of 4-{2'-diethylaminoethylamino)-l,5-nciphthyridin-2-ol (0-6g), m.p. 155-156° 
(Found: C, 64-8; H, 7-9; N, 21-6. C14H20N4O requires C, 64-6; H, 7-7; N, 21-5%). 'H  n.m.r. 
(CDC13): ö 1 07, t, y 7 Hz, CH3CH2; 2 61, q, J  7 Hz, CH2CH3; 2-79, t, CH2NEt2; 3-28, 
complex, CH2NH; 5-70, s, H 3 ;  6-98, b, NH; 7-37, q, y7>8 8-0 Hz, y6>7 4-5 Hz, H 7; 7-70, q, 
y7>8 8-0 Hz, y6t8 1-5 Hz, H 8; 8-39, q, J6,7 4-5 Hz, y6>8 1-5 Hz, H6.
4-(3'-Diethylaminopropylamino)-l,5-naphthyridin-2-ol [J ; R' — OH, R2 = NH(CH2)3NEt2]
4-Chloro-l,5-naphthyridin-2-ol (0-5 g), 3-diethylaminopropylamine (1-8 g), anhydrous sodium 
carbonate (0 -293 g) and n-heptane (10 -0 ml) were heated at 180° for 20 h as described above. 
The yellow solid obtained was subjected to t.l.c. (silica; methanol) and recrystallized from cyclo­
hexane (charcoal) to give white crystals of 4-(3'-diethylaminopropylamino)-l,5-naphthyridin-2-ol 
(0■ 3 g), m.p. 115° (Found, for sample dried at 1003 under vacuum: C,65-7; H, 8 - l ;  N,20-6. 
C15H22N40  requires C, 65 -7; H, 8 -1; N, 20-4%). JH n.m.r. (CDC13): ö 1 -05, t, J 7 Hz, CH3CH2; 
1-87, complex, CH2CH2CH2; 2 -55, q, J 7 Hz, CH2CH3 ; 2 -59, complex, CH2NEt2; 3-35, complex,
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CH2NH; 5 -6 8 ,s, H 3; 7-36, q, J7,8 8 0 Hz, Jb<1 4-5 Hz, H 7; 7-70, q, y7f8 8-OHz, y6f8 1-5 Hz, 
H 8; 8-36, q, / 6.i 4-5 H z ,/6f8 1-5 Hz, H6.
4-(3'-Aminopropylamino)-1,5-naphthyridin-2-ol [3; Rl — OH, R2 =  NH(CH2)2NH2\
4-Chloro-l,5-naphthyridin-2-ol (0-5 g), propane-1,3-diamine (2-05 g), anhydrous sodium 
carbonate (0-3 g) and n-heptane (10 0 ml) were heated at 180° for 20 h. The solid (0-69 g) obtained 
was subjected to chromatography in methanol over a short column of silica, and recrystallized 
from a mixture of methanol and ethyl acetate to give light yellow crystals of 4-{3’-aminopropylamino)-
l ,  5-naphthyridin-2-ol(0• 3 g), m.p. 188-189° (Found, for sample dried at 120° under vacuum: C, 61 0; 
H, 6-7; N, 25 5. CnH^N+O requires C, 60-5; H, 6-5; N, 25-7%). M 218. ‘H n.m.r. (CDC13): 
ö 1 -89, complex, CH2CH2CH2; 2 91, t, CH2NH2; 3• 39, complex, CH2NH; 5-72, s ,H 3 ;  6-8, 
b, NH; 7-38, q, y7i8 8-5 Hz, y6>7 4-5 Hz, H7; 7-72, q, y7>8 8-5 Hz, y6>8 1-5 Hz, H 8; 8-37, q, 
y6,7 4-5 Hz, y6>8 1 • 5 Hz, H 6.
4-(4'-Aminobutylamino)-l,5-naphthyridin-2-ol [3; R1 =  OH, R2 =  NH(CH2)ANH2\
4-Chloro-l,5-naphthyridin-2-ol (0-5 g), butane-1,4-diamine (2-5 g), anhydrous sodium carbonate 
(0-3 g) and n-heptane (10-0 ml) were heated at 180° for 20 h. The product was recrystallized from 
water (charcoal) to give light yellow crystals of 4-{4'-aminobutylamino)-l,5-naphthyridin-2-ol (0 • 60 g),
m. p. 149-150° (Found, for sample dried at 100" under vacuum: C, 61-6; H, 7 0; N, 23-8. 
C12H16N 40  requires C, 62 0; H, 6-9; N, 241% ). M + 1 233. 'H n.m.r. (CDC13): Ö 1-70, 
complex, CH2(CH2)2CH2; 2-78, t, CH2N H 2; 3-32, complex, CH2NH; 5-71, s, H 3; 6-6, b, 
NH; 7-39, q, y7.8 8-5 Hz, y6i7 4-5 Hz, H 7; 7-75, q, y7>8 8-5 Hz, y6,8 1-5 Hz, H 8; 8-36, q, 
y6.7 4-5 Hz, y6>8 i-5 Hz, H6.
4-(5'-Aminopentylamind)-l,5-naphthyridin-2-ol[3\ R l =  OH, R2 =  NH(CH2)SNH2\
4-Chloro-l,5-naphthyridin-2-ol (0-5 g), pentane-1,5-diamine (3 0 g), anhydrous sodium carbonate 
(0-3 g) and n-heptane (10 0 ml) were heated at 180° for 20 h. The product was recrystallized twice 
from water with charcoal filtration to give white crystals of 4-{5'-aminopentylamino')-l ,5-naphthyridin- 
2-ol (0-5 g), m.p. 157-159° (Found: C,63 0; H ,7-3; N ,22-3 . C i3H 18N 40  requires C, 63-4; 
H, 7-4; N, 22-7%). M + 1 247. 'H n.m.r. (CDCI3): ö 1 • 54, complex, CH2(CH2)3CH2; 2• 73, 
complex, CH2NH2; 3-27, complex, CH2NH; 5-71, s, H3; 6-5, b, NH; 7-38, q, y7i8 8-5 Hz, 
y6,7 4-5 Hz, H 7; 7-71, q, y7,8 8-5 Hz, y6>8 1-5 Hz, H8; 8-37, q, J6,7 4-5 Hz, y6>8 1-5 Hz, H6.
4-(6'-Aminohexylamino)-l,5-naphthyridin-2-ol [3; Rl =  OH, R2 — NH(CH2)bNH2]
4-Chloro-l,5-naphthyridin-2-ol (0-4 g), hexane-1,6-diamine (2-57 g), anhydrous sodium carbonate 
(0-24 g) and n-heptane (10 0 ml) were heated at 180° for 20 h. The crude product was extracted 
with ether (3 x 50 ml) and the solid residue was chromatographed in methanol over a short column 
of silica and recrystallized from water with charcoal filtration to afford white crystals of 4-{6'-amino- 
hexylamino)-l,5-naphthyridin-2-ol (0-34 g), m.p. 177-178° (Found, for sample dried at 120° under 
vacuum: C, 64-9; H, 7-9; N, 21-6. C14H20N 40  requires C, 64-6; H, 7-7; N, 21-5%). M  260. 
‘H n.m.r. (CDC13): <5 1-45, complex, CH2(CH2)4CH2; 2-71, complex, CH2N H 2; 3-29, complex, 
CH2NH; 5-71, s, H 3; 6-5, b, NH; 7-39, q, y7,8 8-5 Hz, y6,7 4-5 Hz, H7; 7-72, q, y7>8 8-5 Hz, 
y6j8 1 -5 Hz, H 8; 8-37, q, y6>7 4-5 Hz, y6.8 1-5 Hz, H6.
Toxicity Testing
Each naphthyridine was tested for acute toxicity in three mice by injection intraperitoneally, 
each with a single dose in normal saline or peanut oil, at a dose level of 100 mg/kg of body weight 
[except for Ar-(4,-diethylamino-F-methylbutyl)-l,8-naphthyridin-4-amine which due to toxicity 
at 100 mg/kg was run at 50 mg/kg]. No apparent ill effects were observed and all mice survived to 
and beyond 48 h in the above tests and in control experiments with normal saline and peanut oil.
Preliminary Antimalarial Screen
Mice were injected intraperitoneally with 106 erythrocytes infected with Plasmodium vinckei 
vinckei. After 5 days (and daily thereafter) each mouse was examined for suitable parasitaemia
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levels of 10-20%. ln this, thin blood smears were taken, slides were fixed, stained (Giemsa’s stain) 
and the mean percentage of parasite-infected red cells was determined as the average of two or more 
counts on each slide which varied by no more than ±5%  of the mean value.
At infection levels of preferably 10-20% each test chemical at a dosage of 100 mg/kg of body 
weight [except for /V-O'-diethylamino-r-methylbutyO-LS-naphthyridin^-amine which was at 
50 mg/kg] in 0-4 ml of normal saline or peanut oil was given intraperitoneally to three mice whose 
individual parasitaemia had just previously been determined. Thereafter thin blood smears were 
taken from each mouse at 6, 24 and 48 h and the parasitaemia assessed as above. The results for 
the three mice were then averaged at each time point.
Control tests were made against peanut oil and normal saline, and reference tests run against 
chloroquine and primaquine (as diphosphates).
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^-Substituted 7-Bromo-l,5-naphthyridin-4-amines
Gordon B. Barlin and Weng-Lai Tan
Medical Chemistry Group, John Curtin School of Medical Research, 
Australian National University, P.O. Box 334, Canberra, A.C.T. 2601.
Abstract
A series of new A4-substituted 7-bromo-l,5-naphthyridin-4-amines has been prepared from nicotinic 
acid through 3-bromo-8-chloro-l,5-naphthyridine by nucleophilic replacement of the 8-chloro 
substituent with appropriate amines.
Several of these compounds, namely 7-bromo-./V-(4,-diethylamino-l'-methylbutyl)-l,5-naphthy- 
ridin-4-amine (‘5-azabromoquine’), 4-(7/-bromo-r,5/-naphthyridin-4,-ylamino)-2-(diethylamino- 
methyl)phenol and 7-bromo-jV-(2'-diethylaminoethyl)-l,5-naphthyridin-4-amine showed significant 
antimalarial acivity. Apparent cures were effected when these test chemicals were injected intra- 
peritoneally in a single dose of 200 mg/kg to mice infected with Plasmodium vinckei vinckei.
Introduction
In earlier parts1,2 of this series we described the synthesis and testing against 
Plasmodium vinckei vinckei of a series of 1,8-naphthyridines1 and iV4-substituted 
2-methoxy(and 2-hydroxy)-l,5-naphthyridin-4-amines.2 We now report the 
preparation of a new series of 7V4-substituted 7-bromo-l,5-naphthyridin-4-amines 
and testing against P. vinckei vinckei in mice in which some of these compounds 
showed significant antimalarial activity.
1,5-Naphthyridines have been examined previously for antimalarial activity by 
Adams et al. , 3 Goldberg et al.,4 McCaustland and Cheng,5 and Chen et al.6 
McCaustland and Cheng5 found that 7-chloro-iV-(4'-diethylamino-r-methylbutyl)- 
l,5-naphthyridin-4-amine (‘5-azachloroquine’) possessed very good antimalarial 
activity against P. berghei in mice. It was comparable to chloroquine in activity 
when screened for blood schizontocidal activity, and was much less toxic than 
chloroquine and the existing 4- and 8-aminoquinoline drugs. Chen et al.6 have 
prepared from 4-(r,5'-naphthyridin-4'-ylamino)phenol (also with 2'-methyl and 
6'-methoxy groups) a series of compounds with double Mannich basic chains of the
* Part II, Aust. J. Chem., 1984, 37, 2469.
1 Barlin, G. B., and Tan, W.-L., Aust. J. Chem., 1984, 37, 1065.
2 Barlin, G. B., and Tan, W.-L., Aust. J. Chem., 1984, 37, 2469.
3 Adams, J. T., Bradsher, C. K., Breslow, D. S., Amore, S. T., and Hauser, C. R., J. Am. Chem. Soc., 
1946, 68, 1317.
4 Goldberg, A. A., Theobald, R. S., and Williamson, W., J. Chem. Soc., 1954, 2357.
5 McCaustland, D. J., and Cheng, C. C., J. Heterocycl. Chem., 1970, 7, 467.
6 Chen, C., Zheng, X., Zhu, P., and Guo, H., Yaoxue Zuebao, 1982, 17(2), 112 {Chem. Abstr., 
1982, 97, 6191n).
0004-9425/85/030459S02.00
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/7-aminophenol, and report them to be effective antimalarials. In view of this activity, 
and the absence of activity in 2-methoxy(and 2-hydroxy)-l,5-naphthyridin-4-amines,2 
we have prepared a number of derivatives of 7-bromo-l,5-naphthyridin-4-amine 
(1; R = NHR).  This series, rather than the corresponding 7-chloro-l, 5-naphthyridin- 
4-amines, was examined because 3-bromo-8-chloro-l,5-naphthyridine was more 
readily available than its 3,8-dichloro analogue. The diverse amine side chains 
incorporated in these new compounds varied from the branched alkyl diamine of 
chloroquine, and the straight-chain aliphatic diamines with chain length of 2-6 
carbons which had previously been incorporated in substances showing antimalarial 
activity,7 to the aromatic amine of amodiaquine.
Synthesis
Compounds reported in this paper were prepared from the known ethyl 7-bromo- 
4-hydroxy-l,5-naphthyridine-3-carboxylate8 (2; R = OH, R' = Et)(see Experimental 
section) by hydrolysis in aqueous sodium hydroxide to the corresponding acid 
followed by decarboxylation in refluxing quinoline to 7-bromo-l,5-naphthyridin-4-ol 
(1; R = OH). Chlorination of this hydroxy compound by refluxing for 10 h with 
phosphoryl chloride gave 3-bromo-8-chloro-l,5-naphthyridine (1; R = Cl) in 
good yield.
The 3-bromo-8-chloro-l,5-naphthyridine reacted with 4-amino-2-(diethylamino- 
methyl)phenol hydrochloride in water at 100° to give 4-(7'-bromo-l',5'-naphthyridin- 
4'-ylamino)-2-(diethylaminomethyl)phenol (lb), but with one equivalent of benzene- 
1,4-diamine in aqueous methanol at 100° it gave A,Ar -bis(7"-bromo-r,5"-naphthyri- 
din-4"-yl)benzene-1,4-diamine (3) hydrochloride as the major product and 4-(7'-bromo- 
r,5'-naphthyridin-4'-ylamino)aniline (li) as shown by analyses, and 'H  n.m.r. 
and mass spectral data. Ledöchowski and Chimiak9 report that 9-chloroacridine 
with butane-1,4-diamine (hydrochloride) in phenol at 200° gave vV,A '^-di(acridin- 
9"-yl)butane-l,4-diamine; and 3-chloro-7-methoxy-9-phenoxyacridine with the same 
reagents but at 100° gave both the mono- and bis-acridinyl derivatives. 3-Bromo- 
8-chloro-l,5-naphthyridine reacted with 5-diethylaminopentan-2-amine, 2-diethyl- 
aminoethylamine, 3-diethylaminopropylamine, butane-1,4-diamine, pentane-1,5-di­
amine, hexane-1,6-diamine, and 3-dimethylaminopropylamine each in n-heptane at 
160° for 20 h by replacement of the 8-chloro substituent and formation of the corre­
sponding /V4-substituted 7-bromo-l,5-naphthyridin-4-amines (la,c-h). 3-Bromo- 
8-chloro-l,5-naphthyridine with methanolic sodium methoxide at reflux readily 
gave 3-bromo-8-methoxy-l,5-naphthyridine.
Biological Activities
In vivo evaluation of the compounds described in this paper for antimalarial 
activity against P. vinckei vinckei in preliminary screening in rodents was examined, 
and the results are summarized in Table 1. Prior to these antimalarial studies each 
compound was examined for toxicity and safe dosage levels.
7 Wiselogle, F. Y., ‘A Survey of Antimalarial Drugs 1941-1945’ (J. W. Edwards: Ann Arbor, 
Michigan, 1946).
8 Heindl, J., Keim, H.-W., Dogs, E., Seeger, A., and Herrmann, Ch., Eur. J. Med. Chem.—Chim. 
Ther., 1977, 12, 549.
9 Ledöchowski, Z., and Chimiak, A., Rocz. Chem., 1959, 33, 1207.
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The results in Table 1 reveal that 7-bromo-A^-(4'-diethylamino-T-methylbutyl)- 
l,5-naphthyridin-4-amine (la) (‘5-azabromoquine’), 4-(7'-bromo-T,5'-naphthyridin- 
4'-ylamino)-2-(diethylaminomethyl)phenol (lb), and 7-bromo-A^-(2'-diethylamino- 
ethyl)-l,5-naphthyridin-4-amine (lc) at a dosage of 200 mg/kg had very good anti- 
malarial activity, comparable to that shown by chloroquine at a dosage of 20 mg/kg; 
a count of the mean percentage of parasite-infected red cells at 24 h after administration 
of the chemical showed less than 1 % infection, and no increase was detected during 
the 13-day test. These counts were lower than for infected mice treated with chloro­
quine. Each of these test mice remained alive and healthy at 14 weeks.
7-Bromo-7V-(3'-diethylaminopropyl)-l,5-naphthyridin-4-amine (Id) and 7-bromo- 
Ar-(3'-dimethylaminopropyl)-l,5-naphthyridin-4-amine (lh) showed some antimalarial 
activity at the dosages employed.
Of the naphthyridines with terminal primary amino groups, the highest activity 
was shown by 4-(7'-bromo-T,5'-naphthyridin-4'-ylamino)butylamine (le) which 
decreased to no significant activity in 6-(7'-bromo-T,5,-naphthyridin-4'-ylamino)- 
hexylamine (lg) at the test concentrations of 200 mg/kg.
Relative to ‘bromoquine’10 which has an l d 50 of 72 mg/kg for a single intra- 
peritoneal dose, ‘5-azabromoquine’ (la) is much less toxic with no apparent ill 
effects at a dosage of 200 mg/kg. This observation is consistent with the report by 
McCaustland and Cheng5 that ‘5-azachloroquine’ is less toxic than chloroquine. 
It appears therefore that aza substitution also decreases toxicity.
Experimental
General
Solids for analysis were dried in an oven at 100° unless otherwise specified, and melting points 
were taken in Pyrex capillaries. Analyses were performed by the Australian National University 
Analytical Services Unit. *H n.m.r. spectra were recorded at 90 MHz and 30° with a Jeol FX90 
and Fourier transform spectrometer with digital resolution of 0-12 Hz, with tetramethylsilane in 
CDC13 or CD 3 SOCD3 and sodium 3-trimethylsilylpropanesuIfonate (in D 2 0) as internal standards. 
Mass spectra were recorded on an Incos data system attached to a VG Micro Mass 7070F spectro­
meter with perfluorokerosene as standard.
Ethyl 7-Brorno-4-hydroxy-l,5-naphthyridine-3-carboxylate (2; R — OH, R' = Et)
This compound was prepared from nicotinic acid through 5-bromonicotinic acid, 1 1 , 1 2  its amide, 12  
and 5-bromopyridin-3-amine1 2 , 1 3  which was condensed with diethyl ethoxymethylenemalonate and 
ring-closed in boiling diphenyl ether (not DowthermRA as in ref.8) to the known ethyl 7-bromo- 
4-hydroxy-l,5-naphthyridine-3-carboxylate. 8
7-Bromo-4-hydroxy-l,5-naphthyridine-3-carboxylic Acid (2; R = OH, R' — H)
Ethyl 7-bromo-4-hydroxy-l,5-naphthyridine-3-carboxylate (10 0 g) and 2-5 m sodium hydroxide 
(100 ml) were refluxed for 1 h. The solid dissolved and a gelatinous precipitate was produced. This 
mixture was diluted with boiling water (300 ml) and filtered with charcoal; the filtrate was acidified 
with glacial acetic acid. After cooling, the precipitate ( 8  0g) was filtered off, washed with water 
and dried. A sample was purified by reprecipitation from aqueous sodium hydroxide with glacial
10 Wiselogle, F. Y., ‘A Survey of Antimalarial Drugs 1941-1945’ p. 387 (J. W. Edwards: Ann Arbor, 
Michigan, 1946).
11 Backman, G. B., and Micucci, D. D., J. Am. Chem. Soc., 1948, 70, 2381.
1 2  Garcia, E. E., Greco, C. V., and Hunsberger, E M., J. Am. Chem. Soc., 1960, 82 , 4430.
1 3  Ziegler, F. E., and Bennett, G. B., J. Am. Chem. Soc., 1973, 95, 7461.
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acetic acid to give 7-bromo-4-hydroxy-l,5-naphthyridine-3-carboxylic acid, m.p. > 295° (dec.) (Found: 
C, 40-2; H, 2 0; Br, 29-6; N, 10■ 3. C9H5BrN20 3 requiresC, 40-2; H, 1 -9; Br, 29-7; N, 10-4%). 
‘H n.m.r. (NaOD): S 8-22, d, y6.8 1 0 Hz, H 8; 8-60, br, H 2,6.
7-Bromo-l,5-naplithyridin-4-ol (1; R — OH)
7-Bromo-4-hydroxy-l,5-naphthyridine-3-carboxylic acid (8-0g) was added in portions over 
10 min to stirred refluxing quinoline (400 ml), and the mixture refluxed for 1 h. The mixture was 
cooled and diluted with acetone (1200 ml), and the precipitate was filtered off, washed with acetone 
and dried. The product was reprecipitated from aqueous sodium hydroxide with glacial acetic acid 
to give a white solid (6 0 g). A sample was purified for analysis by sublimation and gave 7-bromo-
1.5- naphthyridin-4-ol, m.p. >360° (Found: C, 43 -1; H ,2-3; N, 12-2. C8H5BrN20  requires 
C, 42-7; H, 2 2; N, 12-4%). 'H n.m.r. (NaOD; 90°): <5 6-64, d, / 2i3 6 Hz, H 3; 8-29, d, / 2,3 
6 0 Hz, H 2; 8-33, d, J„,8 2 Hz, H8; 8-65, d, / 6>8 2 Hz, H6.
3- Bromo-8-chloro-1,5-naphthyridine (1; R =  Cl)
7-Bromo-l,5-naphthyridin-4-ol (7-0 g) and phosphoryl chloride (200 ml) were refluxed for 10 h; 
excess phosphoryl chloride was distilled under reduced pressure and the residue poured onto ice. 
This cold mixture was neutralized with aqueous ammonia, and the solid was filtered off, washed with 
water and dried. It was recrystallized from n-heptane to give white needles of 3-bromo-8-chloro-
1.5- naphthyridine (6 4 g), m.p. 181-183° (Found: C ,39-7; H, 1-6; N, 11-3. C8H4BrClN2 
requires C, 39-4; H, 1-7; N, 11-5%). 'H n.m.r. (CDC!3): ö 1-11, d, 76,7 5-0 Hz, H7; 8-62, d, 
J2,4  2 0 Hz, H 4; 8-85, d, / 6,7 5 0 Hz, H 6; 9 07, d , / 2>4 2 Hz, H 2.
4- {7'-Bromo-V,5'-naphthyridin-4'-ylamino)-2-{diethylaminomethyl)phenol {lb)
3-Bromo-8-chloro-l,5-naphthyridine (0-3 g, 0 0013 mol), 4-amino-2-(diethylaminomethyl)phenol 
dihydrochloride (0-33 g, 0 0013 mol) and water (45 0 ml) were heated with stirring in an oil bath 
at 100° for 2 h. The cooled reaction mixture was adjusted with aqueous ammonia to pH 7-8, and 
the dense yellow precipitate was filtered off, washed with water and dried. It was recrystallized 
from cyclohexane to give yellow crystals of 4-{7'-bromo-V,5'-naphthyridin-4'-ylamino)-2-{diethyl- 
aminoethyl)phenol (0-4g), m.p. 163-165° (Found: C ,56-6; H ,5-3; Br,20 0; N, 13-7.
C19H21BrN40  requires C, 56-9; H ,5-3; Br, 19 9; N, 14 0%). ‘H n.m.r. (CDC13): <5 114 , t, 
J 1 Hz, CH3CH2; 2-67, q, J 7 Hz, CH2CH3; 3-80, s, CH2N; 6-86, d, y2-,3- 5-5 Hz, H 3'; 6-87, d, 
y5i6 8 Hz, H6; 6-99, d, / 3,s 2-5 Hz, H 3; 7-17, q, / 3,5 2-5, J5,6 8 Hz, H 5; 8-2, br, NH; 8-44, 
d, y6.,8. 2 Hz, H8'; 8-48, d, J2\ 3 - 5-5 Hz, H 2'; 8-74, d, / 6.>8. 2 Hz, H 6'.
7-Bromo-H-{4'-diethylamino-V-methylbutyl)-l ,5-naphthyridin-4-amine {la)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine (0-5 g), 5-diethylaminopentan-2-amine 
(3-25 g) and n-heptane were heated in an autoclave at 160° for 20 h. The reaction mixture was 
washed out with methanol and the solvent evaporated. The excess of amine was then removed by 
distillation at c. 100°/0-5 mm. The residue was subjected to thin-layer chromatography (alumina; 
chloroform), and gave the product as a light yellow oil (0-5 g). *H n.m.r. (CDC13): S 1 0 1 , t, 
7 7 Hz, CH3CH2; 1-33, d, /  6-5 H z, CH3CH; 1-62, complex, CH2CH2CHMe; 2-52, q, J 7 Hz 
CH2CH3; 2-50, complex, CH2NEt2; 3-62, complex, CH; 6-52, d, 72i3 5-5 Hz, H3; 8-36, d, 
/ 6 8 2 Hz, H 8; 8-48, d, / 2,3 5• 5 Hz, H 2; 8-65, d, / 6>8 2 Hz, H6.
The 7-bromo-H-{4’-diethylamino-V-methylbutyl)-l ,5-naphthyridin-4-amine dipicrate, prepared in 
and recrystallized from ethanol, had m.p. 220-222° (Found: C, 42-3; H, 3 -8; Br, 9-9; N, 16-8. 
C29H31BrN10O14 requires C, 42-3; H, 3-8; Br, 9-7; N, 17 0%).
7-Bromo-N-{2'-diethylaminoethyl)-1,5-naphthyridin-4-amine (7c)
3-Bromo-8-chloro-l,5-naphthyridine (0-5 g), 2-diethylaminoethylamine (2-5g) and n-heptane 
(10 0 ml) were heated at 160°, and the product was purified as described above to give a yellow oil 
(0 6 g). ‘H n.m.r. (CDC13): <5 1 08, t, J 1 Hz, CH3CH2; 2 63, q, J 1 Hz, CH2CH3; 2-81, complex, 
CH2NEt2; 3-33, complex, CH2NH; 6-50, d, / 2,3 5-5 Hz, H2; 7 0, br, NH; 8• 37, d, / 6,8 2 Hz, 
H8; 8-51, d, y2>3 5-5 Hz, H3; 8-69, d, / 6,8 2 0 Hz, H6.
464 G. B. Barlin and W.-L. Tan
This oil with ethanolic hydrogen bromide gave 7-bromo-H-(2'-diethylaminoethyl)-1,5-naphthyridin-
4-amine dihydrobromide, m.p. 274-276° (from ethanol) (Found: C, 34-9; H ,4 -4 ;  Br, 49-4; 
N, 112. Q 4H 21Br3N 4 requires C. 34-7; H .4 -4 ;  Br, 49-4; N, 11-5%).
7-Bromo-N-(3'-diethylaminopropyl)-1,5-naphthyridin-4-amine (Id)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine (0-5g), 3-diethylaminopropylamine (3 0g) 
and n-heptane (10 0 ml) was heated at 160° to give a light yellow oil (0-6 g). 'H  n.m.r. (CDC13): 
Ö 106, t, J  7 Hz, CH 3C H 2; 1-88, complex, C H 2CH2C H 2; 2-57, q, J  7 Hz, C H 2C H 3; 2-61, 
complex, C H 2NEt2; 3• 36, complex, C H 2N H ; 6-48, d, 72,3 5-5 Hz, H 3; 7-6, br, NH; 8-35, d, 
y6,8 2 Hz, H 8; 8-48, d, y2i3 5-5 Hz, H2; 8-65, d, y6,8 2 Flz, H 6.
A portion of this oil with ethanolic hydrogen bromide gave 7-bromo-N-(3'-diethylaminopropyl)- 
1,5-naphthyridin-4-amine dihydrobromide, m.p. 214-216° (from ethanol) (Found: C, 36-6; H, 4-7; 
Br, 4 8 1 ;  N, 11-5. C 15H21BrN4.2HBr requires C, 36-1; H ,4  6; Br, 48 0; N, 11-2%).
4- (7'-Bromo-1',5'-naphthyridin-4'-ylamino)butylamine (le)
A mixture of 3-bromo-8-chloro-l,5-naphthyridine (0-5 g), butane-1,4-diamine (4-0g) and 
n-heptane (10 0 ml) was heated at 160°, and the product was purified as described above to give a 
low-melting semisolid (0 45 g). *H n.m.r. (CDC13): ö 1-71, complex, C H 2(CH2)2C H 2; 2-78, 
complex, CH 2N H 2; 3-31, complex, C H 2N H; 6-49, d, J2.,3- 5-5 Hz, H 3'; 6-6, br, N H; 8-36, d, 
y6.,8. 2 0 Hz, H 8 ';  8 ■ 50, d, 72.,3- 5-5 Hz, H 2'; 8-65, d, j 6.i8. 2 0 Hz, H 6'. M + 1,296.
This product with ethanolic hydrogen bromide gave 4-(7'-bromo-1',5'-naphthyridin-4'-ylamino)- 
butylamine dihydrobromide, m.p. 225-227° (from ethanol) (Found: C, 32-3; H, 3 9; N, 12-4. 
C 12H 15BrN4.2HBr requires C, 31-5; H, 3-8; N, 12-3%).
5- (7'-Bromo-1',5'-naphthyridin-4'-ylamino)pentylamine (I f )
3-Bromo-8-chloro-l,5-naphthyridine (0-5 g) with pentane-1,5-diamine (4-0 g) and n-heptane 
(10 0 ml) gave a low-melting semisolid (0 - 3 g). ‘H n.m.r. (CDC13): ö 1 -45, complex, C H 2(CH2)3CH 2; 
2-73, complex, C H 2N H 2; 3-30, complex, C H 2N H ; 6-49, d, J 2 ,3- 5-5 Hz, H 3 ';  6-6, br, NH; 
8-36, d, y6 >8- 2 Hz, H 8'; 8-50, d, y2->3- 5-5 Hz, H 2'; 8-65, d, y6.t8. 2 Hz, H 6'. M +  1,310.
The 5-(7'-bromo-1',5'-naphthyridin-4'-ylamino)pentylamine dihydrobromide, prepared in and 
recrystallized from ethanol, had m.p. 244-246° (Found: C, 33-4; H, 4 1 ;  N, 11-4. C 13H 19Br3N 4 
requires C, 33 • 1; H, 4 1 ;  N, 11-9%).
6-(T-Bromo-l’,5’-naphthyridin-4'-ylamino)hexylamine (Ig)
6-(7/-Bromo-r,5'-naphthyridin-4'-ylamino)hexylamine (lg) was prepared from 3-bromo-8-chloro- 
1,5-naphthyridine (0-5 g) and hexane-1,6-diamine (5-0g) in n-heptane (10 0ml).  The product 
was obtained as a low-melting semisolid (0-45 g). 'H  n.m.r. (CDC13): S 1-60, complex, 
CH2(CH2)4C H 2; 2-70, complex, CH2N H 2; 3-29, complex, C H 2NH; 6-50, d, y2-,3- 5-5 Hz, 
H 3'; 8-37, d ,y 6-i8- 2 0  Hz, H 8 ';  8-50, d, y2.t3. 5-5 Hz, H 2 ';  8-66, d, y6.,8- 2 0  Hz, H 6'. M, 323.
This product with ethanolic hydrogen bromide gave 6-(7'-bromo-1',5'-naphthyridin-4'-ylamino)- 
hexylamine dihydrobromide, m.p. 195-197° (from ethanol) (Found: C, 35-2; H, 4-5; N, 11-4. 
C 14H ,4BrN4.2HBr requires C, 34-7; H ,4 -4 ;  N, 11-6%).
7- Bromo-N-(3'-dimethylaminopropyl )-l,5-naphthyridin-4-amine ( lh)
7-Bromo-A-(3'-dimethylaminopropyl)-1,5-naphthyridin-4-amine (1 h) was prepared from 3-bromo-
8- chloro-l,5-naphthyridine (0-5 g) and 3-dimethylaminopropylamine (2-0 g) in n-heptane (10 0 ml). 
The product was obtained as a yellow oil (0 ■ 6 g). 1H n.m.r. (CDC13) : <5 1 • 88, complex, C H 2C H 2C H 2; 
2-26, s, Me2N; 2-43, complex, CH2NMe2; 3■ 36, complex, C H 2N H ; 6-51, d, J 2i3 5-5 Hz, H 3; 
7-1, br, N H; 8-35, d, y6>8 2 Hz, H 8; 8-49, d, y2.3 5• 5 Hz, H 2; 8-65, d, y6,8 2 Hz, H 6.
7- Bromo-N-(3'-dimethylaminopropyl)-1,5-naphthyridin-4-amine dihydrobromide prepared in, and 
recrystallized from, ethanol had m.p. 258-260° (Found: C, 33-2; H ,4 -2 ;  N, 11-8. C i3H 1i,Br3N 4 
requires C, 33 • 1; H, 4-1; N, 11-9%).
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4-{T-Bvomo-V,5'-naphthyridin-4'-ylamino)aniline (//), and N,N'-Bis(7"-bromo-T\5"-naphthyridin- 
4"-yl)benzene-l,4-diamine (3) as the Hydrochloride
3-Bromo-8-chloro-l,5-naphthyridine (0-5g, 0 002 mol), benzene- 1,4-diamine dihydrochloride 
(0-38 g, 0-002 mol), water (20 0 ml) and methanol (5 0 ml) were heated with stirring in an oil 
bath at 100° for 2 h. After cooling the reaction mixture, the yellow precipitate was filtered off and 
recrystallized from water (which was adjusted with hydrochloric acid to pH 2) to give yellow crystals 
of N,'N'-bis(7"-bromo-l",5"-naphthyridin-4"-yl)benzene-1,4-diamine hydrochloride (0-30 g), m.p. 
>360°(Found: C, 47-5; H ,2-7; N, 15-2. C22H14Br2N6.HClrequiresC,47-3; H ,2-7; N, 151%). 
M, 522. JH n.m.r. (CD.,SOCD3): ö 4-69, d, / 2»>3" 6-5 Hz, H3"; 517 , s, H2,3,5,6; 612 , d, 
J2~,a» 6-5 Hz, H 2"; 6-25, d, / 6->8. 2 Hz, H8"; 6-63, d, / 6.,8. 2 Hz, H 6".
The filtrate from the reaction mixture above was adjusted to pH 8-9; the precipitate was filtered 
off, washed with water, dried, and recrystallized from ethanol to give yellow needles of 4-(7'-bromo- 
r,5'-naphthyridin-4'-ylamino)aniline (0-2 g), m.p. 215-216° (Found: C, 53-4; H, 3-6; N, 17-6. 
C ,4Hn BrN4 requires C, 53-4; H, 3-5; N, 17-8%). M + l, 316. 'H n.m.r. (CDC13): <5 6-75, 
d, y2>3 8-5 Hz, H2,6; 6-84, d, J 2 ^  5-5 Hz, H3'; 7-16, d, y2>3 8-5 Hz, H 3,5; 814, br, NH; 
8-41, d, y6.i8. 2 0  Hz, H 8'; 8-48, d, J2.,y  5-5 Hz, H 2'; 8-74, d, y6 ,8- 2 Hz, H6'.
3- Bromo-8-methoxy-l ,5-naphthyridine ( /;  R — OMe)
3-Bromo-8-chloro-l,5-naphthyridine (0-2g) was refluxed with methanolic sodium methoxide 
(from 0-2 g sodium and 20 ml methanol) for 2 h, then the solvent was evaporated. The product 
was extracted into chloroform and subjected to thin-layer chromatography (alumina; chloroform), 
and recrystallized from cyclohexane to give white needles of 3-bromo-8-methoxy-\,5-naphthyridine 
(0 12 g), m.p. 167-169° (Found: C ,4 5 1 ; H ,2 9; N, 11-7. C9H7BrN20  requires C,45-2; 
H, 2 9; N, 11-7%). ‘H n.m.r. (CDCfi): <5 4 15, s, MeO; 7-00, d, / 6.7 5-5 Hz, H7; 8-54, d, 
J 2A 2 0 Hz, H4; 8-82, d, / 6>7 5-5 Hz, H6; 8-95, d, / 2,4 2 Hz, H 2.
Toxicity Testing
Each naphthyridine was tested for acute toxicity in three mice by injection intraperitoneally, 
each with a single dose in normal saline or peanut oil, at a dose of 200 mg/kg of body weight [except 
for 7-bromo-A-(3'-diethylaminopropyl)-l,5-naphthyridin-4-amine (Id) which due to toxicity at 
200 mg/kg was run at 100 mg/kg]. No apparent ill effects were observed, and all mice survived 
to and beyond 8 days in the above tests and in control experiments with normal saline and peanut oil.
Preliminary Antimalarial Screen
This was carried out as described previously2 except that each test chemical was given at a dosage 
of 200 mg/kg of body weight [except for 7-bromo-A-(3'-diethylaminopropyl)-l,5-naphthyridin-
4- amine (Id) which was at 100 mg/kg], and blood counts were made at 9, 24, 48 h and thence daily.
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7-Chloro-l,5-naphthyridin-4-amines
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Abstract
A series of nine mono- and di-Mannich bases, for example 4-(7'-bromo-1 ',5'-naphthyridin-4'-ylamino)- 
2,6-bis(dimethylaminomethyl)phenol derived from 4-(7/-bromo-1 /,5,-naphthyridin-4'-ylamino)phenol 
and several other A4-substituted 7-bromo- and 7-chloro-l,5-naphthyridin-4-amines have been 
prepared.
All these compounds showed significant antimalarial activity when injected intraperitoneally in 
a single dose of 100-200 mg/kg to mice infected with Plasmodium vinckei vinckei. The di-Mannich 
bases appeared to be the most potent and effective in parasite control; however, no deaths were 
observed in infected mice treated with the mono-Mannich compounds.
Introduction
In Parts I1 and II2 of this series we described the synthesis and testing against 
P. vinckei vinckei in mice of a series of 1,8-naphthyridines and N4-substituted 2-meth- 
oxy(and 2-hydroxy)-l,5-naphthyridin-4-amines, and in Part III3 the preparation and 
antimalarial activity of some jV4-substituted 7-bromo-l,5-naphthyridin-4-amines.
In this paper we report the preparation of 4-(7,-bromo-T,5'-naphthyridin-4,-yl- 
amino)phenol (la) and a series of mono- and di-Mannich bases (1 b—j) derived there­
from; together with some chloro analogues (2c-e) of the active bromo compounds 
described here and in Part III.3 This series of mono- and di-Mannich bases were 
prepared because of the relatively high activity of 4-(7'-bromo-T,5'-naphthyridin- 
4'-ylamino)-2-diethylaminomethylphenol observed by us3 and the existence of such 
structures in amodiaquine (Camoquin)4,5 and amopyroquine.5,6 Chen et al? also 
report good antimalarial activity in a series of di-Mannich bases derived from
* Part III, Aust. J. Chem., 1985, 38, 459.
1 Barlin, G. B., and Tan, W.-L., Aust. J. Chem., 1984, 37, 1065.
2 Barlin, G. B., and Tan, W.-L., Aust. J. Chem., 1984, 37, 2469.
3 Barlin, G. B., and Tan, W.-L., Aust. J. Chem., 1985, 38, 459.
4 Burckhalter, J. H., Tendick, F. H., Jones, E. M., Jones, P. A., Holcomb, W. F., and Rawlins, A. L.,
J. Am. Chem. Soc., 1948, 70, 1363.
5 Elslager, E. F., Gold, E. H., Tendick, F. H., Werbel, L. M., and Worth, D. F., J. Heterocycl. 
Chem., 1964, 1, 6.
6 Nobles, W. L., Tietz, R. F., Koh, Y. S., and Burckhalter, J. H., J. Pharm. Sei., 1963, 52, 600.
7 Chen, C., Zheng, X., Zhu, P., and Guo, H., Yaoxue Xuebao, 1982, 17, 112 (Chem. Abstr., 
1982, 97, 6191 n).
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4-(r,5'-naphthyridin-4'-ylamino)phenol and 4-(6'-methoxy-2'-methyl-r,5'-naphthyr- 
idin-4'-ylamino)phenol.
Testing of these bromo- and chloro-l,5-naphthyridines against P. vinckei vinckei 
in mice confirmed the very significant antimalarial activity of these compounds.
Synthesis
3-Bromo-8-chloro-l,5-naphthyridine,3 when heated with aqueous methanolic 
/7-aminophenol hydrochloride at 100°, gave 4-(7'-bromo-r,5'-naphthyridin-4'-yl- 
amino)phenol (la). This product with formalin in ethanol and a moderate amount 
of dimethylamine, dipropylamine or pyrrolidine at reflux gave the mono-Mannich 
bases (lb-d) respectively. 4-(7'-Bromo-r,5'-naphthyridin-4'-ylamino)phenol with 
ethanolic formalin and a large excess of dimethylamine, diethylamine, dipropylamine, 
pyrrolidine, piperidine or morpholine at reflux for 20 h gave the di-Mannich bases 
(le-j). 7-Bromo-/V-(4'-diethylaminobutyl)-l,5-naphthyridin-4-amine (2b) and N,N- 
diethyl-2-(7'-bromo-r,5,-naphthyridin-4'-ylthio)ethylamine (2a) were prepared from 
3-bromo-8-chloro-l,5-naphthyridine with 4-diethylaminobutylamine in n-heptane at 
160°, and refluxing aqueous sodium 2-diethylaminoethanethiolate, respectively.
4,7-Dichloro-l,5-naphthyridine with 4-amino-2-diethylaminomethylphenol dihy­
drochloride in aqueous methanol at 100°, and with 2-diethylaminoethylamine or 4-di­
ethylaminobutylamine in n-heptane at 160° gave the compounds (2c), (2d) and (2e).
Biological Activities
Compounds reported in this paper were examined for antimalarial activity against 
P. vinckei vinckei in mice and the results, averaged for the three mice at each time 
point, are summarized in Table 1. Each compound was examined for toxicity and 
for safe dosage levels prior to the antimalarial studies. The substituted 4-amino-l,5- 
naphthyridines reported here, with one exception only, showed strong antimalarial 
activity leading to significantly reduced parasitaemia 24 h after treatment, and a 
reduction in most cases to less than 1 % at 48 h.
The results reveal that, whereas 4-(7'-bromo-r,5'-naphthyridin-4'-ylamino)phenol 
(la) showed no antimalarial activity, each of its mono-Mannich bases (lb-d) showed 
good activity with a low parasite count at 2-3 days, followed by a rise and then a 
reduction (presumably due to the immunological response) to < 1 % at 14-19 days 
after treatment. This behaviour was similar to that shown by chloroquine in our 
previous paper.3
The di-Mannich bases (le), (lg) and (lh) showed even higher activity with a 
reduction of parasite levels to < 1 % within 48 h of treatment and no observed increase 
thereafter to 4 weeks.
Compounds (If), (li) and (lj) produced similar reductions but at 14 days an 
increase was observed (further details are recorded in Table 1).
7-Bromo-A-(4'-diethylaminobutyl)-l,5-naphthyridin-4-amine (2b) appeared to be 
more effective than its diethylaminopropyl analogue reported previously.3
The sulfide (2a), jV,A-diethyl-2-(7,-bromo-r,5'-naphthyridin-4,-ylthio)ethylamine, 
unlike its nitrogen analogue,3 7-bromo-7V-(2'-diethylaminoethyl)-l,5-naphthyridine, 
showed no antimalarial activity (compare Schönhöfer’s hypothesis8,9).
8 Schönhöfer, F., Hoppe-Seyler's Z. Physiol. Chem., 1942, 274, 1.
9 Thompson, P. E., and Werbel, L. M., in ‘Antimalarial Agents' (Medicinal Chemistry Vol. 12) 
(Ed. G. deStevens) pp. 103, 161 (Academic Press: New York 1972).
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Table 1. Preliminary antimalarial screening results against Plasmodium vinckei vinckei in mice
For details of test procedures see Experimental section. Times given are those after injection of the chemical 
under test. Time: h, hours; d, days; w, weeks; 0 h denotes pretreatment
C o m ­
p o u n d
S o l­
v e n t
D o se
(m g /k g ) O h 9 h
M e a n  p e rc e n ta g e  o f  p a ra s ite - in fe c te d  re d  ce lls  
24  h 48  h  3 d  6 d  8 d  9 d  14 d 19 d 4  w
d a ) PO 200 16 34 62 88 B
( l b ) c NS 200 27 30 9 < 1 < 1 11 8 4 < 1 < 1 < 1
(1c) PO 200 16 27 16 3 5 26 14 5 < 1 < 1 < 1
( l d ) c NS 200 19 26 3 < 1 < 1 25 28 18 < 1 < 1 < 1
( le ) PO 200 18 24 5 < 1 < 1 < 1 <  1 <  1 <  1 <  1 <  1
( l f ) c NS 100 10 9 <  1 <  1 <  1 <  1 <  1 <  1 16 <  1 < 1
( lg ) PO 200 22 32 7 <  1 <  1 <  1 <  1 <  1 < 1 < 1 < 1
( l h ) PO 100 11 11 1 < 1 < 1 < 1 < 1 < 1 < 1 < 1 < 1
(1 0 PO 200 17 13 1 < 1 < 1 < 1 < 1 < 1 63 D
O j) PO 200 15 15 < 1 < 1 < 1 < 1 < 1 < 1 16 E
(2a) PO 200 9 14 29 65 83 B
(2 b )c NS 100 13 17 4 7 12 35 9 5 < 1 < 1 < 1
(2c) PO 200 14 12 1 < 1 < 1 3 15 21 < 1 < 1 < 1
( 2 d )c NS 200 17 20 5 < 1 4 34 19 7 <  1 <  1 < 1
(2 e )c NS 100 13 17 5 2 4 56 22 10 <  1 <  1 < 1
NS — — 27 45 63 88 F
PO — — 19 42 66 85 F
C h lo r o q u in e G NS 40 28 30 4 <  1 <  1 10 71 8 2 H
A po, peanut oil; ns, normal saline.
B All three mice dead. 
c Dihydrobromide.
D Two mice dead, parasitaemia of third mouse < 1 %.
E One mouse dead, parasitaemia of remaining two mice < 1 %. 
F Two of the three mice dead at 3 days.
G Diphosphate.
H All mice dead at 10 days.
R1 R2 R1 R2
CH,NEt2
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The three (V-substituted 7-chloro-l,5-naphthyridin-4-amines (2c-e) produced simi­
lar antimalarial effects: the initial knockdown was followed by a rise in parasitaemia 
which then fell to < 1 % at 14-19 days, through to 4 weeks.
Comparison of the test results for the chloro compound (2e) with its bromo 
analogue (2b) did not reveal any significant differences; but the chloro compounds 
(2c) and (2d), from the evidence presented in Table 1, were apparently less effective 
than their bromo analogues (described in Part III3) which also reduced parasitaemia 
levels to < 1 % within 48 h, but maintained it at that level through to 13 days.
In control experiments it was found that infected mice injected with a single does 
of chloroquine diphosphate ( l d 50 63 mg/kg) at 40 mg/kg initially produced signifi­
cantly lower parasitaemia levels decreasing to < 1 % at 2 days but this then increased 
and the mice died at 10 days. This contrasts with our earlier experiments3 with a 
dosage of 20 mg/kg in which the mice survived to and beyond 14 weeks.
These results at different dose levels may indicate that the variations observed 
between the mono- and di-Mannich bases are due to non-optimal dose levels; these 
differences may be significant in the control of parasitaemia.
Experimental
General
Solids and oils for analysis were dried in an oven at 100° unless otherwise specified. Melting 
points were taken in Pyrex capillaries. Analyses were performed by the Australian National University 
Analytical Services Unit. ‘H n.m.r. spectra were recorded at 90 MHz and 30° with a Jeol FX90 
and Fourier transform spectrometer with digital resolution of 0-12 Hz with tetramethylsilane in 
CDClj or CD3SOCD3.
4-(7' - Bromo-1',5'-naphthyridin-4' -ylamino)phenol (la)
3- Bromo-8-chloro-l,5-naphthyridine3 (2 0 g), /7-aminophenol hydrochloride (l-2 g ), water 
(40 0 ml) and methanol (20 0 ml) were heated with stirring in an oil bath at 100° for 2 h. The 
methanol was then evaporated under reduced pressure and the remaining aqueous solution was 
adjusted to pH 8 with ammonium hydroxide. The yellow precipitate which formed was filtered off, 
washed with water, dried and recrystallized from methanol to give 4-(7'-bromo-l',5'-naphthyridin- 
4'-ylamino)p/ienul (2-5 g), m.p. 245-247° (Found: C, 53-6; H, 3-2; N, 13-2. C 14H10BrN3O 
requires C, 53-2; H ,3-2; N, 13-3%). ‘H n.m.r. (CD3SOCD3): Ö, 6-86, d, / 2.3 9 Hz, H2,6; 
6-86, d, y2.,3' 5-5 Hz, H3'; 7-23, d, / 2>3 9 Hz, H3,5; 8-44, d, Jr ,y  5-5 Hz, H2';’ 8-48, d, / 6.,8. 
2 Hz, H 8'; 8-88, d, / 6->8. 2 Hz, H6'; 9-2, br, NH; 9-4, br, OH.
4-(7'-Bromo-V,5'-naphthyridin-4'-ylamino)-2-dimethylaminomethylphenol (lb)
4- (7,-Bromo-l',5,-naphthyridin-4'-ylamino)phenol (0-5 g), formalin (2 0 ml; 36%), and ethan- 
olic dimethylamine ( 1 0  ml; 33%) in ethanol (10 0 ml) were refluxed with stirring for 20 h. The 
reaction mixture was evaporated under reduced pressure and the residue purified by t.l.c. (silica; 
methanol) to give an oil (0-25 g). ‘H n.m.r. (CDC13): ö, 2-37, s, Me2N; 3 -66, s, CH2N; 6 -85, 
d, y2 >3' 5-5 Hz, H3'; 6-88, d, J5,b 8-5 Hz, H 6; 6-97, d, y3,s 3 Hz, H3; 7-18, q, / 3,5 3 Hz, / 5,6 
8-5 Hz, H 5; 8-2, br, NH; 8-40, d, / 6.,8- 2 0 Hz, H8'; 8-47, d, 72.,3. 5-5 Hz, H2'; 8-71, d, 
y6.,8. 2 Hz, H 6'; 9-8, br, OH.
This oil was treated with ethanolic hydrogen bromide and the product recrystallized from ethanol 
to give yellow crystals of 4-(7'-bromo-V,5'-naphthyridin-4'-ylamino)-2-dimethylaminomethylphenol 
dihydrobromide (0-3 g), m.p. >305° (dec.) (Found: C, 38-4; H, 3-7; N, 10-4. C17HiqBr3 N 4 
requires C, 38-2; H, 3-6; N, 10-5%).
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2-(N,bi-dipropylaminomethyl)phenol (lc)
4-(7,-Bromo-l,,5/-naphthyridin-4'-ylamino)phenol (0-5 g), dipropylamine (0-48 g), formalin 
(2 0 ml; 36%) and ethanol (10 0 ml) were refluxed with stirring for 20 h and the mixture worked 
up as described above. The product was purified by t.l.c. (alumina; chloroform then silica; ethanol)
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and recrystallized from light petroleum (b.p. 60-80°) to give yellow crystals of 4-{7'-bromo-l',5'- 
naphthyridin-4'-ylamino)-2-(N,N-dipropylaminomethyl)phenol (0• 15 g), m.p. 138-139° (Found: 
C, 58-7; H, 5-9; N, 13-2. C21H2SBrN40  requiies C, 58-7; H ,5-9; N, 13-1%). 'H n.m.r. 
(CDCI3): <5, 0-92, t, J 7 Hz, CH3CH2CH2; 1-60, complex, CH3CH2CH2; 2-47, complex, 
CH3CH2CH2; 3 79, s, CH2N; 6-87, d, y2.t3. 5-5 Hz, H 3'; 6-87, d, 75>6 8-5 Hz, H 6; 6-97, d; 
y3,5 2-5 Hz, H3; 7-17, q, / 3>5 2-5 Hz, y5j6 8-5 Hz, H5; 8-2, br, NH; 8-42, d , / 6.,8< 2 Hz, H 8\
8 49, d, Jr.i-  5-5 Hz, H 2'; 8-73, d, J6.,s- 2 Hz, H 6'; 9-4, br, OH.
4-{7'-Bromo-l' ,5'-naphthyridin-4'-ylamino)-2-pyrrolidin-l"-ylmethylphenol {Id)
4-(7'-Bromo-l',5'-naphthyridin-4'-ylamino)phenol (0-5 g), pyrrolidine (015 g), formalin (2 0 ml; 
36%) and ethanol (10 0 ml) were refluxed with stirring for 10 h and worked up as described above. 
The crude product was purified by t.l.c. (silica; methanol) and the oil (0-27 g) [1H n.m.r. (CDC13):
8, 1-86, complex, H3",4"; 2-66, complex, H2",5"; 3-83. s, CH2N; 6-84, d, J2 ,3- 5-5 Hz, H 3 '; 
6 -86, d, y5.6 9 Hz, H 6 ; 6-96; d, / 3.5 2-5 Hz, H 3; 7-15, q, / 3,5 2-5 Hz, J5t6 9 Hz, H 5; 8 -2, br, 
NH; 8-40, d, y6-,8. 2 Hz, H 8'; 8-47, d , / 2->3. 5-5 Hz, H 2'; 8-70, d, y6.,8’ 2 Hz, H 6'; 9-5, br, 
OH] was treated with ethanolic hydrogen bromide and the solid recrystallized from ethanol to give 
4-{7'-bromo-V,5'-naphlhyridin-4'-ylamino)-2-pyrrolidin-l"-ylmethylphenol dihydrobromide, m.p. 318° 
(dec.) (Found: C.41-0; H ,3-8; Br, 42-8; N ,9-6. C19H2lBr3N40  requires C, 40-7; H,3 -8 ; 
Br, 42-7; N, 10 0%).
4-(7'-Bromo-V ,5'-naphthyridin-4' -ylamino)-2,6-bis{dimethy land nomethyl)pheno\ (le)
4-(7,-Bromo-l/,5'-naphthyridin-4/-ylamino)phenol (0-5 g), formalin (10 ml; 36%) and ethanolic 
dimethylamine (30 ml; 33%) were refluxed with stirring for 20 h. The product was isolated as 
described above and purified by t.l.c. (alumina; chloroform) to give 4-{7'-bromo-V ,5’-naphthyridin- 
4'-ylamino)-2,6-bis{dimethylaminomethyl)phenol (0-5 g) as a yellow oil (Found: C, 55-4; H, 5-8; 
N, 16 0. C20H24BrN5O requires C, 55-8; H ,5-6; N, 16-3%). *H n.m.r. (CDC13): 8, 2-33, s, 
Me2N; 3-57, s, CH2N; 5-36, d, / 2.,3. 5-5 Hz, H 3'; 7 06, s, H3,5; 8-2, br, NH; 8 41, d, J6^8. 
2 Hz, H 8'; 8 -49, d, y2.,3. 5 • 5 Hz, H 2'; 8-73, d, J6.,s. 2 Hz, H 6\
The tripicrute was prepared in, and recrystallized from, ethanol. It had m.p. 152-153° (Found: 
C, 4 1 0 ; H, 3 1 ;  N, 171. C20H24BrN5O.3(C6H3N3O7) requires C, 40-8; H, 3 0; N, 17-5%).
4-{7'-Bromo-V,5'-naphthyridin-4' -ylamino)-2,6-bis{diethyIaminomethyl )phenol {1f )
4-(7'-Bromo-l,,5,-naphthyridin-4/-ylamino)phenol (0-5 g), formalin (5 0 ml; 36%), diethyl- 
amine (5 0 ml) and ethanol (10 0 ml) were refluxed with stirring for 20 h. The product was purified 
by t.l.c. (silica; methanol) to give a yellow oil (0-7 g). ‘H n.m.r. (CDC13): 8, 110, t, J 7 Hz, 
CH3CH2; 2-62, q, J 1 Hz, CH3CH2; 3-71, s, CH2N; 6-89, d, 72 ,3- 5 Hz, H 3'; 712 , s, H3,5; 
8-2, br, NH; 8-40, d, J6.,6. 2 Hz, H 8'; 8-48, d, / 2.>3. 5 Hz, H 2'; 8-72, d, 76%8. 2 Hz, H 6'.
A sample of this oil with ethanolic picric acid gave a yellow precipitate which was recrystallized 
from ethanol to yield 4-(7'-bromo-V,5'-naphthyridin-4'-ylamino)-2,6-bis(diethylaminomethyl)phenol 
tripicrate, m.p. 191-193° (Found: C,42-6; H, 3-4; N, 16-4. C24H32BrN50.3(C6H3N30 7)
requires C, 43 0; H, 3-5; N, 16-7%).
4-{7'-Bromo-V,5'-naphthyridin-4'-ylamino)-2,6-bis(N,N-dipropylaminomethyl)phenol (lg )
4-(7'-Bromo-l,,5/-naphthyridin-4/-ylamino)phenyl (0-5 g), formalin (5 0 ml; 36%), dipropyl­
amine (5-0 ml) and ethanol (10 0 ml) were refluxed with stirring for 20 h. The 4-{7'-bromo-l',5'- 
naphthyridin-4'-ylarnino)-2,6-bis(N,N-dipropvlaminomethyl)phenol (0 • 5 g) was isolated as a yellow 
oil after t.l.c. (alumina; ethanol) (Found: C, 61-8; H ,7-5; N, 12-7. C28H40BrN5O requires 
C, 62 0; H, 7-4; N, 12-9%). ‘H n.m.r. (CDC13): 8, 0-89, t, J 7 Hz, CH3CH2CH2; 1-55, complex, 
CH3CH2CH2; 2-45, complex, CH3CH2CH2N; 3-71, s, CH2N; 6 90, d, / 2..3. 5 Hz, H 3'; 713,  
s, H3,5; 8-2, br, NH; 8-40, d, / 6.,8. 2 Hz, H 8'; 8-47, d, y2-,3. 5 Hz, H 2 '; 8-73, d, / 6<>8. 2 Hz, 
H 6'.
The tripicrate was prepared in, and recrystallized from, ethanol. It had m.p. 176-178° (Found: 
C, 45- 0; H, 4 0; N, 15-7. C28H40BrN5O.3(C6H3N3O7) requires C, 44-9; H ,4 0; N, 15-9%).
4-{7'-Bromo-V,5'-naphthyridin-4'-ylamino)-2,6-bis(pyrrolidin-J"-ylmethyl)phenol (lh)
4-(7/-Bromo-l/,5,-naphthyridin-4'-ylamino)phenol (0-5 g), formalin (5 0 ml; 36%), pyrrolidine 
(5-0 ml) and ethanol (10-0 ml) were refluxed with stirring for 20 h. Excess reagents were distilled
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and the product purified by t.l.c. (silica; methanol) to give as a yellow oil 4-(7'-bromo-l',5'-naphthyri- 
din-4'-ylamino)-2,6-bis(pyrrolidin-l"-ylmethyl)phenol (0• 64 g) (Found: C, 59-9; H, 6-2; N, 14-0. 
C24H28BrNsO requires C,59-8; H ,5-9; N, 14-5%). lH n.m.r. (CDCI3): S, 1-83, complex, 
H 3" 4"; 2-63, complex, H2",5"; 3-77, s, CH2N; 6-86, d, 72->3- 5-5 Hz, H 3'; 7 08, s, H3,5; 
8-2, br, NH; 8-40, d, y6.,8. 2 Hz, H 8'; 8-48, d , / 2-,3 5-5 Hz, H 2 '; 8-72, d, y6..8. 2 Hz, H 6'.
4-(7'-Bromo-V ,5'-naphthyridin-4' -ylaniino)-2,6-bis(piperidin-l" -ylmethyl)phenol (7/)
4-(7,-Bromo-r,5,-naphthyridin-4'-ylamino)phenol (0-5 g), formalin (5 0 ml; 36%), piperidine 
(5 0 ml) and ethanol (10 0 ml) were refluxed with stirring for 20 h. Workup was as described above 
to give 4-(7'-bromo-1’,5'-naphthyridii\-4'-ylamino)-2,6-bis(piperidin-l"-ybnethyl)phenol (0-6 g) as a 
yellow oil which became a semi-solid (Found: C, 61 ■ 5; H, 6-5; N, 13• 5. C26H32BrNsO requires 
C,61-2; H ,6-3; N, 13-7%). ‘H n.m.r. (CDC13): <5, 1-55, complex, H 3",4",5"; 2-51, complex, 
H 2",6"; 3-62, s, CH2N; 6-89, d, y2.,3. 5-5 Hz, H 3'; 7-08, s ,H  3,5; 8-2, br, NH; 8-40, d, y6->8, 
2 Hz, H 8'; 8-49, d, y2.t3. 5-5 Hz, H 2'; 8 • 72, d, y6.t8. 2 Hz, H 6'.
4-(7'-Bromo-1',5'-naphthyridin-4'-ylamino)-2,6-bis(morpholin-4"-ylmethyl)phenol (l j )
4-(7'-Bromo-l,,5,-naphthyridin-4,-ylamino)phenol (0-5 g), formalin (5-0ml; 36%), morpholine 
(5 0 ml) and ethanol (10 0 ml) were refluxed as described above. The product was purified by t.l.c. 
(alumina; chloroform) to give as a yellow oil 4-(7'-bromo-1',5'-naphthyridin-4'-ylamino)-2,6- 
bis(morpholin-4"-ylmethyl)phenol (0-56 g) (Found: C, 56-4; H, 5-7; N, 13-2. C24H28BrN50 3
requires C, 56 0; H, 5-5; N, 13-6%). *H n.m.r. (CDC13): <5, 2-57, complex, H2",6"; 3-67, s, 
CH2N ; 3-76, complex, H 3",5"; 6-87, d, y2-,3. 5 • 5 Hz, H 3'; 712, s, H3,5; 8-2, br, NH; 8-42, 
d, y6>fr 2 Hz, H 8 '; 8-50, d, y2-.3. 5-5 Hz, H 2'; 8 • 74, d, y6.,8. 2 Hz, H 6'.
The dipicrate was prepared in and recrystallized from ethanol. It had m.p. 216-218° (Found: 
C, 44-5; H, 3-5; N, 15-6. C24H28BrN50 3.2(C6H3N30 7) requires C, 44-5; H, 3-5; N, 15-8%).
N,N-Diethyl-2-(7'-bromo-1’,5'-naphthyridin-4’-ylthio)ethylamine (2a)
3-Bromo-8-chloro-l,5-naphthyridine (0-3 g) and 2-diethylaminoethylmercaptan hydrochloride 
(0-25 g) in a solution of sodium hydroxide (0-12 g) in ethanol (15 ml) were refluxed for 3 h. The 
mixture was evaporated, the product extracted into chloroform, and subjected to t.l.c. (alumina; 
chloroform). It gave bi,N-diethyl-2-(7'-bromo-r,5'-naphthyridin-4'-ylthio)ethylamine (0-33 g) as a 
brownish yellow oil which slowly crystallized on standing. It had m.p. 64-65° (Found: C, 49-3; 
H, 5-4; N, 12-3. C14H)8BrN3S requires C, 49-4; H ,5-3; N, 12-3%). ‘H n.m.r. (CDC13): Ö,
1 08, t, y 7 Hz, CH3CH2; 2-64, q, J 1 Hz, CH3CH2; 3 05, complex, CH2CH2; 7-37, d, J2f3 
5 Hz, H 3'; 8-51, d, y6.8 2 Hz, H 8'; 8-72, d, y2>3 5 Hz, H 2'; 8-91, d, J6.8 2 Hz, H 6'.
7-Bromo-N-(4'-diethylaminobutyl)-l,5-naphthyridin-4-amine (2b)
3-Bromo-8-chloro-l,5-naphthyridine (0-5 g), 4-diethylaminobutylamine (1 -5 g) and n-heptane 
(10 0 ml) were heated in an autoclave at 160° for 20 h and the product purified as described above. 
The 7-bromo-N-(4'-diethylaminobiityl)-l,5-naphthyridin-4-amine (0-58 g) was obtained as a yellow 
oil (Found: C, 55 0; H, 6-8; N, 16-0. C]6H23BrN4 requires C, 54-7; H, 6-6; N, 16 0%). *H 
n.m.r. (CDC13): ö, 1 02, t, J 1 Hz, CH3CH2; 1 -70, complex, CH2(CH2)2CH2; 2-49, q, J 1 Hz, 
CH3CH2; 2-50, complex, CH2NEt2; 3-34, complex, NHCH2; 6-50, d, J2,3 5-5 Hz, H3; 8-36, 
d, y6t8 2 Hz, H 8; 8-50, d, y2,3 5-5 Hz; H2; 8-65, d, J6,s 2 Hz, H 6.
The dihydrobromide, prepared in and recrystallized from ethanol, had m.p. 237-239° (Found: 
C, 37-5; H, 4-8; N, 10 9. C16H23BrN4.2HBr requires C, 37-5; H ,4-9; N, 10-9%).
4-(7'-Chloro-l',5'-naphthyridin-4'-ylamino)-2-diethylaminomethylphenol (‘5-azaamodiaquine’) (2c)
4,7-Dichloro-l,5-naphthyridine10 (0-2 g), 4-amino-2-diethylaminomethylphenol dihydrochloride 
(0-27 g) water (15 0 ml) and methanol (5-0 ml) were heated with stirring in an oil bath at 100° for
2 h. The methanol was then evaporated under reduced pressure and the aqueous solution adjusted 
with ammonium hydroxide to pH 7-8. The yellow precipitate was collected, washed, dried, and 
recrystallized from cyclohexane to give 4-(7'-chloro-1',5'-naphthyridin-4'-ylamino)-2-diethyIamino-
10 McCaustland, D. J., and Cheng, C. C., J. Heterocycl. Cliem., 1970, 7, 467.
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methylphenol (0-28 g), m.p. 167-169° (Found: C, 64 0; H, 6 0; N, 15-5. C19H21C1N40  requires 
C, 64 0; H ,5-9; N, 15-7%). 'H n.m .r. (CDC13): <5, 1 • 14, t, /  7 Hz, CH3CH2; 2-66, q, /  7 Hz, 
CH3CH2; 3-79, s, CH2N; 6-85, d, J2 t3. 5-5 Hz, H 3 '; 6-86, d, J5i6 8 Hz, H 6; 6-98, d, J3<s 
3 Hz, H 3; 7-17, q, Js,6 8 Hz, / 3,s 3 Hz] H 5; 8-2, br, NH; 8-23, d,’ / 6.,8. 2 Hz, H 8'; 8-50, d, 
J2.t3- 5-5 Hz, H 2'; 8-65, d, 76-,8. 2 Hz, H6'.
7-Chloro-N-(2-diethylaminoethyl)-l,5-naphthyridin-4-amine (2d)
4.7- Dichloro-l,5-naphthyridine (0-4 g), 2-diethylaminoethylamine (1 -2 g) and n-heptane (10 ml) 
were heated in an autoclave at 160° for 20 h. Solvent and excess amine were then removed under 
reduced pressure and the product purified by t.l.c. (alumina; chloroform) to give 7-chloro-~N-(2- 
diethylaminoethyl)-l,5-naphthyridin-4-amine (0-48 g) as a brownish orange oil (Found: C, 60-5; 
H, 7 -1; N, 20 0. C14H19C1N4 requires C, 60-3; H ,6-9; N ,201% ). ’H n.m.r. (CDC13): <5, 
106, t, J 7 Hz, CH3CH2; 2 -61, q, /  7 H z, CH3CH2; 2-79, t, J  6 Hz, CH2NEt2; 3 • 34, complex, 
CH2NH; 6-48, d, y2>3 5-5 H z, H3; 7 0, br, NH; 8-17, d, J6,8 2 Hz, H8; 8-51, d , / 2>3 5-5 Hz, 
H 2; 8-60, d, / 6i8 2 FIz, H6.
The dihydrobromide, prepared in and recrystallized from ethanol, had m.p. 265-267° (Found: 
C, 38-2; H, 4-8; N, 12-4. C l4H19ClN4.2HBr requires C, 38-2; H, 4-8; N, 12-7%).
7-Chloro-H-(4'-diethylaminobutyl)-l,5-nuphthyridin-4-amine (2e)
4.7- Dichloro-l,5-naphthyridine (0-4 g), 4-diethylaminobutylamine (l-5g) and n-heptane (10-0 
ml) were heated at 160° for 20 h as described above. The product was purified by t.l.c. (alumina; 
chloroform) and gave 7-chloro-N-(4'-diethylaminobutyl)-l,5-naphthyridin-4-amine (0 -47 g) as a 
brownish yellow oil (Found: C, 62-6; H, 7-8; N, 18 0. C16H23C1N4 requires C, 62-6; H, 7-6; 
N, 18-3%). ‘H n.m.r. (CDC13): Ö, 102, t, J 7 Hz, CH3CH2; 1-70, complex, CH2(CH2)2CH2; 
2-53, q, J  7 Hz, CH3CH2; 2-57, complex, CH2NEt2; 3-33, complex, CH2N H ; 6-47, d, / 2,3 
5-5 Hz, H 3; 6-7, br, NH; 8-16, d, / 6.8 2 Hz, H8; 8-50, d, / 2,3 5-5 Hz, H2; 8-54, d, J6,s 2 Hz, 
H 6.
The dihydrobroinide, prepared in ethanolic hydrogen bromide and recrystallized from propan- 
2-ol, had m.p. 210-212° (Found: C, 40-8; H, 5-4; N, 11-7. C16H23ClN4.2HBr requires C, 41 0; 
H, 5-4; N, 11-9%).
Toxicity Testing
The naphthyridines were tested for acute toxicity in mice by intraperitoneal injection in normal 
saline or peanut oil. Each test chemical was injected in a single dose of 200 mg/kg of body weight 
[except for 4-(7,-bromo-l,,5,-naphthyridin-4/-ylamino)-2,6-bis(diethylamino and pyrrolidin-l"-yl)- 
methylphenol and 7-bromo(and chloro)-A'-(4/-diethylaminobutyl)-l,5-naphthyridin-4-amine which, 
due to toxicity at 200 mg/kg, were run at 100 mg/kg] to three mice. No apparent ill effects were 
observed and all mice survived to and beyond 4 days in the above tests and in control experiments 
with normal saline and peanut oil.
Preliminary Antimalarial Screen
This was carried out as described previously.2,3 Each test chemical was given at a dosage of 
200 mg/kg of body weight except for 4-(7'-bromo-l'-5,-naphthyridin-4'-ylamino-2,6-bis(diethylamino 
and pyrrolidin-l"-yl)methylphenol and 7-bromo(and chloro)-7V-(4'-diethylaminobutyl)-l,5-naphthyr- 
idin-4-amine which were at 100 mg/kg).
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